Difference between revisions of "FLICR"
Line 5: | Line 5: | ||
!width="50"|Transcript ID | !width="50"|Transcript ID | ||
!width="50"|Gene ID | !width="50"|Gene ID | ||
− | !width="50"|Symbol | + | !width="50"|Symbol || style="width:200px" |
!width="20"|Synonyms | !width="20"|Synonyms | ||
!width="50"|Functional Mechanism | !width="50"|Functional Mechanism |
Revision as of 03:46, 26 August 2019
Transcript ID | Gene ID | Symbol | style="width:200px" | Synonyms | Functional Mechanism | Biological Process | Disease |
---|---|---|---|---|---|---|---|
HSALNT0289501 | HSALNG0141612 | HPVC1 | PE5L,HPV18E5L | NA | pathogenic process | NA | |
HSALNT0289605 | HSALNG0141720 | Alpha 250/ Alpha 280 | NONHSAT104559,lnc-C9orf53-2:1 | NA | NA | NA | |
HSALNT0199632 | HSALNG0096226 | N4BP2L2-IT2 | CG030 | NA | NA | NA | |
HSALNT0171094 | HSALNG0082161 | LINC01150 | 2G7,TCONS_00019134 | NA | pathogenic process | Wilms' tumor | |
HSALNT0289115 | HSALNG0032599 | LINC01587 | C4orf6,aC1 | NA | pathogenic process | neuroblastoma | |
HSALNT0290105 | HSALNG0142220 | NTT | NONHSAT115106 | NA | NA | NA | |
HSALNT0289234 | HSALNG0053252 | RNF217-AS1 | STL | NA | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0280481 | HSALNG0136795 | INE2 | NCRNA00011 | NA | NA | NA | |
HSALNT0289485 | HSALNG0137683 | INE1 | NCRNA00010 | NA | NA | NA | |
HSALNT0289511 | HSALNG0141622 | LINC01565 | C3orf27,GR6 | NA | pathogenic process | leukemia | |
HSALNT0289068 | HSALNG0006924 | LINC00869 | KIAA0493 | NA | NA | NA | |
HSALNT0289430 | HSALNG0026312 | ERC2-IT1 | C1orf1,C3orf51,Po42 | NA | pathogenic process | NA | |
HSALNT0290394 | HSALNG0142509 | Y RNAs | lnc-PDIA4-1:1 | NA | NA | NA | |
HSALNT0289195 | HSALNG0032409 | NOP14-AS1 | C4orf10,RES4-24 | NA | NA | NA | |
HSALNT0290309 | HSALNG0142424 | TncRNA | NONHSAT022116,AF080092,TSU | NA | developmental process | NA | |
HSALNT0289243 | HSALNG0045080 | SMAD5-AS1 | SMAD5O,DAMS | NA | pathogenic process | malignant hematopoietic | |
HSALNT0289025 | HSALNG0062672 | LINC00244 | C7orf4,NCRNA00244 | NA | pathogenic process | preaxial polydactyly | |
HSALNT0289017 | HSALNG0055219 | KIF25-AS1 | C6orf54,NCRNA00300,HGC6.1.1 | NA | pathogenic process | ovarian cancer | |
HSALNT0289332 | HSALNG0055207 | LINC01558 | C6orf123,LINC01557,HGC6.2,dJ431P23.4 | NA | pathogenic process | ovarian cancer | |
HSALNT0289438 | HSALNG0055209 | AFDN-AS1 | C6orf124,MLLT4-AS1,HGC6.4,dJ431P23.3 | NA | pathogenic process | NA | |
HSALNT0289232 | HSALNG0135027 | RFPL3S | RFPL3-AS1,RFPL3-A, NCRNA00005 | NA | pathogenic process | opitz syndrome | |
HSALNT0289393 | HSALNG0134830 | RFPL1S | RFPL1-AS1,RFPL1-A, NCRNA00006 | NA | pathogenic process | NA | |
HSALNT0289500 | HSALNG0141611 | HCG4B | HCG4P6,HCGIV-6,HCGIV.5,HCGIV-06,bCX67J3.3,Em:AB023056.16,bPG309N1.1,bQB90C11.3 | NA | NA | NA | |
HSALNT0289894 | HSALNG0142009 | LINC00294 | NA | NA | NA | NA | |
HSALNT0289345 | HSALNG0140599 | LINC00893 | NA | NA | pathogenic process | hunter syndrome | |
HSALNT0290133 | HSALNG0142248 | PCBP3-OT1 | PCBP3-OT1,FLJ44028 | NA | NA | NA | |
HSALNT0289488 | HSALNG0141599 | BPESC1 | NCRNA00187 | NA | pathogenic process | blepharophimosis syndrome | |
HSALNT0289712 | HSALNG0141827 | COPG2IT1 | CIT1,NCRNA00170,COPG2AS | NA | NA | NA | |
HSALNT0265040 | HSALNG0128978 | LINC00652 | HSPC072 | NA | developmental process | NA | |
HSALNT0289282 | HSALNG0108689 | WASIR2 | NCRNA00286A | NA | NA | NA | |
HSALNT0246856 | HSALNG0119601 | LINC00470 | C18orf2 | NA | pathogenic process | age-related macular degeneration | |
HSALNT0289507 | HSALNG0141618 | LINC00588 | C8orf71,DKFZP434F122 | NA | NA | NA | |
HSALNT0276604 | HSALNG0134754 | TTC28-AS1 | TTC28AS,TTC28-AS,KIAA1648 | NA | NA | NA | |
HSALNT0237577 | HSALNG0114754 | CDRT7 | NCRNA00025,LINC00025 | NA | NA | NA | |
HSALNT0288912 | HSALNG0114755 | CDRT8 | NA | NA | NA | NA | |
HSALNT0275048 | HSALNG0133887 | CECR3 | NA | NA | pathogenic process | cat eye syndrome | |
HSALNT0288915 | HSALNG0133890 | CECR9 | NA | NA | pathogenic process | cat eye syndrome | |
HSALNT0288998 | HSALNG0133878 | HDHD5-AS1 | CECR4,CECR5-AS1,NCRNA00017 | NA | pathogenic process | cat eye syndrome | |
HSALNT0288914 | HSALNG0133878 | CECR5-AS1 | NCRNA00017 | NA | pathogenic process | cat eye syndrome | |
HSALNT0288919 | HSALNG0029809 | CLRN1-AS1 | CLRN1O,UCRP | NA | pathogenic process | usher syndrome type 3 | |
HSALNT0289271 | HSALNG0082585 | TMEM9B-AS1 | C11orf18 | NA | NA | NA | |
HSALNT0289324 | HSALNG0133586 | LINC01547 | C21orf69,C21orf67 | NA | pathogenic process | Down syndrome | |
HSALNT0270409 | HSALNG0131587 | LINC00029 | C20orf51,NCRNA00029,bA305P22.4 | NA | NA | NA | |
HSALNT0289336 | HSALNG0141634 | LINC00529 | C8orf8 | NA | pathogenic process | keratolytic winter erythema | |
HSALNT0288978 | HSALNG0010403 | FLVCR1-AS1 | FLVCR1-DT,LQK1 | NA | NA | NA | |
HSALNT0238050 | HSALNG0114969 | SMCR2 | NA | NA | pathogenic process | Smith-Magenis syndrome | |
HSALNT0289401 | HSALNG0114982 | SMCR5 | NCRNA00034 | NA | pathogenic process | Smith-Magenis syndrome | |
HSALNT0290246 | HSALNG0142361 | SMCR6 | NA | NA | pathogenic process | Smith-Magenis syndrome | |
HSALNT0274626 | HSALNG0133620 | LINC00205 | C21orf86,NCRNA00205, | NA | pathogenic process | NA | |
HSALNT0271512 | HSALNG0132117 | C21orf91-OT1 | NCRNA00285,D21S2089E | NA | NA | NA | |
HSALNT0272596 | HSALNG0132582 | LINC00307 | NCRNA00307,D21S2091E | NA | NA | NA | |
HSALNT0274502 | HSALNG0133549 | TSPEAR-AS2 | C21orf90 | NA | NA | NA | |
HSALNT0274807 | HSALNG0133721 | MCM3AP-AS1 | C21orf85,MCM3APAS,MCM3AP-AS,FLJ10508,NCRNA00031 | NA | NA | NA | |
HSALNT0288888 | HSALNG0133144 | B3GALT5-AS1 | C21orf88 | NA | NA | NA | |
HSALNT0288898 | HSALNG0133127 | BRWD1-AS2 | C21orf87,NCRNA00257,BRWD1-IT2 | NA | NA | NA | |
HSALNT0289031 | HSALNG0133621 | LINC00315 | C21orf93,NCRNA00315 | NA | NA | NA | |
HSALNT0289033 | HSALNG0133612 | LINC00334 | C21orf89,NCRNA00334 | NA | NA | NA | |
HSALNT0289322 | HSALNG0132477 | LINC00314 | C21orf94,NCRNA00314 | NA | NA | NA | |
HSALNT0271821 | HSALNG0132261 | LINC00308 | C21orf74,NCRNA00308,PRED16 | NA | pathogenic process | NA | |
HSALNT0289023 | HSALNG0132537 | LINC00189 | C21orf109,NCRNA00189 | NA | pathogenic process | NA | |
HSALNT0289375 | HSALNG0042788 | NCRUPAR | ncR-uPAR,ncRuPAR,NCRNA00193 | transcriptional regulation | developmental process | NA | |
HSALNT0273467 | HSALNG0133048 | DSCR10 | NA | NA | NA | NA | |
HSALNT0289480 | HSALNG0132984 | DSCR9 | NCRNA00038 | NA | NA | NA | |
HSALNT0290051 | HSALNG0142166 | MDS2 | NA | NA | pathogenic process | myelodysplastic syndrome | |
HSALNT0127810 | HSALNG0060777 | ST7-AS2 | ST7OT2,ST7AS2 | NA | pathogenic process | autism | |
HSALNT0127813 | HSALNG0060778 | ST7-OT3 | ST7OT3,NCRNA00026 | NA | pathogenic process | autism | |
HSALNT0290258 | HSALNG0142373 | ST7-OT4 | NA | NA | pathogenic process | autism | |
HSALNT0290257 | HSALNG0142372 | ST7OT | NONHSAT122926 | NA | NA | NA | |
HSALNT0289372 | HSALNG0074272 | MIR600HG | C9orf45,NCRNA00287,GL012,FLJ22161 | NA | NA | NA | |
HSALNT0013239 | HSALNG0006325 | ATP1A1-AS1 | C1orf203,ATP1A1OS,MGC16179 | NA | NA | NA | |
HSALNT0048563 | HSALNG0022910 | SPATA3-AS1 | NA | NA | NA | NA | |
HSALNT0050859 | HSALNG0024100 | LINC00852 | C3orf42,GHRLOS2,NAG73,GHRL-AS2 | NA | NA | NA | |
HSALNT0069395 | HSALNG0033002 | LINC01096 | NA | NA | NA | NA | |
HSALNT0072367 | HSALNG0034486 | LINC02260 | NA | NA | NA | NA | |
HSALNT0077259 | HSALNG0036896 | LINC01091 | NA | NA | NA | NA | |
HSALNT0096480 | HSALNG0046004 | SAP30L-AS1 | FLJ38109,GALNT10-AS1 | NA | NA | NA | |
HSALNT0098558 | HSALNG0046927 | PRR7-AS1 | NA | NA | NA | NA | |
HSALNT0099356 | HSALNG0047338 | LINC01622 | TCONS_00011202 | NA | NA | NA | |
HSALNT0113415 | HSALNG0053588 | LINC01312 | MGC34034 | NA | NA | NA | |
HSALNT0134652 | HSALNG0064240 | EXTL3-AS1 | C8orf50 | NA | NA | NA | |
HSALNT0138253 | HSALNG0065979 | C8orf34-AS1 | NA | NA | NA | NA | |
HSALNT0154876 | HSALNG0074139 | PSMD5-AS1 | NA | NA | NA | NA | |
HSALNT0163228 | HSALNG0078227 | LINC01553 | C10orf40,AC023904.2 | NA | NA | NA | |
HSALNT0175689 | HSALNG0084463 | LINC00301 | C11orf64,NCRNA00301,MGC39681 | NA | NA | NA | |
HSALNT0247235 | HSALNG0119722 | DLGAP1-AS3 | NA | NA | NA | NA | |
HSALNT0254200 | HSALNG0123001 | CIRBP-AS1 | C19orf23,MGC39338 | NA | NA | NA | |
HSALNT0257335 | HSALNG0124987 | LINC01785 | NA | NA | NA | NA | |
HSALNT0261582 | HSALNG0127139 | LINC01869 | MGC45922 | NA | NA | NA | |
HSALNT0269743 | HSALNG0131262 | LINC01711 | MGC4294 | NA | NA | NA | |
HSALNT0288468 | HSALNG0141311 | FAM41AY1 | FAM41AY | NA | NA | NA | |
HSALNT0288899 | HSALNG0045020 | C5orf66-AS2 | NA | NA | NA | NA | |
HSALNT0288922 | HSALNG0083517 | CSTF3-AS1 | CSTF3-DT | NA | NA | NA | |
HSALNT0288923 | HSALNG0014289 | CYP1B1-AS1 | C2orf58,MGC34824 | NA | NA | NA | |
HSALNT0288957 | HSALNG0025315 | ENTPD3-AS1 | FLJ36665 | NA | NA | NA | |
HSALNT0288970 | HSALNG0071511 | FAM27E3 | MGC42630 | NA | NA | NA | |
HSALNT0288972 | HSALNG0000046 | FAM41C | NA | NA | NA | NA | |
HSALNT0288977 | HSALNG0007223 | FLG-AS1 | NA | NA | NA | NA | |
HSALNT0288983 | HSALNG0105871 | GABPB1-IT1 | FLJ10038 | NA | NA | NA | |
HSALNT0289010 | HSALNG0123950 | ILF3-AS1 | ILF3-DT | NA | NA | NA | |
HSALNT0289034 | HSALNG0097943 | LINC00347 | NA | NA | NA | NA | |
HSALNT0289039 | HSALNG0004105 | LINC00466 | NA | NA | NA | NA | |
HSALNT0289040 | HSALNG0022951 | LINC00471 | C2orf52,MGC43122 | NA | NA | NA | |
HSALNT0289044 | HSALNG0119752 | LINC00526 | C18orf18,MGC17515,HsT959 | NA | NA | NA | |
HSALNT0289048 | HSALNG0106873 | LINC00593 | C15orf50,MGC42951 | NA | NA | NA | |
HSALNT0289050 | HSALNG0022320 | LINC00608 | NA | NA | NA | NA | |
HSALNT0289054 | HSALNG0104144 | LINC00638 | MGC23270 | NA | NA | NA | |
HSALNT0289056 | HSALNG0124410 | LINC00661 | NA | NA | NA | NA | |
HSALNT0289057 | HSALNG0125113 | LINC00662 | NA | NA | NA | NA | |
HSALNT0289062 | HSALNG0024755 | LINC00692 | NA | NA | NA | NA | |
HSALNT0289064 | HSALNG0075805 | LINC00705 | NA | NA | NA | NA | |
HSALNT0289067 | HSALNG0118878 | LINC00868 | C17orf52 | NA | NA | NA | |
HSALNT0130693 | HSALNG0062275 | LINC00996 | NA | NA | NA | NA | |
HSALNT0289101 | HSALNG0089327 | LINC01252 | NA | NA | NA | NA | |
HSALNT0289131 | HSALNG0113283 | LINC02135 | NA | NA | NA | NA | |
HSALNT0289193 | HSALNG0018445 | NIFK-AS1 | NA | NA | NA | NA | |
HSALNT0289244 | HSALNG0008972 | SMG7-AS1 | DKFZP564C196 | NA | NA | NA | |
HSALNT0235326 | HSALNG0113528 | SNAI3-AS1 | MGC23284 | NA | NA | NA | |
HSALNT0215205 | HSALNG0103442 | SNHG10 | C14orf62,FLJ40557,NCRNA00063,LINC00063 | NA | NA | NA | |
HSALNT0289290 | HSALNG0109122 | ZNF205-AS1 | MGC3771 | NA | NA | NA | |
HSALNT0289294 | HSALNG0009820 | LINC00260 | C1orf217,NCRNA00260,MGC5457 | NA | NA | NA | |
HSALNT0289295 | HSALNG0000511 | LINC00337 | C1orf211,NCRNA00337,MGC40168 | NA | NA | NA | |
HSALNT0289298 | HSALNG0076905 | WAC-AS1 | NA | NA | NA | NA | |
HSALNT0289299 | HSALNG0077486 | LINC00839 | NA | NA | NA | NA | |
HSALNT0289303 | HSALNG0089110 | LINC00612 | C12orf33,MGC40170,FLJ41814 | NA | NA | NA | |
HSALNT0289312 | HSALNG0124755 | LINC00663 | MGC39821 | NA | NA | NA | |
HSALNT0289320 | HSALNG0130611 | LINC00494 | NA | NA | NA | NA | |
HSALNT0289330 | HSALNG0039733 | LINC01019 | NA | NA | NA | NA | |
HSALNT0289333 | HSALNG0057380 | LINC00265 | NCRNA00265,NCRNA00265-1 | NA | NA | NA | |
HSALNT0289334 | HSALNG0062824 | LINC00689 | NA | NA | NA | NA | |
HSALNT0289337 | HSALNG0068847 | LINC01591 | NA | NA | NA | NA | |
HSALNT0289340 | HSALNG0072666 | LINC01501 | NA | NA | NA | NA | |
HSALNT0289346 | HSALNG0137712 | LINC01560 | CXorf24 | NA | NA | NA | |
HSALNT0289352 | HSALNG0045051 | LINC01959 | NA | NA | NA | NA | |
HSALNT0289353 | HSALNG0110333 | LINC02175 | NA | NA | NA | NA | |
HSALNT0289354 | HSALNG0064321 | LINC02209 | FAM183CP | NA | NA | NA | |
HSALNT0289359 | HSALNG0107406 | LINGO1-AS1 | NA | NA | NA | NA | |
HSALNT0289362 | HSALNG0119342 | MAFG-AS1 | MAFG-DT | NA | NA | NA | |
HSALNT0289373 | HSALNG0139326 | MORF4L2-AS1 | NA | NA | NA | NA | |
HSALNT0289381 | HSALNG0029035 | NPHP3-AS1 | NCRNA00119 | NA | NA | NA | |
HSALNT0289385 | HSALNG0062543 | PAXIP1-AS1 | NA | NA | NA | NA | |
HSALNT0289413 | HSALNG0082091 | TOLLIP-AS1 | NA | NA | NA | NA | |
HSALNT0289416 | HSALNG0113198 | LINC00311 | TMEM148,NCRNA00311,MGC22001 | NA | NA | NA | |
HSALNT0289422 | HSALNG0069500 | ZNF252P-AS1 | C8orf77 | NA | NA | NA | |
HSALNT0289423 | HSALNG0001624 | ZNF436-AS1 | C1orf213,FLJ90508 | NA | NA | NA | |
HSALNT0289429 | HSALNG0029047 | BFSP2-AS1 | MGC2848 | NA | NA | NA | |
HSALNT0289432 | HSALNG0032263 | CTBP1-AS1 | C4orf42,CTBP1-DT,CTBP1-DT,MGC21675 | NA | NA | NA | |
HSALNT0289436 | HSALNG0039444 | EXOC3-AS1 | C5orf55 | NA | NA | NA | |
HSALNT0289441 | HSALNG0049246 | HCG27 | bPG299F13.9,bCX101P6.9,bQB115I13.2,FLJ40123 | NA | NA | NA | |
HSALNT0289450 | HSALNG0067505 | BAALC-AS2 | C8orf56,BAALCOS,MGC39526 | NA | NA | NA | |
HSALNT0289453 | HSALNG0062877 | FAM87A | NA | NA | NA | NA | |
HSALNT0289459 | HSALNG0078365 | JMJD1C-AS1 | NA | NA | NA | NA | |
HSALNT0289465 | HSALNG0092957 | ATP2B1-AS1 | LINC00936 | NA | NA | NA | |
HSALNT0289466 | HSALNG0093183 | CEP83-AS1 | CEP83-DT | NA | NA | NA | |
HSALNT0289470 | HSALNG0107054 | HEXA-AS1 | C15orf34,FLJ13315 | NA | NA | NA | |
HSALNT0289487 | HSALNG0141598 | BIN3-IT1 | FLJ14107 | NA | NA | NA | |
HSALNT0289490 | HSALNG0141601 | CSNK1G2-AS1 | C19orf34,MGC39696 | NA | NA | NA | |
HSALNT0289508 | HSALNG0141619 | LINC00634 | NA | NA | NA | NA | |
HSALNT0289510 | HSALNG0141621 | LINC00685 | CXYorf10,NCRNA00107,PPP2R3B-AS1,OTTHUMT00000055574 | NA | NA | NA | |
HSALNT0289515 | HSALNG0141626 | SHANK2-AS3 | C11orf76 | NA | NA | NA | |
HSALNT0290073 | HSALNG0142188 | NCBP2-AS2 | NA | NA | NA | NA | |
HSALNT0289502 | HSALNG0141613 | KCNIP4-IT1 | NCRNA00099,UM9-5 | NA | NA | NA | |
HSALNT0289856 | HSALNG0141971 | GTSCR1 | NA | NA | pathogenic process | Gilles de la Tourette syndrome | |
HSALNT0289325 | HSALNG0008917 | LINC00272 | C1orf120,NCRNA00272,RP1-223H12.3 | NA | pathogenic process | prostate cancer | |
HSALNT0288512 | HSALNG0141348 | TTTY9B | NCRNA00132 | NA | NA | NA | |
HSALNT0290155 | HSALNG0142270 | Prion-associated RNAs | NA | NA | pathogenic process | prion disease | |
HSALNT0289444 | HSALNG0062567 | BLACE | NA | NA | pathogenic process | acute B lymphoblastic leukemias | |
HSALNT0060411 | HSALNG0028877 | H1FX-AS1 | C3orf47,FLJ34151 | NA | NA | NA | |
HSALNT0186668 | HSALNG0089868 | LINC00477 | C12orf67,FLJ32894,FAM191B | NA | NA | NA | |
HSALNT0275096 | HSALNG0133923 | LINC00528 | C22orf37,FLJ40542 | NA | NA | NA | |
HSALNT0287824 | HSALNG0140941 | ASMTL-AS1 | CXYorf2,NCRNA00105,ASMTLAS,ASMTL-AS,FLJ13330 | NA | NA | NA | |
HSALNT0288887 | HSALNG0106820 | ANP32A-IT1 | C15orf28,NCRNA00321,FLJ11722,HsT18971 | NA | NA | NA | |
HSALNT0289370 | HSALNG0010128 | MIR29B2CHG | C1orf132,FLJ35650 | NA | NA | NA | |
HSALNT0289396 | HSALNG0007497 | RUSC1-AS1 | C1orf104,FLJ35976 | NA | NA | NA | |
HSALNT0084628 | HSALNG0040236 | LINC01194 | CT49,TAG | NA | pathogenic process | melanoma | |
HSALNT0289468 | HSALNG0103838 | DIO3OS | C14orf134,NCRNA00041,DIO3-AS1,NONHSAT040032,NONHSAT040039,BC111049 | NA | NA | NA | |
HSALNT0121060 | HSALNG0057178 | NPSR1-AS1 | AAA1,IMAGE:4827585 | NA | NA | NA | |
HSALNT0074370 | HSALNG0035535 | LINC00575 | C4orf11 | NA | pathogenic process | NA | |
HSALNT0137345 | HSALNG0065537 | LINC01602 | T1560 | NA | pathogenic process | NA | |
HSALNT0289433 | HSALNG0035768 | FAM13A-AS1 | FAM13A1OS,FAM13AOS,NCRNA00039 | NA | NA | NA | |
HSALNT0289186 | HSALNG0072891 | MIRLET7DHG | NA | NA | NA | NA | |
HSALNT0155254 | HSALNG0074353 | MIR181A2HG | NA | NA | NA | NA | |
HSALNT0289283 | HSALNG0035624 | WDFY3-AS2 | C4orf12,NCRNA00247,FBI4 | NA | NA | NA | |
HSALNT0154555 | HSALNG0073990 | PAPPA-AS1 | PAPPAS,PAPPA-AS,DIPAS,TAF4B,TAF2C2,TAFII105,NCRNA00156 | NA | NA | NA | |
HSALNT0136307 | HSALNG0065020 | LINC00293 | BEYLA | NA | developmental process | NA | |
HSALNT0030983 | HSALNG0014614 | SIX3-AS1 | SIX3OS | NA | developmental process | NA | |
HSALNT0211503 | HSALNG0101546 | OTX2-AS1 | OTX2OS1 | NA | developmental process | NA | |
HSALNT0063422 | HSALNG0030360 | LINC01192 | CT64 | NA | NA | NA | |
HSALNT0217123 | HSALNG0104394 | LINC01193 | CT60,LOC348120 | NA | NA | NA | |
HSALNT0289664 | HSALNG0141779 | C1QTNF9B-AS1 | PCOTH | NA | pathogenic process | prostate cancer | |
HSALNT0289623 | HSALNG0141738 | ATP6V1G2-DDX39B | NA | NA | pathogenic process | dilated cardiomyopathy | |
HSALNT0289498 | HSALNG0141609 | FAM226B | CXorf50B,NCRNA00246B,LINC00246B | NA | NA | NA | |
HSALNT0289321 | HSALNG0133590 | LINC00163 | C21orf134,NCRNA00163,NLC1-A,NLC1A | NA | pathogenic process | narcolepsy | |
HSALNT0289505 | HSALNG0141616 | LINC00165 | C21orf135,NCRNA00165,NLC1-B | NA | NA | NA | |
HSALNT0290297 | HSALNG0142412 | TEA-ncRNAs | ENSG00000251002 | NA | NA | NA | |
HSALNT0274212 | HSALNG0133403 | LINC00322 | C21orf136,NCRNA00322,FLJ16545 | NA | NA | NA | |
HSALNT0289741 | HSALNG0141856 | DHFR upstream transcripts | DHFR minor transcript 5'-UTR,ENSG00000228716,NONHSAT102417 | transcriptional regulation | NA | NA | |
HSALNT0289527 | HSALNG0141642 | 21A | ncRNA 21A,NONHSAT128494 | NA | NA | NA | |
HSALNT0289409 | HSALNG0080181 | TLX1NB | TD1,TDI,APT-B7 | NA | pathogenic process | leukemogenesis | |
HSALNT0289662 | HSALNG0141777 | C15orf2 | NA | NA | pathogenic process | Angelman syndrome | |
HSALNT0290097 | HSALNG0142212 | NPAP1 | NA | NA | pathogenic process | Angelman syndrome | |
HSALNT0217406 | HSALNG0104530 | PWRN2 | NCRNA00199 | NA | pathogenic process | Prader-Willi syndrome | |
HSALNT0289227 | HSALNG0104528 | PWRN1 | NCRNA00198 | NA | pathogenic process | Prader-Willi syndrome | |
HSALNT0262816 | HSALNG0127793 | MIMT1 | MIM1,NCRNA00067,LINC00067 | NA | NA | NA | |
HSALNT0289180 | HSALNG0000682 | MIR34AHG | NA | NA | NA | NA | |
HSALNT0289357 | HSALNG0049203 | LINC02570 | XXbac-BPG27H4.8 | NA | pathogenic process | MHC-associated diseases | |
HSALNT0290177 | HSALNG0142292 | RNY1 | NA | NA | pathogenic process | cervix cancer;prostate cancer;colorectal cancer;bladder cancer;kidney cancer;lung cancer | |
HSALNT0289378 | HSALNG0129114 | NKX2-2-AS1 | NKX2-2AS | transcriptional regulation | pathogenic process | NA | |
HSALNT0290151 | HSALNG0142266 | PR antisense transcripts | FJ515872.1,NONHSAT023851 | transcriptional regulation | NA | NA | |
HSALNT0180290 | HSALNG0086714 | PGR-AS1,PR antisense transcripts | AT1,AT2,AT3 | NA | NA | NA | |
HSALNT0289607 | HSALNG0141722 | anti-NOS2A | NA | NA | pathogenic process | meningioma;glioblastoma | |
HSALNT0289687 | HSALNG0141802 | CDKN1A-AS1 | p21NAT | transcriptional regulation | NA | NA | |
HSALNT0289166 | HSALNG0103805 | MEG9 | LINC00584 | NA | NA | NA | |
HSALNT0116668 | HSALNG0055114 | RPS6KA2-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289384 | HSALNG0073983 | PAPPA-AS2 | AGU1 | NA | NA | NA | |
HSALNT0262802 | HSALNG0127785 | ZIM2-AS1 | ZIM2as | NA | NA | NA | |
HSALNT0289824 | HSALNG0141939 | Evf2 | Evf-2,Dlx6as1,Dlx6os1,ENSG00000231764, ENST00000430027.2,lnc-DLX5-3:1 | transcriptional regulation | NA | NA | |
HSALNT0289481 | HSALNG0134495 | ADORA2A-AS1 | C22orf45,FLJ34651 | NA | NA | NA | |
HSALNT0290146 | HSALNG0142261 | POU5F1P4 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290033 | HSALNG0142148 | LSINCT1 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290034 | HSALNG0142149 | LSINCT10 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290035 | HSALNG0142150 | LSINCT11 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290036 | HSALNG0142151 | LSINCT12 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290037 | HSALNG0142152 | LSINCT2 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290038 | HSALNG0142153 | LSINCT3 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290039 | HSALNG0142154 | LSINCT4 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290041 | HSALNG0142156 | LSINCT6 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290042 | HSALNG0142157 | LSINCT7 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290043 | HSALNG0142158 | LSINCT8 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0290044 | HSALNG0142159 | LSINCT9 | NA | NA | pathogenic process | lung cancer;breast cancer | |
HSALNT0289676 | HSALNG0141791 | CAR Intergenic 10 | FLJ31066,NONHSAT016928,lnc-FANK1-3:1 | transcriptional regulation | NA | NA | |
HSALNT0290032 | HSALNG0142147 | LRRC3DN | C21orf30,DKFZP434C128 | transcriptional regulation | NA | NA | |
HSALNT0266984 | HSALNG0129985 | SNHG11 | C20orf198,LINC00101,NCRNA00101 | NA | pathogenic process | obesity | |
HSALNT0289880 | HSALNG0141995 | KRASP1 | NONHSAT113225,ENSG00000220635 | ceRNA | NA | NA | |
HSALNT0006368 | HSALNG0003376 | CYP4A22-AS1 | ncRNA-a3 | transcriptional regulation | NA | NA | |
HSALNT0027470 | HSALNG0013045 | LINC00570 | ncRNA-a5 | transcriptional regulation | NA | NA | |
HSALNT0289066 | HSALNG0003381 | LINC00853 | PDZK1IP1-AS1,ncRNA-a4 | transcriptional regulation | NA | NA | |
HSALNT0289936 | HSALNG0142051 | lincRNA-ROR | ROR,lincRNA-ST8SIA3,ENSG00000258609,NONHSAT059436 | NA | NA | NA | |
HSALNT0289705 | HSALNG0141820 | CHL1-AS2 | NA | NA | pathogenic process | adolescent idiopathic scoliosis | |
HSALNT0076084 | HSALNG0036316 | SEC24B-AS1 | 1/2-SBSRNA4 | siRNA | NA | NA | |
HSALNT0290137 | HSALNG0142252 | PDZRN3-AS1 | NA | NA | pathogenic process | type 2 diabetes | |
HSALNT0290237 | HSALNG0142352 | SCAANT1 | ATXN7-AS1 | transcriptional regulation | pathogenic process | spinocerebellar ataxia | |
HSALNT0289594 | HSALNG0141709 | AK123790 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289911 | HSALNG0142026 | LINC01451 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290401 | HSALNG0142516 | ZNF350-AS1 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289845 | HSALNG0141960 | GADD45G | NA | NA | pathogenic process | pituitary adenoma | |
HSALNT0289410 | HSALNG0043357 | TMEM161B-AS1 | AK082072,linc-POLR3G-8,ENSG00000247828 | NA | NA | NA | |
HSALNT0289736 | HSALNG0141851 | DAPK1 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290048 | HSALNG0142163 | MAP3K14 | MAP3K14 | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290150 | HSALNG0142265 | PPP3CB | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0151531 | HSALNG0072477 | DAPK1-IT1 | NA | NA | pathogenic process | NA | |
HSALNT0288990 | HSALNG0041256 | GDNF-AS1 | GDNFOS | transcriptional regulation | pathogenic process | Alzheimer's disease | |
HSALNT0029702 | HSALNG0014093 | BIRC6-AS2 | megamind | NA | developmental process | NA | |
HSALNT0029692 | HSALNG0014085 | BIRC6-AS1 | NA | NA | NA | NA | |
HSALNT0289310 | HSALNG0116623 | LINC00854 | NA | NA | NA | NA | |
HSALNT0290332 | HSALNG0142447 | uc.73 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289841 | HSALNG0141956 | FR0257520 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290104 | HSALNG0142219 | NRG1 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289689 | HSALNG0141804 | CDKN2B-AS11 | NA | NA | pathogenic process;developmental process | stroke | |
HSALNT0289690 | HSALNG0141805 | CDKN2B-AS12 | NA | NA | pathogenic process | glioma | |
HSALNT0289691 | HSALNG0141806 | CDKN2B-AS13 | NA | NA | pathogenic process | plexiform neurofibroma | |
HSALNT0289697 | HSALNG0141812 | CDKN2B-AS7 | NA | NA | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0289826 | HSALNG0141941 | FADS1 | NA | NA | pathogenic process | lipid metabolism disorder | |
HSALNT0289698 | HSALNG0141813 | CDKN2B-AS8 | NA | NA | pathogenic process | melanoma | |
HSALNT0289696 | HSALNG0141811 | CDKN2B-AS6 | NA | NA | pathogenic process | neuroblastoma | |
HSALNT0289699 | HSALNG0141814 | CDKN2B-AS9 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0289688 | HSALNG0141803 | CDKN2B-AS10 | NA | NA | pathogenic process | stroke | |
HSALNT0288950 | HSALNG0031716 | ENST00000456816 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0290021 | HSALNG0142136 | LOC389332 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0290306 | HSALNG0142421 | TMEM72 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289641 | HSALNG0141756 | BC029135 | NA | NA | pathogenic process | renal clear cell cancer | |
HSALNT0290374 | HSALNG0142489 | X91348 | NA | NA | pathogenic process | renal clear cell cancer | |
HSALNT0289694 | HSALNG0141809 | CDKN2B-AS4 | NA | NA | pathogenic process | cancer | |
HSALNT0289692 | HSALNG0141807 | CDKN2B-AS2 | NA | NA | pathogenic process | coronary heart disease | |
HSALNT0289693 | HSALNG0141808 | CDKN2B-AS3 | NA | NA | pathogenic process | intracranial aneurysm | |
HSALNT0289695 | HSALNG0141810 | CDKN2B-AS5 | NA | NA | pathogenic process | type 2 diabetes | |
HSALNT0290319 | HSALNG0142434 | T-UCRs | NA | NA | pathogenic process | neuroblastoma | |
HSALNT0289530 | HSALNG0141645 | 51A | NA | splicing regulation | pathogenic process | Alzheimer's disease | |
HSALNT0290163 | HSALNG0142278 | RAB4B-EGLN2 | NA | NA | pathogenic process | cancer | |
HSALNT0290167 | HSALNG0142282 | RERT | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0265263 | HSALNG0129088 | LINC00237 | NCRNA00237 | NA | pathogenic process | macrocephaly;obesity | |
HSALNT0267186 | HSALNG0130081 | LINC01370 | HI-LNC25,HILNC25 | NA | pathogenic process | type 2 diabetes | |
HSALNT0289114 | HSALNG0046884 | LINC01574 | HI-LNC12,TCONS_00009551 | NA | pathogenic process | type 2 diabetes | |
HSALNT0290159 | HSALNG0142274 | PTHLH | NA | NA | pathogenic process | brachydactyly | |
HSALNT0189394 | HSALNG0091306 | CISTR | CISTR-ACT,CISTRACT,re52431 | transcriptional regulation | pathogenic process | brachydactyly | |
HSALNT0289862 | HSALNG0141977 | HELLPAR | LINC-HELLP | NA | pathogenic process | HELLP syndrome | |
HSALNT0289904 | HSALNG0142019 | LINC01125 | NA | NA | pathogenic process | uremia | |
HSALNT0289544 | HSALNG0141659 | AC002511.1 | LINC01531 | NA | pathogenic process | enterovirus 71 infection | |
HSALNT0289609 | HSALNG0141724 | AP000688.29 | AP000688.2 | NA | pathogenic process | enterovirus 71 infection | |
HSALNT0289832 | HSALNG0141947 | FFAR2 | NA | NA | pathogenic process | enterovirus 71 infection | |
HSALNT0290222 | HSALNG0142337 | RP4-620F22.3 | AC099063.2 | NA | pathogenic process | enterovirus 71 infection | |
HSALNT0290227 | HSALNG0142342 | RP5-843L14.1 | LINC01716 | NA | pathogenic process | enterovirus 71 infection | |
HSALNT0287285 | HSALNG0140617 | MAGEA8-AS1 | RP5-869M20.2 | NA | NA | NA | |
HSALNT0289019 | HSALNG0094159 | LHX5-AS1 | locus4010 | NA | NA | NA | |
HSALNT0288902 | HSALNG0023597 | CAPN10-AS1 | CAPN10-DT,locus959 | NA | NA | NA | |
HSALNT0289404 | HSALNG0076463 | STAM-AS1 | locus3182 | NA | NA | NA | |
HSALNT0148276 | HSALNG0070806 | PTENP1-AS | PTENpg1-asRNA | transcriptional regulation | NA | NA | |
HSALNT0289562 | HSALNG0141677 | AF116616 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289589 | HSALNG0141704 | AK094838 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289620 | HSALNG0141735 | ASLNC00339 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289629 | HSALNG0141744 | BC002350 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289651 | HSALNG0141766 | BC091525 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289652 | HSALNG0141767 | BE503655 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289753 | HSALNG0141868 | ENO1 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289835 | HSALNG0141950 | FKBP10 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0290064 | HSALNG0142179 | MYHAS | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289985 | HSALNG0142100 | LncRNA-LALR1 | NA | transcriptional regulation | pathogenic process | liver cancer | |
HSALNT0289934 | HSALNG0142049 | lincRNA-LALR1 | NA | transcriptional regulation | pathogenic process | NA | |
HSALNT0091577 | HSALNG0043527 | NR2F1-AS1 | FLJ42709 | NA | NA | NA | |
HSALNT0289709 | HSALNG0141824 | CK19 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289943 | HSALNG0142058 | Llme23 | NA | NA | pathogenic process | melanoma | |
HSALNT0289553 | HSALNG0141668 | AC096655.1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289178 | HSALNG0137593 | MIR222HG | Lnc-Ang362 | NA | pathogenic process | Ang II-associated cardiovascular disease | |
HSALNT0289261 | HSALNG0032541 | STX18-AS1 | LOC100507266 | NA | pathogenic process | atrial septal defect | |
HSALNT0289849 | HSALNG0141964 | GHSR | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289850 | HSALNG0141965 | GHSROS | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289210 | HSALNG0072923 | PCAT7 | PCAN-R2 | NA | pathogenic process | prostate cancer | |
HSALNT0289702 | HSALNG0141817 | CES1P1 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289892 | HSALNG0142007 | LINC00210 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290006 | HSALNG0142121 | LOC100506974 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290219 | HSALNG0142334 | RP3-508I15.14 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290243 | HSALNG0142358 | SLC6A6 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290342 | HSALNG0142457 | uc003bgl.1 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289075 | HSALNG0008302 | LINC00970 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0211868 | HSALNG0101725 | SALRNA1 | SAL-RNA1,XLOC_023166 | NA | developmental process | NA | |
HSALNT0222267 | HSALNG0106957 | SALRNA3 | SAL-RNA3,XLOC_025918 | NA | developmental process | NA | |
HSALNT0222274 | HSALNG0106960 | SALRNA2 | SAL-RNA2,XLOC_025931 | NA | developmental process | NA | |
HSALNT0289428 | HSALNG0021790 | GPR1-AS | GPR1-AS1,GPR1AS | transcriptional regulation | NA | NA | |
HSALNT0226207 | HSALNG0108743 | LINC00235 | NA | NA | pathogenic process | anorexia nervosa | |
HSALNT0289526 | HSALNG0141641 | 1B FGF-antisense transcripts | NA | NA | pathogenic process | endometriosis | |
HSALNT0290171 | HSALNG0142286 | RNA polymerase III-dependent lncRNAs | NA | NA | pathogenic process | diffuse cerebral hypomyelination | |
HSALNT0290168 | HSALNG0142283 | REST/CoREST-regulated lncRNAs | NA | NA | pathogenic process | Huntington disease | |
HSALNT0289606 | HSALNG0141721 | Alu lncRNAs | NA | NA | pathogenic process | macular degeneration | |
HSALNT0290358 | HSALNG0142473 | UCH1LAS | NA | NA | pathogenic process | Parkinson's disease | |
HSALNT0290244 | HSALNG0142359 | SLC7A2-IT1A/B | NA | NA | pathogenic process | progressive encephalopathy with severe infantile anorexia | |
HSALNT0289877 | HSALNG0141992 | Kcna2-AS | NA | NA | pathogenic process | neuropathic pain | |
HSALNT0289191 | HSALNG0053305 | NCOA7-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0290020 | HSALNG0142135 | LOC389023 | NA | transcriptional regulation | pathogenic process | psychiatric disease | |
HSALNT0175124 | HSALNG0084108 | PTPRJ-AS1 | NA | transcriptional regulation | NA | NA | |
HSALNT0289654 | HSALNG0141769 | BM742401 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289331 | HSALNG0049950 | LINC00951 | lincRNA-uc003opf.1,FLJ41649 | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0290130 | HSALNG0142245 | PAWR | NA | NA | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0290264 | HSALNG0142379 | T-ALL-R-LncR1 | NA | NA | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0289599 | HSALNG0141714 | AK130977 | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0289625 | HSALNG0141740 | AX746718 | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0289738 | HSALNG0141853 | DDR2 | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0290003 | HSALNG0142118 | LOC100131831 | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0290144 | HSALNG0142259 | POT1-AS1 | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0290253 | HSALNG0142368 | SNORA17B | NA | NA | pathogenic process | malignant pleural mesothelioma | |
HSALNT0207421 | HSALNG0099625 | GAS6-AS1 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289838 | HSALNG0141953 | FMR5 | NA | NA | pathogenic process | fragile X syndrome | |
HSALNT0208907 | HSALNG0100287 | FOXG1-AS1 | FOXG1-AS | NA | pathogenic process | autism spectrum disorder | |
HSALNT0290263 | HSALNG0142378 | SYNGAP1-AS1 | SYNGAP1-AS | NA | pathogenic process | autism spectrum disorder | |
HSALNT0290176 | HSALNG0142291 | RNase MRP | NA | NA | pathogenic process | cartilage hair hypoplaisia | |
HSALNT0289469 | HSALNG0105872 | GABPB1-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0289009 | HSALNG0075528 | IDI2-AS1 | C10orf110,IDI2-A,HT009,Em:AC022536.4 | NA | NA | NA | |
HSALNT0289093 | HSALNG0044716 | LINC01184 | FLJ33630 | NA | NA | NA | |
HSALNT0290108 | HSALNG0142223 | OGT | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290077 | HSALNG0142192 | ncNRFR | NA | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0290337 | HSALNG0142452 | uc001lsz | NA | NA | pathogenic process | gastric cancer;prostate cancer;liver cancer;lung cancer | |
HSALNT0289087 | HSALNG0021008 | LINC01090 | NA | NA | pathogenic process | post-traumatic stress disorder | |
HSALNT0289746 | HSALNG0141861 | DQ786227 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289981 | HSALNG0142096 | lncRNA-DQ786227 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289876 | HSALNG0141991 | JADRR | LINC00915,lncRNA-JADE | transcriptional regulation | pathogenic process | breast cancer | |
HSALNT0290254 | HSALNG0142369 | SOX2OT-S1 | NA | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0290404 | HSALNG0142519 | SOX2OT-S2 | NA | NA | pathogenic process | NA | |
HSALNT0289870 | HSALNG0141985 | HOXA13 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0078946 | HSALNG0037661 | SMAD1-AS1 | ENST00000513542 | NA | pathogenic process | ventricular septal defects | |
HSALNT0087329 | HSALNG0041545 | FGF10-AS1 | RP11-473L15.2 | transcriptional regulation | pathogenic process | ventricular septal defects | |
HSALNT0290318 | HSALNG0142433 | TUC339 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289819 | HSALNG0141934 | ERICD | LINC01130,TCONS_00014875,ERIC | transcriptional regulation | pathogenic process | retinoblastoma | |
HSALNT0289615 | HSALNG0141730 | ARA | NA | NA | pathogenic process | cancer | |
HSALNT0289822 | HSALNG0141937 | ESCCAL-5 | NA | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0290074 | HSALNG0142189 | ncC11orf49 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290076 | HSALNG0142191 | ncHDAC5 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290078 | HSALNG0142193 | ncRAB31 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290080 | HSALNG0142195 | ncSRPK1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0018253 | HSALNG0008819 | OVAAL | LINC01131,OVAL | NA | pathogenic process | ovarian cancer | |
HSALNT0289884 | HSALNG0141999 | LALR | NA | transcriptional regulation | pathogenic process | hepatocelluar cancer | |
HSALNT0289701 | HSALNG0141816 | CEACAMP8 | CEACAMP8 | NA | pathogenic process | pre-eclampsia | |
HSALNT0290018 | HSALNG0142133 | LOC284100 | NA | NA | pathogenic process | pre-eclampsia | |
HSALNT0290023 | HSALNG0142138 | LOC391533 | NA | NA | pathogenic process | pre-eclampsia | |
HSALNT0189558 | HSALNG0091365 | LINC01154 | NA | NA | NA | NA | |
HSALNT0196616 | HSALNG0094870 | THRIL | BRI3BP-AS1,BRI3BPAS1,Linc1992,TCONS_00020260 | transcriptional regulation | pathogenic process | Kawasaki disease | |
HSALNT0289235 | HSALNG0098080 | RNF219-AS1 | NA | NA | pathogenic process | blood pressure | |
HSALNT0289561 | HSALNG0141676 | AF086415 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289583 | HSALNG0141698 | AK056098 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289590 | HSALNG0141705 | AK095147 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289600 | HSALNG0141715 | AK294004 | NA | transcriptional regulation | pathogenic process | nasopharyngeal cancer | |
HSALNT0289612 | HSALNG0141727 | AP5M1 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0290110 | HSALNG0142225 | ORAOV1 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0290210 | HSALNG0142325 | RP1-179N16.3 | Z95152.1 | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0037026 | HSALNG0017545 | LINC01159 | linc-Brn1b | NA | developmental process | NA | |
HSALNT0289014 | HSALNG0137988 | KANTR | KDM5C adjacent non-coding transcript | NA | developmental process | NA | |
HSALNT0289905 | HSALNG0142020 | LINC01157 | TCONS_00010378,linc-Enc1 | NA | developmental process | NA | |
HSALNT0289460 | HSALNG0087416 | APOA1-AS | NA | transcriptional regulation | NA | NA | |
HSALNT0290400 | HSALNG0142515 | ZNF300P1 | ZNF300P1 | NA | pathogenic process | ovarian cancer | |
HSALNT0289750 | HSALNG0141865 | EEF1A1P9 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289796 | HSALNG0141911 | ENST00000318333 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289797 | HSALNG0141912 | ENST00000374520 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289800 | HSALNG0141915 | ENST00000422362 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289808 | HSALNG0141923 | ENST00000455912 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289809 | HSALNG0141924 | ENST00000456007 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289810 | HSALNG0141925 | ENST00000456185 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289817 | HSALNG0141932 | EPOR | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289913 | HSALNG0142028 | LINC01550 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0290142 | HSALNG0142257 | PMS2P5 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0290269 | HSALNG0142384 | TCF7 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0290345 | HSALNG0142460 | uc003jfz.2 | NA | NA | pathogenic process | gastric cardia adenocarcinoma | |
HSALNT0289095 | HSALNG0018112 | LINC01191 | VIN,lnc-ACTR3 | transcriptional regulation | pathogenic process | influenza A virus | |
HSALNT0288976 | HSALNG0140165 | FIRRE | LINC01200 | transcriptional regulation | NA | NA | |
HSALNT0289097 | HSALNG0046284 | LINC01202 | NA | NA | NA | NA | |
HSALNT0290271 | HSALNG0142386 | TCONS_00014512 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290272 | HSALNG0142387 | TCONS_00014978 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290274 | HSALNG0142389 | TCONS_00024647 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290279 | HSALNG0142394 | TCONS_00090092_MEG3 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290280 | HSALNG0142395 | TCONS_l2_00000179 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290283 | HSALNG0142398 | TCONS_l2_00004424 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290284 | HSALNG0142399 | TCONS_l2_00006843 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290289 | HSALNG0142404 | TCONS_l2_00014091 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290291 | HSALNG0142406 | TCONS_l2_00018070 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290292 | HSALNG0142407 | TCONS_l2_00020565 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290293 | HSALNG0142408 | TCONS_l2_00021262 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0290296 | HSALNG0142411 | TCONS_l2_00030560 | NA | NA | pathogenic process | hepatoblastoma | |
HSALNT0289927 | HSALNG0142042 | lincRNA1611 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290149 | HSALNG0142264 | Ppp3ca | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290265 | HSALNG0142380 | TC0100223 | NA | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0290267 | HSALNG0142382 | TC0101686 | NA | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0290268 | HSALNG0142383 | TC1500845 | NA | NA | pathogenic process | ovarian cancer | |
HSALNT0289318 | HSALNG0128589 | LAMP5-AS1 | NA | NA | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0234022 | HSALNG0112916 | LINC01228 | lincRNA-DYNLRB2-2 | NA | pathogenic process | NA | |
HSALNT0162654 | HSALNG0077963 | SGMS1-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0289206 | HSALNG0126202 | PCAT19 | LOC100505495,LINC01190 | NA | pathogenic process | prostate cancer | |
HSALNT0289521 | HSALNG0115583 | ABHD15-AS1 | linc-TP53I13,lnc-TP53I13 | NA | pathogenic process | cardiometabolic disease | |
HSALNT0289100 | HSALNG0069570 | LINC01230 | linc-DMRT2,lnc-DRMT2,TCONS_00015639 | NA | pathogenic process | cardiometabolic disease | |
HSALNT0249183 | HSALNG0120583 | PCAT18 | LINC01092 | NA | pathogenic process | prostate cancer | |
HSALNT0290029 | HSALNG0142144 | LOC728606 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0288956 | HSALNG0094171 | ENST00000547963.1 | NA | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0289802 | HSALNG0141917 | ENST00000435885 | NA | NA | pathogenic process | oesophageal squamous cell cancer | |
HSALNT0205898 | HSALNG0098920 | LINC01232 | FLJ41590,TCONS_00021520 | NA | pathogenic process | NA | |
HSALNT0257311 | HSALNG0124979 | LINC01233 | XLOC_013014 | NA | pathogenic process | NA | |
HSALNT0183247 | HSALNG0088110 | SENCR | FLI1-AS1 | NA | pathogenic process | vascular SMC phenotype | |
HSALNT0289296 | HSALNG0010286 | LINC00467 | C1orf97,MGC14801 | NA | pathogenic process | neuroblastoma | |
HSALNT0143586 | HSALNG0068435 | CASC21 | LINC01244,CARLo-2 | NA | pathogenic process | NA | |
HSALNT0288906 | HSALNG0068424 | CASC19 | LINC01245,CARLo-6 | NA | pathogenic process | NA | |
HSALNT0289754 | HSALNG0141869 | ENSG00000135253.9 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289755 | HSALNG0141870 | ENSG00000147753.5 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289756 | HSALNG0141871 | ENSG00000196096 | AC079610.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289757 | HSALNG0141872 | ENSG00000197251.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289758 | HSALNG0141873 | ENSG00000203325 | AL445248.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289759 | HSALNG0141874 | ENSG00000206129 | AC006305.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289760 | HSALNG0141875 | ENSG00000215231.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289761 | HSALNG0141876 | ENSG00000215374.4 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289762 | HSALNG0141877 | ENSG00000215808.2 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289763 | HSALNG0141878 | ENSG00000226496.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289764 | HSALNG0141879 | ENSG00000229563.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289765 | HSALNG0141880 | ENSG00000230133.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289766 | HSALNG0141881 | ENSG00000230544.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289767 | HSALNG0141882 | ENSG00000231133.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289768 | HSALNG0141883 | ENSG00000231185 | AC010317.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289769 | HSALNG0141884 | ENSG00000232021.2 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289770 | HSALNG0141885 | ENSG00000232046.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289771 | HSALNG0141886 | ENSG00000232956.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289772 | HSALNG0141887 | ENSG00000233154.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289773 | HSALNG0141888 | ENSG00000233251 | AC007743.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289774 | HSALNG0141889 | ENSG00000235285.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289775 | HSALNG0141890 | ENSG00000237036.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289776 | HSALNG0141891 | ENSG00000237548.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289777 | HSALNG0141892 | ENSG00000240453.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289778 | HSALNG0141893 | ENSG00000241269.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289779 | HSALNG0141894 | ENSG00000245910.3 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289780 | HSALNG0141895 | ENSG00000248176 | AC109349.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289781 | HSALNG0141896 | ENSG00000249364 | AC112206.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289782 | HSALNG0141897 | ENSG00000249772 | AC026427.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289783 | HSALNG0141898 | ENSG00000250195 | AC109927.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289784 | HSALNG0141899 | ENSG00000250608 | AC010210.1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289785 | HSALNG0141900 | ENSG00000254154 | AL359075.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289786 | HSALNG0141901 | ENSG00000255471 | AP001528.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289787 | HSALNG0141902 | ENSG00000256218 | AC007848.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289788 | HSALNG0141903 | ENSG00000259150.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289789 | HSALNG0141904 | ENSG00000259334.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289790 | HSALNG0141905 | ENSG00000259484.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289791 | HSALNG0141906 | ENSG00000259758.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289793 | HSALNG0141908 | ENSG00000263753.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289794 | HSALNG0141909 | ENSG00000264772 | AC016876.2 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289795 | HSALNG0141910 | ENSG00000266952.1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289828 | HSALNG0141943 | FAM66B | FAM66E | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289895 | HSALNG0142010 | LINC00336 | C6orf227,NCRNA00336 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289899 | HSALNG0142014 | LINC00929 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289906 | HSALNG0142021 | LINC01204 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289912 | HSALNG0142027 | LINC01538 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289915 | HSALNG0142030 | LINC01721 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289916 | HSALNG0142031 | LINC01762 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289917 | HSALNG0142032 | LINC01798 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0290247 | HSALNG0142362 | SMIM2-IT1 | C13orf44-IT1 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0290316 | HSALNG0142431 | TTTY7 | CLONE795723,LINC00129,NCRNA00129A,TTTY7B,TTY7,TTTY7 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289872 | HSALNG0141987 | HTTAS_v1 | NA | transcriptional regulation | pathogenic process | Huntington disease | |
HSALNT0290175 | HSALNG0142290 | RNA-a | NA | transcriptional regulation | pathogenic process | Opitz-Kaveggia syndrome | |
HSALNT0289525 | HSALNG0141640 | 116HG | NA | transcriptional regulation | pathogenic process | Prader-Willi syndrome | |
HSALNT0290320 | HSALNG0142435 | U1 spliceosomal lncRNA | NA | NA | pathogenic process | Parkinson's disease | |
HSALNT0289102 | HSALNG0039360 | LINC01262 | TCONS_l2_00021807,RP11-462G22.1 | ceRNA | pathogenic process | Parkinson's disease | |
HSALNT0289681 | HSALNG0141796 | CCAT1-L | NA | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0290062 | HSALNG0142177 | MT-LIPCAR | uc022bqs.1,LIPCAR | NA | pathogenic process | heart disease | |
HSALNT0289941 | HSALNG0142056 | LIPCAR | NA | NA | pathogenic process | heart failure | |
HSALNT0200965 | HSALNG0096756 | TUSC8 | LINC01071,XLOC_010588 | NA | pathogenic process | cervical cancer | |
HSALNT0161787 | HSALNG0077519 | LINC01264 | RP11-124O11.2 | NA | pathogenic process | breast cancer | |
HSALNT0289733 | HSALNG0141848 | D4Z4 | NA | NA | pathogenic process;developmental process | facioscapulohumeral muscular dystrophy | |
HSALNT0289678 | HSALNG0141793 | CARL | NA | ceRNA | pathogenic process | myocardial infarction | |
HSALNT0289923 | HSALNG0142038 | linc-CBR1-2 | NA | NA | pathogenic process | lung cancer | |
HSALNT0243354 | HSALNG0117819 | WFDC21P | WAP four-disulfide core domain 21,pseudogene | transcriptional regulation | pathogenic process | DC dysfunction | |
HSALNT0290232 | HSALNG0142347 | RUNX1 | NA | NA | pathogenic process | acute myeloid leukemia | |
HSALNT0290234 | HSALNG0142349 | RUNXOR | NA | NA | pathogenic process | hematopoietic malignancies | |
HSALNT0289979 | HSALNG0142094 | lncRNA-CIR | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0290368 | HSALNG0142483 | VIM2P | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0289879 | HSALNG0141994 | KRAS1P | NA | NA | pathogenic process | cancer | |
HSALNT0290054 | HSALNG0142169 | MINA | NA | NA | pathogenic process | esophageal squamous cell cancer;gastric cancer;lung cancer;hepatocelluar cancer | |
HSALNT0289270 | HSALNG0117279 | TMEM92-AS1 | RP11-893F2.9,lncRNA-508851,TCONS_00025237 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0288900 | HSALNG0054937 | CAHM | LINC00468 | NA | pathogenic process | colorectal cancer | |
HSALNT0289593 | HSALNG0141708 | AK123657 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289659 | HSALNG0141774 | BX648207 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289660 | HSALNG0141775 | BX649059 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289846 | HSALNG0141961 | GAS2L3 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289633 | HSALNG0141748 | BC011663 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289867 | HSALNG0141982 | HIV1230 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290045 | HSALNG0142160 | M14574 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290245 | HSALNG0142360 | SLCO5A1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290326 | HSALNG0142441 | uc.341 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290344 | HSALNG0142459 | uc003iqu | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290346 | HSALNG0142461 | uc003tfx | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289950 | HSALNG0142065 | lnc-AL355149.1-1 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0290001 | HSALNG0142116 | lnc-ZNF674-1 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0286909 | HSALNG0140423 | LINC00632 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289105 | HSALNG0014134 | LINC01317 | NA | NA | NA | NA | |
HSALNT0234804 | HSALNG0113279 | LINC01081 | TCONS_00024764 | transcriptional regulation | pathogenic process | alveolar capillary dysplasia | |
HSALNT0289840 | HSALNG0141955 | FOSB | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289587 | HSALNG0141702 | AK093543 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289732 | HSALNG0141847 | D16366 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289814 | HSALNG0141929 | ENST00000501583 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290273 | HSALNG0142388 | TCONS_00018278 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289907 | HSALNG0142022 | LINC01374 | TCONS_00018278 | NA | pathogenic process | NA | |
HSALNT0231106 | HSALNG0111452 | CASC22 | LINC01373,TCONS_00024290,LincRNA-ENST00000515084 | NA | pathogenic process | breast cancer | |
HSALNT0058246 | HSALNG0027843 | LINC00882 | NA | ceRNA | pathogenic process | airway diseases | |
HSALNT0018288 | HSALNG0008840 | KIAA1614-AS1 | RP11-46A10.4 | ceRNA | pathogenic process | airway smooth muscle (ASM) disease | |
HSALNT0142310 | HSALNG0067913 | LINC00536 | NA | NA | pathogenic process | trichorhinophalangeal syndrome | |
HSALNT0034200 | HSALNG0016063 | LBX2-AS1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0149799 | HSALNG0071679 | ENST00000414223 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290012 | HSALNG0142127 | LOC105374631 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290305 | HSALNG0142420 | TMEM179 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290315 | HSALNG0142430 | TSPAN8 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290334 | HSALNG0142449 | uc001aka.2 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290339 | HSALNG0142454 | uc001vjj.1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290343 | HSALNG0142458 | uc003erl.1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290354 | HSALNG0142469 | uc009wkz.1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0027893 | HSALNG0013204 | MYCNUT | MYCNUN,lncUSMycN | NA | pathogenic process | neuroblastoma | |
HSALNT0273205 | HSALNG0132900 | LINC01436 | AP000688.8 | NA | pathogenic process | Down syndrome | |
HSALNT0266116 | HSALNG0129435 | MIR663AHG | RP3-410C9.1 | NA | pathogenic process | turner syndrome | |
HSALNT0289108 | HSALNG0080498 | LINC01435 | RP11-215N21.1,TCONS_00018040 | NA | pathogenic process | NA | |
HSALNT0289674 | HSALNG0141789 | CADM3-AS1 | NA | NA | pathogenic process | bladder cancer | |
HSALNT0289882 | HSALNG0141997 | KRT19P3 | NA | NA | pathogenic process | bladder cancer | |
HSALNT0290310 | HSALNG0142425 | TNXA | NA | NA | pathogenic process | bladder cancer | |
HSALNT0008750 | HSALNG0004412 | ZRANB2-AS2 | NA | NA | NA | NA | |
HSALNT0289745 | HSALNG0141860 | DMTF1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290059 | HSALNG0142174 | MRUL | NA | transcriptional regulation | pathogenic process | gastric cancer | |
HSALNT0185163 | HSALNG0089050 | FAM66C | NA | NA | NA | NA | |
HSALNT0289476 | HSALNG0132414 | CYYR1-AS1 | NA | NA | NA | NA | |
HSALNT0289535 | HSALNG0141650 | AA174084 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0266298 | HSALNG0129511 | ABALON | INXS | splicing regulation | pathogenic process | renal cell cancer | |
HSALNT0290370 | HSALNG0142485 | VTRNA2-1 | CBL-3,CBL3,MIR886,MIRN886,VTRNA2,hsa-mir-886,hvg-5,nc886,svtRNA2-1a | NA | pathogenic process | gastric cancer | |
HSALNT0289619 | HSALNG0141734 | ASK00420 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0289749 | HSALNG0141864 | EBIC | NA | transcriptional regulation | pathogenic process | cervical cancer | |
HSALNT0290299 | HSALNG0142414 | TI09485 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290300 | HSALNG0142415 | TI10124 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290301 | HSALNG0142416 | TI13831 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290302 | HSALNG0142417 | TI18318 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290303 | HSALNG0142418 | TI21327 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290304 | HSALNG0142419 | TI22687 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0290307 | HSALNG0142422 | TMPOP2 | NA | transcriptional regulation | pathogenic process | cervical cancer | |
HSALNT0289570 | HSALNG0141685 | AK021444 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289601 | HSALNG0141716 | AK307796 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289801 | HSALNG0141916 | ENST00000425785 | SEC63P1 | NA | pathogenic process | colorectal cancer | |
HSALNT0289871 | HSALNG0141986 | HOXB-AS3 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290367 | HSALNG0142482 | URHC | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289085 | HSALNG0098166 | LINC01080 | TCONS_00021856 | NA | pathogenic process | Alzheimer's disease | |
HSALNT0289751 | HSALNG0141866 | EFNA3 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289798 | HSALNG0141913 | ENST00000395084 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289829 | HSALNG0141944 | FAM83A-AS1 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290164 | HSALNG0142279 | RAD1 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289585 | HSALNG0141700 | AK056988 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289638 | HSALNG0141753 | BC017743 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290156 | HSALNG0142271 | PRR26 | C10orf108 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290349 | HSALNG0142464 | uc003yqb.1 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289675 | HSALNG0141790 | CAI2 | NA | NA | pathogenic process | neuroblastoma | |
HSALNT0289673 | HSALNG0141788 | CADM1-AS1 | NA | transcriptional regulation | pathogenic process | renal clear cell cancer | |
HSALNT0290313 | HSALNG0142428 | TSLC1-AS1 | NA | NA | pathogenic process | glioma | |
HSALNT0013359 | HSALNG0006378 | LINC01525 | lnc-MAN1A2-1 | NA | pathogenic process | squamous cell cancer | |
HSALNT0109106 | HSALNG0051540 | LINC01526 | Lnc-FAM46A-1 | NA | pathogenic process | squamous cell cancer | |
HSALNT0162774 | HSALNG0078013 | LINC01468 | lnc-MBL2-4 | NA | pathogenic process | squamous cell cancer | |
HSALNT0289110 | HSALNG0074718 | LINC01503 | lnc-PPP2R4-5 | NA | pathogenic process | tongue squamous cell cancer | |
HSALNT0289968 | HSALNG0142083 | lnc-MBL2-4:3 | NA | NA | pathogenic process | tongue squamous cell cancer | |
HSALNT0289993 | HSALNG0142108 | lnc-STXBP5-1 | NA | NA | pathogenic process | tongue squamous cell cancer | |
HSALNT0289563 | HSALNG0141678 | AF118081 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289597 | HSALNG0141712 | AK124939 | NA | NA | pathogenic process | pulmonary adenocarcinoma | |
HSALNT0290153 | HSALNG0142268 | PRAS | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290249 | HSALNG0142364 | SNAR-A1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289929 | HSALNG0142044 | lincRNA-BC2 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289930 | HSALNG0142045 | lincRNA-BC4 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289931 | HSALNG0142046 | lincRNA-BC5 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289932 | HSALNG0142047 | lincRNA-BC8 | NA | NA | pathogenic process | breast cancer | |
HSALNT0083190 | HSALNG0039551 | LINC01511 | RP11-325I22.2 | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290026 | HSALNG0142141 | LOC440905 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0083190 | HSALNG0039551 | LINC01511 | RP11-325I22.2 | NA | NA | NA | |
HSALNT0289552 | HSALNG0141667 | AC079776.2 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289720 | HSALNG0141835 | CTA-363E6.2 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289901 | HSALNG0142016 | LINC00987 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290185 | HSALNG0142300 | RP11-1C1.7 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290197 | HSALNG0142312 | RP11-445K13.2 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290199 | HSALNG0142314 | RP11-473M20.11 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290213 | HSALNG0142328 | RP11-893F2.6 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290217 | HSALNG0142332 | RP13-514E23.1 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290218 | HSALNG0142333 | RP1-90D4.3 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290220 | HSALNG0142335 | RP4-575N6.5 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290226 | HSALNG0142341 | RP5-826L7.1 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290378 | HSALNG0142493 | XLOC_003286 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290379 | HSALNG0142494 | XLOC_003405 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290389 | HSALNG0142504 | XLOC_012255 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290056 | HSALNG0142171 | MIR21 | NA | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0289621 | HSALNG0141736 | ASncmtRNAs | NA | transcriptional regulation | pathogenic process | cancer | |
HSALNT0289316 | HSALNG0022090 | LINC01614 | LCAL4,TCONS_00003105 | NA | pathogenic process | lung cancer | |
HSALNT0289982 | HSALNG0142097 | lncRNA-FER1L4 | NA | ceRNA | pathogenic process | gastric cancer | |
HSALNT0290016 | HSALNG0142131 | LOC283177 | NA | NA | pathogenic process | diffuse large B-cell lymphoma | |
HSALNT0289003 | HSALNG0134860 | HORMAD2-AS1 | MTMR3-AS1,NONHSAG033653 | NA | pathogenic process | type 1 diabetes;bowel disease | |
HSALNT0290372 | HSALNG0142487 | WNT4 | NA | NA | pathogenic process | endometriosis | |
HSALNT0289540 | HSALNG0141655 | AB074278 | NA | NA | pathogenic process | bladder cancer | |
HSALNT0290166 | HSALNG0142281 | RCCRT1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0289043 | HSALNG0043862 | LINC00491 | BC008363 | NA | pathogenic process | pancreatic ductal adenocarcinoma | |
HSALNT0289632 | HSALNG0141747 | BC008363 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0289858 | HSALNG0141973 | H1.3 | NA | NA | pathogenic process | ovarian cancer | |
HSALNT0289896 | HSALNG0142011 | LINC00582 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289301 | HSALNG0141635 | LINC01537 | RP11-169D4.1-001 | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0289551 | HSALNG0141666 | AC026166.2 | MTCO1P5 | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0290184 | HSALNG0142299 | RP11-169D4.1-001 | NA | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0289545 | HSALNG0141660 | AC006050.3 | NA | NA | pathogenic process | lung squamous cell cancer | |
HSALNT0289556 | HSALNG0141671 | AC138128.1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289818 | HSALNG0141933 | ERCC1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290061 | HSALNG0142176 | MT1DP | MT1DP | NA | pathogenic process | liver cancer | |
HSALNT0289578 | HSALNG0141693 | AK023096 | NA | NA | pathogenic process | Wilmsâ tumor;uterine leiomyomas | |
HSALNT0289112 | HSALNG0003560 | LINC01562 | RP11-296A18.3 | transcriptional regulation | pathogenic process | intervertebral disc degeneration | |
HSALNT0289567 | HSALNG0141682 | AK000974 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289579 | HSALNG0141694 | AK024118 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289645 | HSALNG0141760 | BC040204 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290321 | HSALNG0142436 | U79277 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289869 | HSALNG0141984 | HOST2 | NA | ceRNA | pathogenic process | epithelial ovarian cancer | |
HSALNT0289368 | HSALNG0135509 | MGAT3-AS1 | TapSAKI | NA | pathogenic process | acute kidney injury | |
HSALNT0289624 | HSALNG0141739 | ATXN7L3B | NA | NA | pathogenic process | spinocerebellar ataxia | |
HSALNT0289990 | HSALNG0142105 | lnc-SCA7 | NA | ceRNA | pathogenic process | spinocerebellar ataxia | |
HSALNT0290004 | HSALNG0142119 | LOC100287482 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290383 | HSALNG0142498 | XLOC_007697 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290384 | HSALNG0142499 | XLOC_008559 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290385 | HSALNG0142500 | XLOC_009911 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0289813 | HSALNG0141928 | ENST00000480739 | RPL13AP23 | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290111 | HSALNG0142226 | OS9 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0290324 | HSALNG0142439 | uc.283-plus | NA | NA | pathogenic process | glioma | |
HSALNT0289117 | HSALNG0051652 | LINC01611 | RP1-90L14.1,TCONS_l2_00025430 | NA | pathogenic process | diabetic retinopathy | |
HSALNT0289529 | HSALNG0141644 | 2900055J20Rik | 2900055J20Rik | NA | pathogenic process | left ventricular hypertrophy | |
HSALNT0289792 | HSALNG0141907 | ENSG00000261777 | AC012184.3 | NA | pathogenic process | prostate cancer | |
HSALNT0289618 | HSALNG0141733 | Asb3 | NA | NA | pathogenic process | cardiovascular and renal disease | |
HSALNT0289703 | HSALNG0141818 | Chac2 | NA | NA | pathogenic process | cardiovascular and renal disease | |
HSALNT0290139 | HSALNG0142254 | Pex11b | NA | NA | pathogenic process | cardiovascular and renal disease | |
HSALNT0290255 | HSALNG0142370 | Sp5 | NA | NA | pathogenic process | cardiovascular and renal disease | |
HSALNT0211639 | HSALNG0101614 | PSMA3-AS1 | FLJ31306 | NA | pathogenic process | NA | |
HSALNT0289319 | HSALNG0141639 | LINC00493 | LOC388789 | NA | pathogenic process | NA | |
HSALNT0288903 | HSALNG0126842 | CARD8-AS1 | LOC100505812 | transcriptional regulation | pathogenic process | leukemia and neuroblastoma | |
HSALNT0064729 | HSALNG0030929 | KCNMB2-AS1 | RP11-385J1.2 | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289548 | HSALNG0141663 | AC013264.2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289857 | HSALNG0141972 | GUCY1B2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290190 | HSALNG0142305 | RP11-385J1.2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290216 | HSALNG0142331 | RP1-317E23.3 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290317 | HSALNG0142432 | TUBA4B | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290375 | HSALNG0142490 | XLOC_000371 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290397 | HSALNG0142512 | Z82214.3 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289735 | HSALNG0141850 | DALIR | DALI | transcriptional regulation | NA | NA | |
HSALNT0290376 | HSALNG0142491 | XLOC_000620 | NA | NA | pathogenic process | H. pylori-related diseases | |
HSALNT0290380 | HSALNG0142495 | XLOC_004122 | NA | NA | pathogenic process | H. pylori-related diseases | |
HSALNT0290381 | HSALNG0142496 | XLOC_004562 | NA | NA | pathogenic process | H. pylori-related diseases | |
HSALNT0290382 | HSALNG0142497 | XLOC_005912 | NA | NA | pathogenic process | H. pylori-related diseases | |
HSALNT0290391 | HSALNG0142506 | XLOC_014388 | NA | NA | pathogenic process | H. pylori-related diseases | |
HSALNT0290028 | HSALNG0142143 | LOC652276 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290162 | HSALNG0142277 | R05532 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0098175 | HSALNG0046752 | LINC01411 | RP11-267A15.1 | NA | pathogenic process | prostate cancer | |
HSALNT0290025 | HSALNG0142140 | LOC401317 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289726 | HSALNG0141841 | CTD-2574D22.4 | AC120114.2 | NA | pathogenic process | osteoarthritis | |
HSALNT0290141 | HSALNG0142256 | PMS2L2 | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0289974 | HSALNG0142089 | lncRNA-422 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289520 | HSALNG0133454 | AATBC | NA | NA | pathogenic process | bladder cancer | |
HSALNT0289311 | HSALNG0141637 | LINC00974 | NA | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0089943 | HSALNG0042820 | ZBED3-AS1 | NA | NA | developmental process | NA | |
HSALNT0289116 | HSALNG0135958 | LINC01589 | CTA-941F9.9,TCONS_00029353 | NA | pathogenic process | NA | |
HSALNT0289910 | HSALNG0142025 | LINC01426 | NA | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0290341 | HSALNG0142456 | uc002yug.2 | NA | splicing regulation | pathogenic process | esophageal squamous cell cancer | |
HSALNT0290250 | HSALNG0142365 | SNCG | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289949 | HSALNG0142064 | lnc-AF085935 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289996 | HSALNG0142111 | lnc-uc003wbd | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289559 | HSALNG0141674 | AF085935 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290347 | HSALNG0142462 | uc003wbd | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290098 | HSALNG0142213 | NR_001284 | TNXA | NA | pathogenic process | chronic thromboembolic pulmonary hypertension | |
HSALNT0290327 | HSALNG0142442 | uc.343 | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0289196 | HSALNG0094525 | NRAV | DYNLL1-AS1 | transcriptional regulation | pathogenic process | influenza A virus | |
HSALNT0290140 | HSALNG0142255 | PLEC | NA | NA | pathogenic process | chronic obstructive pulmonary disease | |
HSALNT0290172 | HSALNG0142287 | UCSC-2000-3182 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | |
HSALNT0290173 | HSALNG0142288 | UCSC-9199-1005 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | |
HSALNT0290174 | HSALNG0142289 | CombinedLit_316_550 | NA | NA | pathogenic process | chronic obstructive pulmonary disease | |
HSALNT0289714 | HSALNG0141829 | CR613944 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289933 | HSALNG0142048 | lincRNA-CALCA | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290200 | HSALNG0142315 | RP11-501G6.1 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290208 | HSALNG0142323 | RP11-672F9.1 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290405 | HSALNG0142520 | C14orf132 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289937 | HSALNG0142052 | lincRNA-TSPAN8 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290225 | HSALNG0142340 | RP5-1014O16.1 | AC244098.1 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290275 | HSALNG0142390 | TCONS_00026102 | NA | NA | pathogenic process | atrial fibrillation | |
HSALNT0290277 | HSALNG0142392 | TCONS_00032546 | NA | NA | pathogenic process | atrial fibrillation | |
HSALNT0289037 | HSALNG0096978 | LINC00441 | RB1-DT,ncRNA-RB1 | NA | pathogenic process | NA | |
HSALNT0289661 | HSALNG0141776 | C1401f132 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289141 | HSALNG0039030 | LINC02365 | LVCAT8 | NA | pathogenic process | NA | |
HSALNT0288885 | HSALNG0095161 | ADGRD1-AS1 | LACAT8 | NA | NA | NA | |
HSALNT0289142 | HSALNG0034152 | LINC02475 | LVCAT1 | NA | NA | NA | |
HSALNT0289542 | HSALNG0141657 | Abhd11os | NA | NA | pathogenic process | neurodegenerative diseases | |
HSALNT0288895 | HSALNG0124521 | BISPR | NA | NA | pathogenic process | virus infection | |
HSALNT0233975 | HSALNG0112910 | MAFTRR | linc-MAF-4 | transcriptional regulation | NA | NA | |
HSALNT0290058 | HSALNG0142173 | MRAK052686 | NA | NA | pathogenic process | nonalcoholic fatty liver disease | |
HSALNT0290221 | HSALNG0142336 | RP4-583P15.10 | AL121845.1 | NA | pathogenic process | breast cancer | |
HSALNT0211341 | HSALNG0101470 | KTN1-AS1 | C14orf33,MYCLo-3 | NA | pathogenic process | colorectal cancer | |
HSALNT0266752 | HSALNG0129835 | DLGAP4-AS1 | CCAT7 | NA | pathogenic process | colorectal cancer | |
HSALNT0289682 | HSALNG0141797 | CCAT3 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289684 | HSALNG0141799 | CCAT8 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289898 | HSALNG0142013 | LINC00659 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289683 | HSALNG0141798 | CCAT7 | NA | NA | pathogenic process | NA | |
HSALNT0289627 | HSALNG0141742 | BALR-2 | NA | NA | pathogenic process | B cell acute lymphoblastic leukemia | |
HSALNT0289948 | HSALNG0142063 | lnc-ACACA-1 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289953 | HSALNG0142068 | lnc-BMP2-2 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289955 | HSALNG0142070 | lnc-CPN2-1 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289958 | HSALNG0142073 | lnc-FOXG1-2 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289960 | HSALNG0142075 | lnc-FZD1-2 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289962 | HSALNG0142077 | lnc-ITPR2-3 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289965 | HSALNG0142080 | lnc-LCP2-2 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289988 | HSALNG0142103 | lnc-RP3-368B9 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289991 | HSALNG0142106 | lnc-SLC30A4-1 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289992 | HSALNG0142107 | lnc-SPAM1-6 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289995 | HSALNG0142110 | lnc-TTC34-3 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0222064 | HSALNG0106856 | DRAIC | NA | NA | pathogenic process | prostate cancer;glioma;cancer;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | |
HSALNT0005037 | HSALNG0002618 | LINC01137 | LOC728431 | NA | pathogenic process | NA | |
HSALNT0290390 | HSALNG0142505 | XLOC_014172 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290014 | HSALNG0142129 | LOC149086 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290183 | HSALNG0142298 | RP11-160H22.5 | AL121983.2 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289945 | HSALNG0142060 | LNC00964-3 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289616 | HSALNG0141731 | Arid2-IR | NA | NA | pathogenic process | renal inflammation | |
HSALNT0289716 | HSALNG0141831 | CR619813 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289739 | HSALNG0141854 | DDX6P1 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289938 | HSALNG0142053 | lincRNA-ZNF532 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0290011 | HSALNG0142126 | LOC105372753 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0290013 | HSALNG0142128 | LOC105377769 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0290205 | HSALNG0142320 | RP11-58D2.1 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0288946 | HSALNG0105101 | ENST00000434223 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0288947 | HSALNG0082178 | ENST00000442037 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0288953 | HSALNG0088449 | ENST00000540136 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290103 | HSALNG0142218 | NR_038125 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290136 | HSALNG0142251 | PDLIM3 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290335 | HSALNG0142450 | uc001gch.1 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290336 | HSALNG0142451 | uc001gzl.3 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290351 | HSALNG0142466 | uc004bbl.1 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290369 | HSALNG0142484 | VNN2 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289577 | HSALNG0141692 | AK022798 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289663 | HSALNG0141778 | C1orf74 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289602 | HSALNG0141717 | AKR7L | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289711 | HSALNG0141826 | COL3A1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289878 | HSALNG0141993 | KCNE2 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289636 | HSALNG0141751 | BC015134 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289713 | HSALNG0141828 | CR594506 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289928 | HSALNG0142043 | lincRNA-BBOX1-2 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0271719 | HSALNG0132223 | LINC00320 | PRED14,FLJ37539 | NA | pathogenic process;developmental process | cortical white matter | |
HSALNT0289823 | HSALNG0141938 | EVADR | NA | NA | pathogenic process | pancreatic cancer;lung cancer;colorectal cancer;rectal cancer | |
HSALNT0289944 | HSALNG0142059 | Lnc_bc060912 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289952 | HSALNG0142067 | lnc-bc060912 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289613 | HSALNG0141728 | APF | NA | ceRNA | pathogenic process | myocardial infarction | |
HSALNT0289617 | HSALNG0141732 | AS Uchl1 | NA | NA | pathogenic process | Parkinson's disease | |
HSALNT0289104 | HSALNG0099739 | LINC01296 | FLJ39632 | NA | pathogenic process | colorectal cancer | |
HSALNT0290403 | HSALNG0142518 | ZXF2 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290113 | HSALNG0142228 | P14695 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290114 | HSALNG0142229 | P16984 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290115 | HSALNG0142230 | P19780 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290116 | HSALNG0142231 | P23099 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290117 | HSALNG0142232 | P24363 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290118 | HSALNG0142233 | P28210 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290120 | HSALNG0142235 | P33863 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290121 | HSALNG0142236 | P4091 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290122 | HSALNG0142237 | P6391 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290123 | HSALNG0142238 | P6488 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290124 | HSALNG0142239 | P700 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290125 | HSALNG0142240 | P8611 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290126 | HSALNG0142241 | P8725 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290127 | HSALNG0142242 | P8860 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290128 | HSALNG0142243 | P9745 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289269 | HSALNG0044864 | TH2LCRR | TH2-LCR | transcriptional regulation | pathogenic process | allergic asthma | |
HSALNT0289964 | HSALNG0142079 | lnc-LCE5A-1 | NA | NA | pathogenic process | laryngeal cancer;head and neck squamous cell cancer | |
HSALNT0055198 | HSALNG0026441 | FAM3D-AS1 | lnc-KCTD6-3 | NA | pathogenic process | tongue cancer;pharyngeal cancer;head and neck squamous cell cancer;laryngeal cancer | |
HSALNT0289843 | HSALNG0141958 | FRLnc1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0242005 | HSALNG0117109 | ENST00000575202 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0288952 | HSALNG0089220 | ENST00000539009 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0288954 | HSALNG0089242 | ENST00000544591 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289752 | HSALNG0141867 | EHHADH-AS1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289812 | HSALNG0141927 | ENST00000468960 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290276 | HSALNG0142391 | TCONS_00026506 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0189952 | HSALNG0091595 | LRP1-AS | NA | transcriptional regulation | pathogenic process | Alzheimer's disease | |
HSALNT0032045 | HSALNG0015125 | LINC01122 | FLJ30838,AC007092.1 | NA | NA | NA | |
HSALNT0289565 | HSALNG0141680 | AI364715 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289921 | HSALNG0142036 | LINC0949 | NA | NA | pathogenic process | systemic lupus erythematosus | |
HSALNT0289680 | HSALNG0141795 | CCAL | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289079 | HSALNG0077354 | LINC00993 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289811 | HSALNG0141926 | ENST00000460164 | NA | NA | pathogenic process | triple-negative breast cancer | |
HSALNT0290282 | HSALNG0142397 | TCONS_l2_00003938 | NA | NA | pathogenic process | triple-negative breast cancer | |
HSALNT0289888 | HSALNG0142003 | LGALS3 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289963 | HSALNG0142078 | lnc-KCMF1-2:1 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289967 | HSALNG0142082 | lnc-LLPH-2:1 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289971 | HSALNG0142086 | lnc-PLA2R1-1:1 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289972 | HSALNG0142087 | lnc-PSD4-1:14 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290066 | HSALNG0142181 | n335550 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290070 | HSALNG0142185 | n340790 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290072 | HSALNG0142187 | n386477 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290286 | HSALNG0142401 | TCONS_l2_00010365 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0288944 | HSALNG0129184 | ENST00000422494 | NA | NA | NA | NA | |
HSALNT0289118 | HSALNG0038513 | LINC01612 | RP11-789C1.1,TCONS_00008319 | NA | pathogenic process | gastric cancer | |
HSALNT0289610 | HSALNG0141725 | AP001439.2 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289671 | HSALNG0141786 | CACNAICAS3 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289853 | HSALNG0141968 | GS1-5L10.1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289875 | HSALNG0141990 | INTS7 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290065 | HSALNG0142180 | MYLK-AS1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290157 | HSALNG0142272 | PRSS21 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290202 | HSALNG0142317 | RP11-528G1.2 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290207 | HSALNG0142322 | RP11-643M14.1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290209 | HSALNG0142324 | RP11-789C1.1 | LINC01612 | NA | pathogenic process | gastric cancer | |
HSALNT0290314 | HSALNG0142429 | TSNAX-DISC1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290386 | HSALNG0142501 | XLOC_010235 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289558 | HSALNG0141673 | AF075041 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289564 | HSALNG0141679 | AF339813 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289575 | HSALNG0141690 | AK022029 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289576 | HSALNG0141691 | AK022159 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289604 | HSALNG0141719 | AL389956 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0289640 | HSALNG0141755 | BC023629 | NA | NA | pathogenic process | pancreatic cancer | |
HSALNT0290096 | HSALNG0142211 | NONHSAT125629 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290393 | HSALNG0142508 | XR_250621.1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0288951 | HSALNG0033002 | ENST00000503938 | NA | NA | pathogenic process | triple-negative breast cancer | |
HSALNT0290085 | HSALNG0142200 | NONHSAT012762 | NA | NA | pathogenic process | triple-negative breast cancer | |
HSALNT0289151 | HSALNG0023952 | LMCD1-AS1 | NA | NA | pathogenic process | acute kidney injury | |
HSALNT0289926 | HSALNG0142041 | linc-PXN-1 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290281 | HSALNG0142396 | TCONS_l2_00001418 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290285 | HSALNG0142400 | TCONS_l2_00008237 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290287 | HSALNG0142402 | TCONS_l2_00011130 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290288 | HSALNG0142403 | TCONS_l2_00013175 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290294 | HSALNG0142409 | TCONS_l2_00022611 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290295 | HSALNG0142410 | TCONS_l2_00022670 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290352 | HSALNG0142467 | uc004bdv.3 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290363 | HSALNG0142478 | ULK4P2 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289942 | HSALNG0142057 | LK4P2 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289538 | HSALNG0141653 | AB019562 | NA | NA | pathogenic process | hypopharyngeal squamous cell cancer | |
HSALNT0091661 | HSALNG0043585 | ENST00000503710 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289806 | HSALNG0141921 | ENST00000445734 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289807 | HSALNG0141922 | ENST00000448093 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289815 | HSALNG0141930 | ENST00000502941 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290340 | HSALNG0142455 | uc002nbr.3 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290348 | HSALNG0142463 | uc003xut. | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290356 | HSALNG0142471 | uc021re1.1 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289549 | HSALNG0141664 | AC016745.3 | AC016745.1 | NA | pathogenic process | glioma | |
HSALNT0290180 | HSALNG0142295 | RP11-128A17.1 | AC078909.1 | NA | pathogenic process | glioma | |
HSALNT0290377 | HSALNG0142492 | XLOC_001711 | NA | NA | pathogenic process | glioma | |
HSALNT0289975 | HSALNG0142090 | lncRNA-AK058003 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289061 | HSALNG0034072 | LINC00682 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289305 | HSALNG0089456 | LINC01559 | FLJ33810 | NA | pathogenic process | Huntington disease | |
HSALNT0289854 | HSALNG0141969 | GSTT1-AS1 | NA | transcriptional regulation | pathogenic process | mycobacterium tuberculosis infection | |
HSALNT0289978 | HSALNG0142093 | lncRNA-CD244 | NA | transcriptional regulation | pathogenic process | tuberculosis infection | |
HSALNT0289237 | HSALNG0068014 | SAMD12-AS1 | NA | NA | pathogenic process | neuroblastoma | |
HSALNT0290179 | HSALNG0142294 | RP11-119F7.4 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290278 | HSALNG0142393 | TCONS_00068220 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0285573 | HSALNG0139654 | DANT1 | NA | transcriptional regulation | NA | NA | |
HSALNT0288926 | HSALNG0139662 | DANT2 | NA | transcriptional regulation | NA | NA | |
HSALNT0290399 | HSALNG0142514 | ZMAT1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289554 | HSALNG0141669 | AC100865.1 | NA | NA | pathogenic process | coronary artery disease | |
HSALNT0289228 | HSALNG0105273 | RAD51-AS1 | TODRA | transcriptional regulation | pathogenic process | breast cancer | |
HSALNT0289743 | HSALNG0141858 | DKFZP434K028 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289630 | HSALNG0141745 | BC002811 | NA | NA | pathogenic process | astrocytoma | |
HSALNT0290387 | HSALNG0142502 | XLOC_010967 | NA | NA | pathogenic process | astrocytoma | |
HSALNT0288955 | HSALNG0084672 | ENST00000545440 | NA | NA | pathogenic process | pediatric acute myeloid leukemia | |
HSALNT0288981 | HSALNG0133391 | FRGCA | LncRNA-AP001631.9 | NA | pathogenic process | gastric cancer | |
HSALNT0289611 | HSALNG0141726 | AP001631.9 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289976 | HSALNG0142091 | LncRNA-AP001631.9 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289686 | HSALNG0141801 | CD99P1 | NA | ceRNA | pathogenic process | idiopathic pulmonary fibrosis | |
HSALNT0289119 | HSALNG0074097 | LINC01613 | n341773 | NA | pathogenic process | idiopathic pulmonary fibrosis | |
HSALNT0289844 | HSALNG0141959 | FTH1P3 | FTH1P3 | NA | pathogenic process | oral squamous cell cancer | |
HSALNT0289855 | HSALNG0141970 | GTF2IRD2P1 | GTF2IRD2P1 | NA | pathogenic process | oral squamous cell cancer | |
HSALNT0290135 | HSALNG0142250 | PDIA3F | NA | NA | pathogenic process | oral squamous cell cancer | |
HSALNT0289329 | HSALNG0026562 | LINC00994 | NA | NA | pathogenic process | inflammatory bowel disease | |
HSALNT0289208 | HSALNG0077290 | PCAT5 | LINC01452,TPCAT-10-36067 | NA | pathogenic process | prostate cancer | |
HSALNT0114870 | HSALNG0054158 | LUADT1 | NA | transcriptional regulation | pathogenic process | lung adenocarcinoma | |
HSALNT0289154 | HSALNG0107133 | LOXL1-AS1 | NA | NA | pathogenic process | exfoliation syndrome | |
HSALNT0289734 | HSALNG0141849 | DACOR1 | TCONS_00023265 | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0289060 | HSALNG0114548 | LINC00675 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0288889 | HSALNG0070759 | B4GALT1-AS1 | NA | transcriptional regulation | pathogenic process | NA | |
HSALNT0289348 | HSALNG0083371 | LINC01616 | n341006 | NA | pathogenic process | Alzheimer's disease | |
HSALNT0290068 | HSALNG0142183 | n336934 | NA | NA | pathogenic process | Alzheimer's disease | |
HSALNT0290240 | HSALNG0142355 | SIRT1-AS | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290198 | HSALNG0142313 | RP11-457M11.2 | NA | ceRNA | pathogenic process | lung adenocarcinoma | |
HSALNT0150768 | HSALNG0072141 | LINC01507 | XLOC_000303 | NA | pathogenic process | colorectal cancer | |
HSALNT0289903 | HSALNG0142018 | LINC01057 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289914 | HSALNG0142029 | LINC01617 | C8orf23,NCRNA00249,XLOC_006844 | NA | pathogenic process | colorectal cancer | |
HSALNT0290015 | HSALNG0142130 | LOC152578 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0072252 | HSALNG0034426 | LINC01618 | LOC152578 | NA | pathogenic process | NA | |
HSALNT0156870 | HSALNG0075266 | NALT1 | MIR4674HG,LINC01573,TCONS_l2_00029132 | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0289083 | HSALNG0045290 | MALINC1 | LINC01024,MA-linc1 | NA | pathogenic process | human breast and lung cancer | |
HSALNT0289902 | HSALNG0142017 | LINC01024 | MA-linc1 | NA | pathogenic process | osteosarcoma;lung cancer | |
HSALNT0289120 | HSALNG0071043 | LINC01627 | RP11-397D12.4 | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289121 | HSALNG0015617 | LINC01628 | AC007403.1 | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289820 | HSALNG0141935 | ERICH1-AS1 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290193 | HSALNG0142308 | RP11-397D12.4 | LINC01627 | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289122 | HSALNG0102605 | LINC01629 | linc-KIAA1737-2 | transcriptional regulation | pathogenic process | hypoxic and inflammatory renal epithelial injury | |
HSALNT0290161 | HSALNG0142276 | PTPRG-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289980 | HSALNG0142095 | lncRNA-DLEU1 | NA | ceRNA | pathogenic process | breast cancer | |
HSALNT0289983 | HSALNG0142098 | lncRNA-Hh | NA | NA | pathogenic process | breast cancer | |
HSALNT0288986 | HSALNG0072437 | GAS1RR | LncRNA-Hh | NA | pathogenic process | breast cancer | |
HSALNT0288908 | HSALNG0005250 | CCDC18-AS1 | ENST00000440778.1 | NA | pathogenic process | adolescent idiopathic scoliosis | |
HSALNT0289055 | HSALNG0132813 | LINC00649 | TCONS_00028768 | NA | pathogenic process | adolescent idiopathic scoliosis | |
HSALNT0289219 | HSALNG0075966 | PRKCQ-AS1 | ENST00000414894.1 | NA | pathogenic process | adolescent idiopathic scoliosis | |
HSALNT0290203 | HSALNG0142318 | RP11-567G11.1 | LINC02041 | NA | pathogenic process | pancreatic cancer | |
HSALNT0289805 | HSALNG0141920 | ENST00000438550 | RPS24P1 | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0290083 | HSALNG0142198 | NONHSAG011351 | NA | NA | pathogenic process | type 1 diabetes | |
HSALNT0290049 | HSALNG0142164 | MCHR2-AS1 | NA | NA | pathogenic process | psychiatric disease | |
HSALNT0289799 | HSALNG0141914 | ENST00000414355 | NA | NA | pathogenic process | cadmium toxicology | |
HSALNT0290241 | HSALNG0142356 | SKP2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289837 | HSALNG0141952 | FLJ90757 | NA | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0290017 | HSALNG0142132 | LOC283663 | NA | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0290019 | HSALNG0142134 | LOC338651 | NA | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0290132 | HSALNG0142247 | PCATs | NA | NA | pathogenic process | prostate cancer | |
HSALNT0086786 | HSALNG0041277 | EGFLAM-AS1 | lncRNA-LOWEG | NA | pathogenic process | gastric cancer | |
HSALNT0290031 | HSALNG0142146 | LOWEG | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289635 | HSALNG0141750 | BC014579 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289721 | HSALNG0141836 | CTB-167B5.2 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289863 | HSALNG0141978 | HELLS | NA | NA | pathogenic process | leukemia | |
HSALNT0290195 | HSALNG0142310 | RP11-401P9.4 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290252 | HSALNG0142367 | SNHG19 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289557 | HSALNG0141672 | AF070632 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289569 | HSALNG0141684 | AK021443 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289728 | HSALNG0141843 | CTD-3080P12.3 | NA | ceRNA | pathogenic process | gastric cancer | |
HSALNT0289987 | HSALNG0142102 | lncRNA-n336928 | NA | NA | pathogenic process | bladder cancer | |
HSALNT0289723 | HSALNG0141838 | CTC-523E23.5 | AC008555.2 | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0289724 | HSALNG0141839 | CTD-2246P4.1 | NA | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0290055 | HSALNG0142170 | MIR132 | MIRN132,miRNA132,mir-132 | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0290189 | HSALNG0142304 | RP11-363G2.4 | NA | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0290191 | HSALNG0142306 | RP11-38F22.1 | LINC02424 | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0290223 | HSALNG0142338 | RP4-639J15.1 | AC006967.2 | NA | pathogenic process | intervertebral disc degeneration | |
HSALNT0290233 | HSALNG0142348 | RUNX1-IT1 | C21orf96 | NA | pathogenic process | gastric cancer | |
HSALNT0288943 | HSALNG0053446 | ENST00000415964 | NA | NA | pathogenic process | pediatric acute myeloid leukemia | |
HSALNT0290009 | HSALNG0142124 | LOC101927497 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289956 | HSALNG0142071 | lnc-CYP4A22-2/3 | NA | NA | pathogenic process | clear cell renal cell cancer | |
HSALNT0289999 | HSALNG0142114 | lnc-ZNF180-2 | NA | NA | pathogenic process | renal clear cell cancer | |
HSALNT0290086 | HSALNG0142201 | NONHSAT037832 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289658 | HSALNG0141773 | BX647187 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0288920 | HSALNG0017086 | CNNM3-DT | LOC100506036 | NA | NA | NA | |
HSALNT0289584 | HSALNG0141699 | AK056155 | NA | NA | pathogenic process | Loeys-Dietz syndrome | |
HSALNT0290057 | HSALNG0142172 | MR1 | NA | NA | pathogenic process | Loeys-Dietz syndrome | |
HSALNT0289543 | HSALNG0141658 | AC002454.1 | AC002454.1 | NA | pathogenic process | endometriosis | |
HSALNT0289909 | HSALNG0142024 | LINC01420 | NA | NA | pathogenic process | systemic lupus erythematosus | |
HSALNT0289531 | HSALNG0141646 | 53BP1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290101 | HSALNG0142216 | NR_024118 | NA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0290239 | HSALNG0142354 | SGO1-AS1 | SGOL1-AS1 | NA | pathogenic process | lung cancer | |
HSALNT0289293 | HSALNG0127764 | ZNF667-AS1 | MORT | NA | pathogenic process | breast cancer | |
HSALNT0289984 | HSALNG0142099 | lncRNA-HIF2PUT | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0288945 | HSALNG0018617 | ENST00000433673 | AC068282.1 | NA | pathogenic process | polycystic ovary syndrome | |
HSALNT0288948 | HSALNG0008353 | ENST00000454271 | AL021940.1 | NA | pathogenic process | polycystic ovary syndrome | |
HSALNT0289495 | HSALNG0141606 | ENST00000432431 | AC023128.1 | NA | pathogenic process | polycystic ovary syndrome | |
HSALNT0289918 | HSALNG0142033 | LINC01828 | NA | NA | pathogenic process | polycystic ovary syndrome | |
HSALNT0290388 | HSALNG0142503 | XLOC_011402 | NA | NA | pathogenic process | polycystic ovary syndrome | |
HSALNT0289873 | HSALNG0141988 | ICAM-1 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289668 | HSALNG0141783 | C5T1lncRNA | NA | transcriptional regulation | pathogenic process | rheumatoid arthritis | |
HSALNT0289667 | HSALNG0141782 | C5T1 | NA | NA | pathogenic process | NA | |
HSALNT0289666 | HSALNG0141781 | C5-OT1 | C5T1lncRNA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289626 | HSALNG0141741 | AX800134 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290338 | HSALNG0142453 | uc001ncr | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290330 | HSALNG0142445 | uc.48+ | NA | NA | pathogenic process | diabetic neuropathic pain | |
HSALNT0289098 | HSALNG0038313 | LINC01207 | NA | transcriptional regulation | pathogenic process | lung adenocarcinoma | |
HSALNT0289628 | HSALNG0141743 | BALR-6 | NA | transcriptional regulation | pathogenic process | B-lymphoblastic leukemia | |
HSALNT0290022 | HSALNG0142137 | LOC389641 | NA | NA | pathogenic process | Pancreatic ductal adenocarcinoma | |
HSALNT0289725 | HSALNG0141840 | CTD-2541M15 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289940 | HSALNG0142055 | LINK-A | NA | NA | pathogenic process | triple-negative breast cancer | |
HSALNT0290107 | HSALNG0142222 | NUTF2P3 | NUTF2P3 | NA | pathogenic process | pancreatic cancer | |
HSALNT0290095 | HSALNG0142210 | NONHSAT123350 | NA | NA | pathogenic process | renal clear cell cancer | |
HSALNT0290362 | HSALNG0142477 | UHRF1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290366 | HSALNG0142481 | UPAT | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289307 | HSALNG0114404 | LINC00324 | FLJ34790,MGC104931 | NA | pathogenic process | NA | |
HSALNT0289969 | HSALNG0142084 | lnc-MX1-1 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0290024 | HSALNG0142139 | LOC400891 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0289883 | HSALNG0141998 | LA16c-313D11.11 | NA | ceRNA | pathogenic process | endometrial cancer | |
HSALNT0290192 | HSALNG0142307 | RP11-395G23.3 | AC027031.2 | NA | pathogenic process | endometrial cancer | |
HSALNT0289742 | HSALNG0141857 | DILC | NA | transcriptional regulation | pathogenic process | liver cancer | |
HSALNT0289957 | HSALNG0142072 | lnc-DILC | NA | transcriptional regulation | pathogenic process | liver cancer | |
HSALNT0289581 | HSALNG0141696 | AK027294 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290371 | HSALNG0142486 | WISP1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0206117 | HSALNG0099020 | FGF14-AS2 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290131 | HSALNG0142246 | PCAT2 | CARLo-4,PCA2,TCONS_00015167 | NA | pathogenic process | prostate cancer | |
HSALNT0289528 | HSALNG0141643 | 2700086A05Rik | 2700086A05Rik | NA | pathogenic process | idiopathic pulmonary fibrosis | |
HSALNT0290251 | HSALNG0142366 | SNED1 | NA | NA | pathogenic process | Idiopathic pulmonary fibrosis | |
HSALNT0290333 | HSALNG0142448 | uc.77 | NA | NA | pathogenic process | idiopathic pulmonary fibrosis | |
HSALNT0289816 | HSALNG0141931 | ENST00000537266 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289860 | HSALNG0141975 | HAGLROS | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289881 | HSALNG0141996 | KRT18P55 | KRT18P55 | NA | pathogenic process | gastric cancer | |
HSALNT0229266 | HSALNG0110450 | IL21R-AS1 | NA | NA | pathogenic process | coronary artery disease | |
HSALNT0290112 | HSALNG0142227 | OTTHUMT00000387022 | NA | NA | pathogenic process | coronary artery disease | |
HSALNT0000551 | HSALNG0000226 | PRKCZ-AS1 | RP11-181G12.2 | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0030981 | HSALNG0014612 | LINC01833 | RP11-89,K21.1 | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0290214 | HSALNG0142329 | RP11-89K21 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0165271 | HSALNG0079188 | LINC00857 | NA | NA | pathogenic process | lung cancer | |
HSALNT0290109 | HSALNG0142224 | OR3A4 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290046 | HSALNG0142161 | MAGI1-IT1 | NA | ceRNA | pathogenic process | cardiac hypertrophy | |
HSALNT0290242 | HSALNG0142357 | SLC26A4-AS1 | NA | ceRNA | pathogenic process | cardiac hypertrophy | |
HSALNT0289302 | HSALNG0141636 | KRT7-AS | NA | NA | pathogenic process | gastric cancer | |
HSALNT0218672 | HSALNG0105101 | LINC01852 | ENST00000434223 | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290178 | HSALNG0142293 | RP11-1008C21.2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289592 | HSALNG0141707 | AK123072 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289573 | HSALNG0141688 | AK021954 | NA | NA | pathogenic process | atherosclerosis | |
HSALNT0288916 | HSALNG0105961 | CERNA1 | LOC100129973 | ceRNA | pathogenic process | cardiovascular disease | |
HSALNT0018525 | HSALNG0008959 | LAMC1-AS1 | lnc-LAMC2-1:1 | NA | pathogenic process | colorectal cancer | |
HSALNT0290087 | HSALNG0142202 | NONHSAT040387 | NA | NA | pathogenic process | atrial fibrillation | |
HSALNT0290092 | HSALNG0142207 | NONHSAT098586 | NA | NA | pathogenic process | atrial fibrillation | |
HSALNT0289213 | HSALNG0108626 | PCSK6-AS1 | NA | NA | NA | NA | |
HSALNT0289637 | HSALNG0141752 | BC016831 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289874 | HSALNG0141989 | IGKV | NA | NA | pathogenic process | breast cancer | |
HSALNT0290196 | HSALNG0142311 | RP11-434D9.1 | AC112206.2 | NA | pathogenic process | breast cancer | |
HSALNT0289885 | HSALNG0142000 | LCAL6 | NA | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289650 | HSALNG0141765 | BC088254 | NA | NA | pathogenic process | myocardial hypertrophy | |
HSALNT0289596 | HSALNG0141711 | AK124454 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289731 | HSALNG0141846 | CYP4B1-PS1 | NA | NA | pathogenic process | diabetic nephropathy | |
HSALNT0289106 | HSALNG0094020 | LINC01405 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290259 | HSALNG0142374 | ST8SIA6-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289278 | HSALNG0047244 | TRIM52-AS1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0289634 | HSALNG0141749 | BC012900 | NA | NA | pathogenic process | ulcerative colitis | |
HSALNT0274011 | HSALNG0133283 | UMODL1-AS1 | FLJ33471 | NA | pathogenic process | breast cancer | |
HSALNT0289454 | HSALNG0075449 | ARRDC1-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289456 | HSALNG0071200 | FAM74A3 | OTTHUMG00000067149 | NA | pathogenic process | breast cancer | |
HSALNT0289834 | HSALNG0141949 | FH | NA | NA | pathogenic process | Fumarase deficiency | |
HSALNT0289961 | HSALNG0142076 | lnc-HOXC4-3:1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289994 | HSALNG0142109 | lnc-TEAD4-1:1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290270 | HSALNG0142385 | TCONS_00003876 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289825 | HSALNG0141940 | EVI1 | NA | transcriptional regulation | pathogenic process | hepatocellular cancer | |
HSALNT0290235 | HSALNG0142350 | SARCC | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0290360 | HSALNG0142475 | ucoo2kmd.1 | NA | ceRNA | pathogenic process | colorectal cancer | |
HSALNT0289015 | HSALNG0001020 | KAZN-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289722 | HSALNG0141837 | CTB-89H12.4 | AC021078.1 | ceRNA | pathogenic process | prostate cancer | |
HSALNT0289496 | HSALNG0141607 | EPB41L4A-AS2 | FLJ11235 | NA | pathogenic process | lung cancer;breast cancer;kidney cancer | |
HSALNT0289146 | HSALNG0004554 | LINC02567 | ENST00000427806 | NA | pathogenic process | attention deficit hyperactivity disorder | |
HSALNT0289833 | HSALNG0141948 | FGFR3-AS1 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289707 | HSALNG0141822 | CILinc01 | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0289708 | HSALNG0141823 | CILinc02 | NA | NA | pathogenic process | osteoarthritis | |
HSALNT0286597 | HSALNG0140235 | LINC00629 | LINC00629AB,LINC00629C,LINC00629D,LINC00629 | NA | pathogenic process | choriocarcinoma | |
HSALNT0289665 | HSALNG0141780 | C2dat1 | NA | NA | pathogenic process | ischemic brain injury | |
HSALNT0289217 | HSALNG0057357 | POU6F2-AS2 | FLJ12971 | protein localization | pathogenic process | oesophageal squamous cell cancer | |
HSALNT0289946 | HSALNG0142061 | lnc13 | NA | NA | pathogenic process | celiac disease | |
HSALNT0289729 | HSALNG0141844 | CTD903 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290093 | HSALNG0142208 | NONHSAT104436 | NA | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0289550 | HSALNG0141665 | AC024560.2 | AC024560.1 | NA | pathogenic process | cervical cancer | |
HSALNT0289483 | HSALNG0134219 | ENST00000436681 | AP000552.1 | NA | pathogenic process | congenital heart defect | |
HSALNT0289536 | HSALNG0141651 | AA584040 | NA | NA | pathogenic process | congenital heart defect | |
HSALNT0289537 | HSALNG0141652 | AA709223 | NA | NA | pathogenic process | congenital heart defect | |
HSALNT0289657 | HSALNG0141772 | BX478947 | NA | NA | pathogenic process | congenital heart defect | |
HSALNT0247515 | HSALNG0119819 | LINC00668 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289719 | HSALNG0141834 | CRNDE-h | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0142879 | HSALNG0068121 | SMILR | NA | NA | pathogenic process | vascular pathologies | |
HSALNT0290396 | HSALNG0142511 | Z38 | NA | NA | pathogenic process | breast cancer | |
HSALNT0197213 | HSALNG0095037 | LINC00507 | NA | NA | developmental process | NA | |
HSALNT0289086 | HSALNG0113270 | LINC01082 | TCONSNA00024492 | NA | pathogenic process | alveolar capillary dysplasia with misalignment of pulmonary veins | |
HSALNT0289094 | HSALNG0015253 | LINC01185 | FLJ16341 | NA | pathogenic process | NA | |
HSALNT0290160 | HSALNG0142275 | PTPRD-AS1 | NA | NA | pathogenic process | ovarian cancer | |
HSALNT0290186 | HSALNG0142301 | RP11-254I22.1 | MIR583HG | NA | pathogenic process | ovarian cancer | |
HSALNT0290204 | HSALNG0142319 | RP11-57P19.1 | AC009432.1 | NA | pathogenic process | ovarian cancer | |
HSALNT0290211 | HSALNG0142326 | RP11-80H5.7 | AL157400.4 | NA | pathogenic process | ovarian cancer | |
HSALNT0290215 | HSALNG0142330 | RP1-223E5.4 | AL441883.1 | NA | pathogenic process | ovarian cancer | |
HSALNT0290224 | HSALNG0142339 | RP4-799P18.3 | AL122008.4 | NA | pathogenic process | ovarian cancer | |
HSALNT0289126 | HSALNG0045514 | LINC01844 | LOC101926975 | NA | pathogenic process | hirschsprung disease | |
HSALNT0289947 | HSALNG0142062 | Lnc34a | NA | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0289150 | HSALNG0075977 | LINP1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289951 | HSALNG0142066 | lncARSR | NA | ceRNA | pathogenic process | renal cell cancer | |
HSALNT0289392 | HSALNG0005967 | RBM15-AS1 | AS-RBM15 | translational control | pathogenic process | acute megakaryocytic leukemia | |
HSALNT0290089 | HSALNG0142204 | NONHSAT073641 | NA | NA | pathogenic process | vascular diseases | |
HSALNT0290027 | HSALNG0142142 | LOC572558 | NA | NA | pathogenic process | bladder cancer | |
HSALNT0289582 | HSALNG0141697 | AK033210 | NA | NA | pathogenic process;developmental process | bronchopulmonary dysplasia | |
HSALNT0289848 | HSALNG0141963 | GClnc1 | NA | transcriptional regulation | pathogenic process | gastric cancer | |
HSALNT0289572 | HSALNG0141687 | AK021630 | NA | NA | pathogenic process | Parkinson's disease | |
HSALNT0289603 | HSALNG0141718 | AL049437 | NA | NA | pathogenic process | Parkinson's disease | |
HSALNT0290007 | HSALNG0142122 | LOC100507661 | NA | NA | pathogenic process | thyroid cancer | |
HSALNT0289084 | HSALNG0122663 | LINC01029 | NA | NA | pathogenic process | cognitive functions and neuronal plasticity | |
HSALNT0290169 | HSALNG0142284 | RMEL3 | NA | NA | pathogenic process | melanoma | |
HSALNT0289959 | HSALNG0142074 | lnc-FRG2C-3 | NA | NA | pathogenic process | ankylosing spondylitis | |
HSALNT0289966 | HSALNG0142081 | lnc-LIN54-1 | NA | NA | pathogenic process | ankylosing spondylitis | |
HSALNT0289997 | HSALNG0142112 | lnc-USP50-2 | NA | NA | pathogenic process | ankylosing spondylitis | |
HSALNT0290000 | HSALNG0142115 | lnc-ZNF354A-1 | NA | NA | pathogenic process | ankylosing spondylitis | |
HSALNT0288949 | HSALNG0017887 | ENST00000455309 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0289920 | HSALNG0142035 | LINC02384 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0289998 | HSALNG0142113 | Lnc-UTS2D-1:1 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0290067 | HSALNG0142182 | n336161 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0290069 | HSALNG0142184 | n340599 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0290099 | HSALNG0142214 | NR_002712 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0290290 | HSALNG0142405 | TCONS_l2_00014794 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0290170 | HSALNG0142285 | RMRP | CHH,NME1R,RRP2,RMRP | ceRNA | pathogenic process | gastric cancer | |
HSALNT0289900 | HSALNG0142015 | LINC00961 | NA | NA | pathogenic process | ovarian cancer | |
HSALNT0289077 | HSALNG0068551 | LINC00977 | NA | NA | pathogenic process | primary spontaneous pneumothorax | |
HSALNT0289560 | HSALNG0141675 | AF085995 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289566 | HSALNG0141681 | AK000053 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289571 | HSALNG0141686 | AK021595 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289574 | HSALNG0141689 | AK022024 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289595 | HSALNG0141710 | AK124307 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289639 | HSALNG0141754 | BC020384 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289642 | HSALNG0141757 | BC030759 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289715 | HSALNG0141830 | CR615992 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289954 | HSALNG0142069 | lnc-CC3 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0289614 | HSALNG0141729 | APOC1P1-3 | NA | transcriptional regulation | pathogenic process | breast cancer | |
HSALNT0290365 | HSALNG0142480 | UNMIBC | NA | transcriptional regulation | pathogenic process | bladder cancer | |
HSALNT0290323 | HSALNG0142438 | uc.167 | NA | NA | pathogenic process | ventricular septal defects | |
HSALNT0290212 | HSALNG0142327 | RP11-838N2.4 | GAPLINC | ceRNA | pathogenic process | glioblastoma | |
HSALNT0289109 | HSALNG0121223 | LINC01478 | NA | NA | pathogenic process | blood pressure | |
HSALNT0289313 | HSALNG0016990 | LINC00342 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289677 | HSALNG0141792 | CAR10 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289365 | HSALNG0141638 | MAPT-AS1 | NA | transcriptional regulation | pathogenic process | Parkinson's disease | |
HSALNT0289679 | HSALNG0141794 | CAT104 | NA | ceRNA | pathogenic process | breast cancer | |
HSALNT0290260 | HSALNG0142375 | STXBP5-AS1 | NA | ceRNA | pathogenic process | breast cancer | |
HSALNT0289861 | HSALNG0141976 | HAR1 | NA | NA | pathogenic process | Huntington disease | |
HSALNT0290359 | HSALNG0142474 | UCHL1-AS1 | NA | translational control | pathogenic process | Parkinson's disease | |
HSALNT0290238 | HSALNG0142353 | SCAANT1-AS | NA | NA | pathogenic process | spinocerebellar ataxia | |
HSALNT0289648 | HSALNG0141763 | BC041488 | NA | transcriptional regulation | pathogenic process | bladder cancer | |
HSALNT0290188 | HSALNG0142303 | RP11-359E19.2 | AC022733.1 | transcriptional regulation | pathogenic process | bladder cancer | |
HSALNT0289669 | HSALNG0141784 | C6orf176-TV1 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289670 | HSALNG0141785 | C6orf176-TV2 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0289851 | HSALNG0141966 | GIHCG | NA | transcriptional regulation | pathogenic process | hepatocellular cancer | |
HSALNT0289649 | HSALNG0141764 | BC087858 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0290353 | HSALNG0142468 | uc004cov.4 | NA | NA | pathogenic process | hypertrophic cardiomyopathy | |
HSALNT0290357 | HSALNG0142472 | uc022bqu.1 | NA | NA | pathogenic process | hypertrophic cardiomyopathy | |
HSALNT0127837 | HSALNG0060796 | CFTR-AS1 | BGas | transcriptional regulation | pathogenic process | cystic fibrosis | |
HSALNT0046367 | HSALNG0021858 | MYOSLID | NA | NA | pathogenic process | vascular smooth muscle cell (VSMC) contractile phenotype | |
HSALNT0290331 | HSALNG0142446 | uc.63 | NA | NA | pathogenic process | breast cancer | |
HSALNT0290106 | HSALNG0142221 | numb | NA | NA | pathogenic process | uveal melanoma | |
HSALNT0289847 | HSALNG0141962 | GCASPC | TCONS_00011605,RP1-56L9.7-001,lnc-SOD2-1 | NA | pathogenic process | gallbladder cancer | |
HSALNT0289568 | HSALNG0141683 | AK001094 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289588 | HSALNG0141703 | AK093735 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289631 | HSALNG0141746 | BC003519 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0290100 | HSALNG0142215 | NR_003573 | ANXA2P2 | NA | pathogenic process | gastric cancer | |
HSALNT0290119 | HSALNG0142234 | P2RX7-V3 | NA | NA | pathogenic process | uveal melanoma | |
HSALNT0290308 | HSALNG0142423 | TMSB4 | NA | ceRNA | pathogenic process | osteoarthritis | |
HSALNT0288928 | HSALNG0090163 | DDX11-AS1 | CONCR | NA | pathogenic process | NA | |
HSALNT0290052 | HSALNG0142167 | MELOE | NA | NA | pathogenic process | melanoma | |
HSALNT0290231 | HSALNG0142346 | RSU1P2 | RSU1P2 | ceRNA | pathogenic process | cervical cancer | |
HSALNT0290165 | HSALNG0142280 | RBMY2FP | RBMY2FP | NA | NA | hepatocellular cancer | |
HSALNT0290071 | HSALNG0142186 | n375709 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289748 | HSALNG0141863 | DUXAP8 | DUXAP8 | NA | NA | gastric cancer | |
HSALNT0290030 | HSALNG0142145 | LOC729966 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290143 | HSALNG0142258 | POIR | NA | ceRNA | pathogenic process | periodontitis | |
HSALNT0067481 | HSALNG0031988 | MELTF-AS1 | MFI2-AS1,AC068302.3 | NA | pathogenic process | osteosarcoma | |
HSALNT0290053 | HSALNG0142168 | MFI2 | NA | NA | pathogenic process | osteosarcoma | |
HSALNT0289922 | HSALNG0142037 | linc-223 | NA | ceRNA | pathogenic process | acute myeloid leukemia | |
HSALNT0014603 | HSALNG0006859 | LINC01138 | LINC00875,FLJ39739 | NA | pathogenic process | prostate cancer | |
HSALNT0290262 | HSALNG0142377 | SUZ12P1 | SUZ12P1 | NA | pathogenic process | prostate cancer | |
HSALNT0290005 | HSALNG0142120 | LOC100505976 | NA | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0290392 | HSALNG0142507 | XLOC_l2_010636 | NA | NA | pathogenic process | laryngeal squamous cell cancer | |
HSALNT0090295 | HSALNG0043014 | RASGRF2-AS1 | CTC-459I6.1 | NA | pathogenic process | sepsis-induced endothelial dysfunction | |
HSALNT0289852 | HSALNG0141967 | GPC3-AS1 | NA | transcriptional regulation | pathogenic process | hepatocellular cancer | |
HSALNT0189472 | HSALNG0091321 | HOXC-AS1 | NA | transcriptional regulation | pathogenic process | atherosclerosis | |
HSALNT0289157 | HSALNG0057557 | LUARIS | lncRNA#32 | transcriptional regulation | NA | NA | |
HSALNT0289371 | HSALNG0044828 | MIR3936HG | LOC553103,SLC22A5-AS1 | NA | pathogenic process | gastric cancer;nasopharyngeal cancer | |
HSALNT0290148 | HSALNG0142263 | Ppp1r1b | NA | transcriptional regulation | pathogenic process | congenital heart defect | |
HSALNT0289038 | HSALNG0099182 | LINC00460 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290194 | HSALNG0142309 | RP1-13P20.6 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0290364 | HSALNG0142479 | Unigene56159 | NA | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0290355 | HSALNG0142470 | uc009yby.1 | NA | NA | pathogenic process | renal cell cancer | |
HSALNT0289406 | HSALNG0048011 | TFAP2A-AS2 | HIPSTR | NA | developmental process | NA | |
HSALNT0289704 | HSALNG0141819 | Chaer | NA | transcriptional regulation | pathogenic process | cardiac hypertrophy | |
HSALNT0289865 | HSALNG0141980 | HIF-2α | NA | NA | pathogenic process | NA | |
HSALNT0211378 | HSALNG0101489 | LINC00520 | C14orf34 | NA | pathogenic process | breast cancer | |
HSALNT0087374 | HSALNG0041561 | MRPS30-DT | BRCAT54 | NA | pathogenic process | breast cancer | |
HSALNT0289388 | HSALNG0092662 | PPP1R12A-AS1 | R12A-AS1 | translational control | NA | NA | |
HSALNT0289013 | HSALNG0088600 | ITFG2-AS1 | NA | NA | NA | NA | |
HSALNT0290088 | HSALNG0142203 | NONHSAT041499 | NA | NA | pathogenic process | schizophrenia | |
HSALNT0290091 | HSALNG0142206 | NONHSAT089447 | NA | NA | pathogenic process | schizophrenia | |
HSALNT0289970 | HSALNG0142085 | lnc-NKX2-3-1 | NA | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0289989 | HSALNG0142104 | lnc-RTN4R-1 | NA | transcriptional regulation | pathogenic process | acute lymphoblastic leukemia | |
HSALNT0289821 | HSALNG0141936 | ERL | NA | NA | pathogenic process | Marek's disease | |
HSALNT0192459 | HSALNG0092867 | LINC02258 | RP11-248E9.5 | NA | pathogenic process | pneumonia | |
HSALNT0241871 | HSALNG0117085 | SKAP1-AS1 | RP11-456D7.1 | NA | pathogenic process | pneumonia | |
HSALNT0289439 | HSALNG0049760 | DINOL | DINO | NA | NA | NA | |
HSALNT0288901 | HSALNG0000547 | CAMTA1-DT | lncCAMTA1 | transcriptional regulation | pathogenic process | liver cancer | |
HSALNT0290328 | HSALNG0142443 | uc.345 | NA | transcriptional regulation | pathogenic process | pancreatic cancer | |
HSALNT0290060 | HSALNG0142175 | MSNP1AS | NA | translational control | pathogenic process | autism spectrum disorder | |
HSALNT0289376 | HSALNG0004596 | NEXN-AS1 | C1orf118,FLJ90637 | NA | pathogenic process | lung cancer | |
HSALNT0183194 | HSALNG0088083 | LINC02098 | RP11-702B10.1 | NA | pathogenic process | esophageal cancer | |
HSALNT0198055 | HSALNG0095473 | PSPC1-AS2 | RP11-523H24.3 | NA | pathogenic process | esophageal cancer | |
HSALNT0289155 | HSALNG0114857 | LRRC75A-AS1 | C17orf45,NCRNA00188,C17orf76-AS1,FAM211A-AS1,MGC40157 | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289220 | HSALNG0077999 | PRKG1-AS1 | RP11-573I11.2 | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289262 | HSALNG0076970 | SVIL-AS1 | RP11-534G20.3 | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289281 | HSALNG0108169 | VPS33B-DT | NA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289804 | HSALNG0141919 | ENST00000438399 | NA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0290228 | HSALNG0142343 | RPKG1-AS1 | NA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0290350 | HSALNG0142465 | uc004afb.1 | NA | NA | pathogenic process | rheumatoid arthritis | |
HSALNT0289398 | HSALNG0135015 | SLC5A4-AS1 | RP1-90G24.10 | NA | pathogenic process | gastric cancer | |
HSALNT0289411 | HSALNG0063964 | TNFRSF10A-AS1 | RP11-1149O23.2 | NA | pathogenic process | gastric cancer | |
HSALNT0289727 | HSALNG0141842 | CTD-2616J11.14 | AC008750.7 | NA | pathogenic process | gastric cancer | |
HSALNT0290182 | HSALNG0142297 | RP11-150O12.3 | AC124067.4 | NA | pathogenic process | gastric cancer | |
HSALNT0289730 | HSALNG0141845 | CXCL1P1 | CXCL1P1 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289803 | HSALNG0141918 | ENST00000438347 | CCND3P1 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289897 | HSALNG0142012 | LINC00601 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289503 | HSALNG0141614 | KIAA0087 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0289827 | HSALNG0141942 | FAM212B-AS1 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290010 | HSALNG0142125 | LOC102723552 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290181 | HSALNG0142296 | RP11-140I24 | LINC01568 | NA | pathogenic process | endometrial cancer | |
HSALNT0290201 | HSALNG0142316 | RP11-501O2 | LINC02046 | NA | pathogenic process | endometrial cancer | |
HSALNT0290206 | HSALNG0142321 | RP11-600K151 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0290084 | HSALNG0142199 | NONHSAG051968 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290090 | HSALNG0142205 | NONHSAT076747 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0290094 | HSALNG0142209 | NONHSAT122730 | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0138768 | HSALNG0066240 | MIR2052HG | NA | transcriptional regulation | pathogenic process | breast cancer | |
HSALNT0289096 | HSALNG0096884 | LINC01198 | NA | NA | pathogenic process | glioma | |
HSALNT0289274 | HSALNG0096821 | TPT1-AS1 | NA | NA | pathogenic process | glioma | |
HSALNT0289924 | HSALNG0142039 | linc-cdh4-2 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0144641 | HSALNG0068878 | LINC02055 | RP1130-1 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289737 | HSALNG0141852 | DBCCR1 | NA | transcriptional regulation | pathogenic process | bladder cancer | |
HSALNT0289547 | HSALNG0141662 | AC012065.7 | NA | NA | pathogenic process | chronic lymphocytic leukemia | |
HSALNT0289229 | HSALNG0116565 | RAMP2-AS1 | NA | NA | pathogenic process | glioblastoma | |
HSALNT0289591 | HSALNG0141706 | AK098081 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289644 | HSALNG0141759 | BC037331 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289646 | HSALNG0141761 | BC040303 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289717 | HSALNG0141832 | CR749831 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289250 | HSALNG0040073 | SNHG18 | NA | NA | pathogenic process | glioma | |
HSALNT0106140 | HSALNG0050030 | FOXP4-AS1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0026202 | HSALNG0012584 | RNASEH1-AS1 | LOC100506054 | NA | pathogenic process | colorectal cancer | |
HSALNT0288993 | HSALNG0088026 | GSEC | ST3GAL4-AS1,DCPS-AS1,FLJ39051 | NA | pathogenic process | colorectal cancer | |
HSALNT0060264 | HSALNG0028799 | DNAJB8-AS1 | NA | NA | NA | NA | |
HSALNT0248137 | HSALNG0120059 | CHMP1B-AS1 | NA | NA | NA | NA | |
HSALNT0021970 | HSALNG0010602 | TGFB2-AS1 | NR_046268 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0078323 | HSALNG0037356 | SLC7A11-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0134663 | HSALNG0064248 | INTS9-AS1 | ENST00000520055 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0231572 | HSALNG0111641 | MMP2-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0267869 | HSALNG0130456 | SLC12A5-AS1 | RP11-465L10.10 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0288921 | HSALNG0002415 | CSMD2-AS1 | ENST00000434181 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0288997 | HSALNG0052934 | HDAC2-AS2 | ENST00000421891 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289012 | HSALNG0105327 | INO80-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289140 | HSALNG0075065 | LINC02247 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289161 | HSALNG0059170 | MAGI2-AS3 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289188 | HSALNG0062699 | MNX1-AS2 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289245 | HSALNG0140277 | SMIM10L2B-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289407 | HSALNG0102543 | TGFB3-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289457 | HSALNG0073036 | HSD17B3-AS1 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289919 | HSALNG0142034 | LINC02246 | NA | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289288 | HSALNG0100050 | ZNF710-AS1 | ENST00000558334 | NA | pathogenic process | early-onset preeclampsia | |
HSALNT0289266 | HSALNG0007188 | TDRKH-AS1 | RP11-98D18.9 | NA | pathogenic process | NA | |
HSALNT0289128 | HSALNG0057684 | LINC01952 | AC004854.4 | NA | pathogenic process | recurrent miscarriage | |
HSALNT0290075 | HSALNG0142190 | NCF4-AS1 | CTA-833B7.2 | NA | pathogenic process | recurrent miscarriage | |
HSALNT0289360 | HSALNG0029603 | LNCSRLR | lncRNA-SRLR | transcriptional regulation | pathogenic process | renal cell cancer | |
HSALNT0288918 | HSALNG0021529 | CFLAR-AS1 | ALS2CR10 | NA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0289710 | HSALNG0141825 | COL1A2-AS1 | TCONS_00013888,lncRNA8975-1 | transcriptional regulation | pathogenic process | hypertrophic scar | |
HSALNT0075075 | HSALNG0035847 | LNCPRESS2 | lncPRESS2 | transcriptional regulation | NA | NA | |
HSALNT0011289 | HSALNG0005432 | LINC01930 | EU358092 | NA | pathogenic process | schizophrenia | |
HSALNT0097120 | HSALNG0046325 | HMMR-AS1 | NA | NA | pathogenic process | basal-like breast cancer | |
HSALNT0184498 | HSALNG0088703 | CCND2-AS1 | CCND2-AS2 | NA | pathogenic process | glioma | |
HSALNT0289045 | HSALNG0030884 | LINC00578 | NA | NA | pathogenic process | major depression disorder | |
HSALNT0288884 | HSALNG0026576 | ADAMTS9-AS1 | NA | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0080041 | HSALNG0038152 | FAM198B-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0103007 | HSALNG0048820 | LINC00240 | C6orf41,NCRNA00240,bA373D17.1 | ceRNA | pathogenic process | esophageal squamous cell cancer | |
HSALNT0289071 | HSALNG0122453 | LINC00909 | NA | NA | NA | NA | |
HSALNT0289509 | HSALNG0141620 | LINC00680 | NA | NA | NA | NA | |
HSALNT0129070 | HSALNG0061394 | LINC00513 | AC016831.7 | NA | NA | NA | |
HSALNT0289129 | HSALNG0115960 | LINC02001 | RP11-1094M14.11 | NA | NA | NA | |
HSALNT0289215 | HSALNG0092950 | POC1B-AS1 | RP11-734K2.4 | NA | NA | NA | |
HSALNT0289241 | HSALNG0060049 | SLC12A9-AS1 | RP11-126L15.4 | NA | NA | NA | |
HSALNT0289275 | HSALNG0050617 | TRAM2-AS1 | NA | NA | NA | NA | |
HSALNT0002243 | HSALNG0001176 | LINC01772 | ENSG00000226029 | ceRNA | pathogenic process | oesophageal cancer | |
HSALNT0288941 | HSALNG0009693 | ELF3-AS1 | ENST00000415582 | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289134 | HSALNG0025450 | LINC02158 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289350 | HSALNG0133329 | LINC01671 | BC041455 | NA | pathogenic process | breast cancer | |
HSALNT0289124 | HSALNG0132343 | LINC01684 | lnc-JAM2-6 | NA | pathogenic process | nonalcoholic fatty liver disease | |
HSALNT0289036 | HSALNG0096092 | LINC00365 | NA | NA | pathogenic process | esophageal cancer | |
HSALNT0289111 | HSALNG0043625 | LINC01554 | C5orf27,FLJ38821,FIS | NA | pathogenic process | esophageal cancer | |
HSALNT0289132 | HSALNG0136701 | LINC02154 | GS1-600G8.5 | NA | pathogenic process | esophageal cancer | |
HSALNT0137721 | HSALNG0065704 | LINC02155 | RP11-705O24.1 | NA | pathogenic process | esophageal cancer | |
HSALNT0225363 | HSALNG0108398 | LINC02157 | RP11-327J17.1 | NA | pathogenic process | esophageal cancer | |
HSALNT0289133 | HSALNG0090758 | LINC02156 | RP1-90J4.1 | NA | pathogenic process | esophageal cancer | |
HSALNT0133924 | HSALNG0063832 | LINC02153 | NA | NA | pathogenic process | major depression disorder | |
HSALNT0181656 | HSALNG0087394 | LINC02151 | TCONS_00019174 | NA | pathogenic process | major depression disorder | |
HSALNT0227367 | HSALNG0109385 | LINC02152 | NA | NA | pathogenic process | major depression disorder | |
HSALNT0029246 | HSALNG0013844 | BRE-AS1 | NA | NA | NA | NA | |
HSALNT0289251 | HSALNG0056623 | SNHG26 | AC005682.5 | NA | pathogenic process | bladder urothelial cancer | |
HSALNT0252719 | HSALNG0122284 | LIVAR | lnc18q22.2 | NA | pathogenic process | nonalcoholic steatohepatiti | |
HSALNT0289074 | HSALNG0031832 | LINC00969 | ENST00000453324 | NA | pathogenic process | lung squamous cell cancer | |
HSALNT0289138 | HSALNG0140259 | LINC02243 | ENST00000441841 | NA | pathogenic process | lung squamous cell cancer | |
HSALNT0289399 | HSALNG0039449 | SLC9A3-AS1 | UC011CLY.2 | NA | pathogenic process | lung squamous cell cancer | |
HSALNT0288934 | HSALNG0126602 | DM1-AS | NA | NA | pathogenic process | myotonic dystrophy type 1 | |
HSALNT0009014 | HSALNG0004475 | LINC02238 | RP4-788P17.1 | NA | pathogenic process | B cell lymphoma | |
HSALNT0289163 | HSALNG0043374 | MEF2C-AS2 | CTC-467M3.1 | NA | pathogenic process | diffuse large B-cell lymphoma | |
HSALNT0289181 | HSALNG0003824 | MIR4422HG | RP11-101C11.1 | NA | pathogenic process | diffuse large B-cell lymphoma | |
HSALNT0289403 | HSALNG0082800 | SPON1-AS1 | RP11-21,L19.1 | NA | pathogenic process | diffuse large B-cell lymphoma | |
HSALNT0289461 | HSALNG0083610 | CD44-AS1 | RP1-68D18.4 | NA | pathogenic process | diffuse large B-cell lymphoma | |
HSALNT0262277 | HSALNG0127560 | LILRB1-AS1 | AC009892.10 | NA | pathogenic process | NA | |
HSALNT0289546 | HSALNG0141661 | AC009892.10 | LILRB1-AS1 | NA | NA | B cell lymphoma | |
HSALNT0282241 | HSALNG0137635 | LINC01186 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289168 | HSALNG0131657 | MHENCR | NA | ceRNA | pathogenic process | melanoma | |
HSALNT0072994 | HSALNG0034801 | LINC02232 | RP11-707A18.1 | NA | pathogenic process | NA | |
HSALNT0080161 | HSALNG0038220 | LINC02233 | RP11-6C14.1 | NA | pathogenic process | NA | |
HSALNT0084027 | HSALNG0039930 | LINC02236 | RP11-332J15.1 | NA | pathogenic process | NA | |
HSALNT0091870 | HSALNG0043678 | LINC02234 | RP11-455B3.1 | NA | pathogenic process | NA | |
HSALNT0139521 | HSALNG0066607 | LINC02235 | RP11-354A14.1 | NA | pathogenic process | NA | |
HSALNT0142040 | HSALNG0067779 | LINC02237 | RP11-1101K5.1 | NA | pathogenic process | NA | |
HSALNT0289135 | HSALNG0111295 | LINC02179 | RP11-189E14.4 | NA | pathogenic process | NA | |
HSALNT0289351 | HSALNG0132340 | LINC01689 | AP000469.2 | NA | pathogenic process | NA | |
HSALNT0289137 | HSALNG0091963 | LINC02231 | RP11-766N7.4 | NA | pathogenic process | Esophageal squamous cell cancer | |
HSALNT0220239 | HSALNG0105903 | MIR4713HG | RP11-108K3.1 | NA | pathogenic process | colorectal cancer | |
HSALNT0288967 | HSALNG0037858 | FAM160A1-DT | RP11-610P16.1 | NA | pathogenic process | colorectal cancer | |
HSALNT0289239 | HSALNG0021423 | SATB2-AS1 | NA | translational control | pathogenic process | osteosarcoma | |
HSALNT0289512 | HSALNG0141623 | LINC01826 | lnc-MKI67IP-3 | ceRNA | pathogenic process | atherosclerosis | |
HSALNT0289024 | HSALNG0104253 | LINC00226 | C14orf97,NCRNA00226 | NA | pathogenic process | pancreatic ductaladenocarcinoma | |
HSALNT0082192 | HSALNG0039173 | F11-AS1 | NA | NA | NA | NA | |
HSALNT0219108 | HSALNG0105295 | SPINT1-AS1 | RP11-532F12.5 | NA | pathogenic process | melanoma | |
HSALNT0289177 | HSALNG0088950 | MIR200CHG | U47924.27 | NA | pathogenic process | melanoma | |
HSALNT0289328 | HSALNG0031153 | LINC00888 | NA | NA | pathogenic process | melanoma | |
HSALNT0289309 | HSALNG0116205 | LINC00672 | NA | transcriptional regulation | pathogenic process | endometrial cancer | |
HSALNT0289198 | HSALNG0085691 | P4HA3-AS1 | NA | NA | pathogenic process | parkinson's disease | |
HSALNT0197312 | HSALNG0095075 | TMEM132D-AS1 | LOC283352 | NA | pathogenic process | human dermal fibroblasts | |
HSALNT0289472 | HSALNG0113128 | ATP2C2-AS1 | RP11-517C16.2-001 | NA | NA | NA | |
HSALNT0233849 | HSALNG0112863 | WWOX-AS1 | RP11-190D6.2 | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0128829 | HSALNG0061246 | FLNC-AS1 | NA | NA | pathogenic process | cervical squamous cancer | |
HSALNT0289889 | HSALNG0142004 | LIF-AS1 | Lnc-LIF-AS | NA | pathogenic process | cervical squamous cancer | |
HSALNT0011283 | HSALNG0005428 | DPYD-AS2 | NA | NA | pathogenic process | cervical squamous cancer | |
HSALNT0289836 | HSALNG0141951 | FLICR | NA | transcriptional regulation | pathogenic process | autoimmune diabete | |
HSALNT0289356 | HSALNG0090563 | LINC02402 | ENST00000550337.1 | NA | pathogenic process | diabetes | |
HSALNT0137118 | HSALNG0065453 | CERNA3 | CTA | ceRNA | pathogenic process | osteosarcoma | |
HSALNT0090838 | HSALNG0043312 | LINC02488 | CTD-2316B1 | NA | pathogenic process | NA | |
HSALNT0174947 | HSALNG0083979 | LINC02489 | CTD-2589M5 | NA | pathogenic process | NA | |
HSALNT0220441 | HSALNG0105991 | LINC02490 | RP11-209E8 | NA | pathogenic process | NA | |
HSALNT0289260 | HSALNG0045650 | STK32A-AS1 | CTC-255N20 | NA | pathogenic process | NA | |
HSALNT0289143 | HSALNG0055190 | LINC02487 | NA | NA | pathogenic process | squamous cell cancer | |
HSALNT0095585 | HSALNG0045503 | SPRY4-AS1 | THCAT68 | NA | pathogenic process | bladder cancer | |
HSALNT0288927 | HSALNG0090908 | DDN-AS1 | CAT1507 | NA | pathogenic process | bladder cancer | |
HSALNT0012862 | HSALNG0006150 | SLC16A1-AS1 | NA | NA | pathogenic process | acute myocardial infarction | |
HSALNT0289412 | HSALNG0000276 | TNFRSF14-AS1 | ENST00000416860.2 | NA | pathogenic process | acute myocardial infarction | |
HSALNT0259139 | HSALNG0125745 | LINC00665 | NA | NA | NA | NA | |
HSALNT0040268 | HSALNG0019085 | DARS-AS1 | NA | NA | pathogenic process | renal disease | |
HSALNT0288913 | HSALNG0125425 | CEBPA-AS1 | CEBPA-DT | NA | pathogenic process | gastric cancer | |
HSALNT0289011 | HSALNG0057479 | INHBA-AS1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0288988 | HSALNG0067472 | GASAL1 | GASL1 | NA | pathogenic process | liver cancer | |
HSALNT0289127 | HSALNG0021881 | LINC01857 | AC079767.4 | NA | pathogenic process | tuberculosis | |
HSALNT0289091 | HSALNG0004949 | LINC01140 | FLJ41676 | NA | NA | NA | |
HSALNT0281957 | HSALNG0137521 | PINCR | NA | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0289344 | HSALNG0139543 | LINC00890 | NA | NA | pathogenic process | leiomyoma | |
HSALNT0019828 | HSALNG0009573 | LINC00862 | C1orf98,SMIM16 | NA | pathogenic process | cystic fibrosis | |
HSALNT0073790 | HSALNG0035237 | LINC02562 | RP11-44F21.5 | NA | pathogenic process | cystic fibrosis | |
HSALNT0263101 | HSALNG0127961 | LINC02560 | CTD-2619J13.13 | NA | pathogenic process | cystic fibrosis | |
HSALNT0289144 | HSALNG0088252 | LINC02551 | RP11-890B15.2 | NA | pathogenic process | cystic fibrosis | |
HSALNT0289458 | HSALNG0078773 | DDIT4-AS1 | RP11-442H21.2 | NA | pathogenic process | cystic Fibrosis | |
HSALNT0288992 | HSALNG0089423 | GPRC5D-AS1 | RP11-392P7.6 | NA | pathogenic process | colorectal cancer | |
HSALNT0289386 | HSALNG0015768 | PCBP1-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0289405 | HSALNG0044141 | STARD4-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0201547 | HSALNG0097004 | LINC00462 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0207103 | HSALNG0099453 | SOX1-OT | LINC00403 | NA | pathogenic process | NA | |
HSALNT0002131 | HSALNG0001107 | SLC25A34-AS1 | RP11-169K16.4 | NA | NA | NA | |
HSALNT0289218 | HSALNG0075163 | PPP1R26-AS1 | NA | NA | pathogenic process | breast cancer | |
HSALNT0289047 | HSALNG0064310 | LINC00589 | C8orf75,TSLNC8 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289516 | HSALNG0141627 | TPM1-AS | TPM1-AS1 | splicing regulation | pathogenic process | esophageal cancer | |
HSALNT0289314 | HSALNG0141631 | LINC01101 | FLJ14816 | NA | pathogenic process | HPV-induced cervical neoplasia | |
HSALNT0289147 | HSALNG0018748 | LINC02572 | AC079776.2 | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0096804 | HSALNG0046188 | LINC02202 | NA | NA | NA | NA | |
HSALNT0289076 | HSALNG0027511 | LINC00973 | CTD-2021J15.2 | NA | pathogenic process | colorectal cancer | |
HSALNT0288625 | HSALNG0141401 | TTTY10 | NCRNA00133 | NA | pathogenic process | colorectal cancer | |
HSALNT0289323 | HSALNG0133418 | LINC00319 | C21orf125,NCRNA00319,PRED49,FLJ38036 | ceRNA | pathogenic process | lung cancer | |
HSALNT0015533 | HSALNG0007394 | IL6R-AS1 | RP11-350G8.5 | NA | NA | NA | |
HSALNT0090330 | HSALNG0043020 | CKMT2-AS1 | NA | NA | NA | NA | |
HSALNT0012995 | HSALNG0006203 | HIPK1-AS1 | NA | NA | NA | NA | |
HSALNT0289216 | HSALNG0050214 | POLH-AS1 | RP3-337H4.8 | NA | NA | NA | |
HSALNT0289276 | HSALNG0053237 | TRDN-AS1 | HRAT13 | NA | NA | NA | |
HSALNT0289159 | HSALNG0069213 | LY6E-DT | LOC100133669 | NA | pathogenic process | ovarian cancer | |
HSALNT0289434 | HSALNG0040409 | BASP1-AS1 | LOC285696 | NA | pathogenic process | NA | |
HSALNT0288991 | HSALNG0069691 | GLIS3-AS1 | C9orf70,MGC16153 | NA | NA | NA | |
HSALNT0288896 | HSALNG0070213 | BNC2-AS1 | RP11-62F24.2 | NA | pathogenic process | gastric cancer | |
HSALNT0289292 | HSALNG0078947 | ZNF503-AS1 | NA | NA | pathogenic process | age-related macular degeneration | |
HSALNT0159506 | HSALNG0076434 | VIM-AS1 | NA | NA | pathogenic process | endometrial cancer | |
HSALNT0288882 | HSALNG0011058 | ACBD3-AS1 | RP11-275I14.4 | NA | pathogenic process | endometrial cancer | |
HSALNT0289156 | HSALNG0005074 | LRRC8C-DT | FLJ27354 | NA | pathogenic process | endometrial cancer | |
HSALNT0289447 | HSALNG0058889 | ELN-AS1 | CTB-51J22.1 | NA | pathogenic process | endometrial cancer | |
HSALNT0076712 | HSALNG0036645 | LINC02264 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0093666 | HSALNG0044495 | LINC02201 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0271685 | HSALNG0132198 | LINC02573 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289125 | HSALNG0015785 | LINC01816 | LOC100133985 | NA | pathogenic process | gastric cancer | |
HSALNT0289355 | HSALNG0091335 | LINC02381 | LOC400043 | NA | pathogenic process | gastric cancer | |
HSALNT0289366 | HSALNG0029874 | MBNL1-AS1 | LOC401093 | NA | pathogenic process | gastric cancer | |
HSALNT0289513 | HSALNG0141624 | MIR4697HG | LINC00947,LOC283174 | NA | pathogenic process | gastric cancer | |
HSALNT0289073 | HSALNG0065480 | LINC00968 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0114453 | HSALNG0053963 | NMBR-AS1 | RP11-137J7.2 | NA | pathogenic process | non-melanoma skin cancer | |
HSALNT0289300 | HSALNG0077499 | LINC01518 | NA | NA | pathogenic process | non-melanoma skin cancer | |
HSALNT0003783 | HSALNG0002009 | LINC02574 | RP11-288L9.1 | transcriptional regulation | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0032721 | HSALNG0015486 | LINC02579 | AC007365.1 | NA | pathogenic process | NA | |
HSALNT0030828 | HSALNG0014519 | LINC02580 | AC093609.1 | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0032808 | HSALNG0015519 | LINC02576 | NA | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0127022 | HSALNG0060386 | LINC02577 | NA | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0154722 | HSALNG0074062 | LINC02578 | RP11-127L21.1 | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0288962 | HSALNG0084388 | FAM111A-DT | NA | NA | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0289148 | HSALNG0133545 | LINC02575 | AP001065.15 | transcriptional regulation | pathogenic process | UVB-irradiated KC & non-melanoma skin cancer | |
HSALNT0025249 | HSALNG0012143 | KIF26B-AS1 | RP11-62I21.1 | NA | NA | NA | |
HSALNT0177212 | HSALNG0085146 | RPS6KB2-AS1 | AP003419.16 | NA | pathogenic process | agingâassociated idiopathic pulmonary fibrosis | |
HSALNT0289072 | HSALNG0090150 | LINC00941 | lncRNA-MUF | ceRNA | pathogenic process | hepatocellular cancer | |
HSALNT0289338 | HSALNG0075045 | LINC00094 | FLJ35348,bA374P20.3 | NA | pathogenic process | lung squamous cell cancer | |
HSALNT0114192 | HSALNG0053894 | FILNC1 | NA | translational control | pathogenic process | renal tumor | |
HSALNT0289199 | HSALNG0128600 | PARAL1 | NA | ceRNA | pathogenic process | obesity | |
HSALNT0244832 | HSALNG0118528 | SOX9-AS1 | FLJ37644 | transcriptional regulation | NA | NA | |
HSALNT0289236 | HSALNG0118528 | ROCR | LINC02095 | transcriptional regulation | NA | NA | |
HSALNT0056667 | HSALNG0027060 | LINC02027 | LOC728290 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289424 | HSALNG0141124 | TTTY22 | NCRNA00147 | NA | NA | NA | |
HSALNT0289069 | HSALNG0030090 | LINC00880 | NA | NA | NA | NA | |
HSALNT0252974 | HSALNG0122396 | LINC02582 | CTD-2354A18.1 | NA | pathogenic process | colorectal cancer | |
HSALNT0289035 | HSALNG0097712 | LINC00364 | LncRNA00364 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0060981 | HSALNG0029189 | NCK1-DT | NCK1-AS1,SLC35G2-AS1 | ceRNA | pathogenic process | cervical cancer | |
HSALNT0288890 | HSALNG0067505 | BAALC-AS1 | lncFZD6,FZD6-DT | transcriptional regulation | pathogenic process | liver cancer | |
HSALNT0046602 | HSALNG0021972 | CPS1-IT1 | CPS1-IT,CPS1IT,CPS1IT1,PRO0132 | NA | pathogenic process | hepatocellular cancer;lung cancer;intrahepatic cholangiocarcinoma | |
HSALNT0289445 | HSALNG0059740 | DLX6-AS1 | DLX6-A, DLX6A, Evf-2,NCRNA00212,NCRNA00212,FLJ34048 | transcriptional regulation | pathogenic process | split hand/split foot malformation disorder;lung adenocarcinoma | |
HSALNT0289891 | HSALNG0142006 | LINC00114 | NA | NA | NA | NA | |
HSALNT0289415 | HSALNG0138601 | TSIX | LINC00013,NCRNA00013,XIST-A, XIST-AS1,XISTAS | transcriptional regulation | pathogenic process | systemic sclerosis | |
HSALNT0217334 | HSALNG0104503 | MKRN3-AS1 | ZNF127A, MKRN3A, MKRN3-A,FNZ127,NCRNA00009,ZNF127-AS | NA | pathogenic process | Prader-Willi syndrome | |
HSALNT0290256 | HSALNG0142371 | SRA | lnc-SRA1-1:1,SRA1,ENSG00000213523 | transcriptional regulation | pathogenic process | nonalcoholic fatty liver disease;polycystic ovary syndrome;ovarian cancer;dilated cardiomyopathy;cardiomyopathy;breast cancer;laryngeal squamous cell cancer;uterus cancer | |
HSALNT0289442 | HSALNG0049271 | HCP5 | 6S2650E,D6S2650E,P5-1 | NA | pathogenic process | AIDS | |
HSALNT0289284 | HSALNG0083476 | WT1-AS | WIT1,WIT-1,WT1A, WT1-AS1 | transcriptional regulation | pathogenic process | gastric cancer;primary myelofibrosis;hepatocellular cancer;Wilms' tumor;acute myeloid leukemia | |
HSALNT0289421 | HSALNG0082235 | KCNQ1OT1 | KCNQ1-AS2,KCNQ10T1,Kncq1,KvDMR1,KvLQT1-A, LIT1,NCRNA00012 | transcriptional regulation | pathogenic process | prostate cancer;colorectal cancer;hepatocelluar cancer;acute myocardial infarction;kidney cancer;Beckwith-Wiedemann syndrome;breast cancer | |
HSALNT0263784 | HSALNG0128372 | PCNA-AS1 | PCNAA, PCNA-AS | transcriptional regulation | pathogenic process | gastric cancer;hepatocelluar cancer | |
HSALNT0289524 | HSALNG0049107 | HCG9 | PERB11,HCGIX,HCGIX4,HCGIX-4 | NA | NA | NA | |
HSALNT0289264 | HSALNG0103448 | TCL6 | TCL6e1,TNG2,TNG1 | NA | pathogenic process;developmental process | renal cell cancer;leukemia | |
HSALNT0289203 | HSALNG0072040 | PCA3 | DD3,NCRNA00019,PCAT3 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer | |
HSALNT0289462 | HSALNG0082178 | H19 | ASM,ASM1,BW, D11S813E,LINC00008,NCRNA00008,WT2 | transcriptional regulation;ceRNA | developmental process;pathogenic process | prostate cancer;glioma;cancer;breast cancer;ovarian cancer;Marek's disease;gestational trophoblastic diseases;glioblastoma;non-small cell lung cancer;hyperhomocysteinemia;congenital heart defect;congenital hyperinsulinism;pancreatic cancer;Beckwith-Wiedemann syndrome;endometriosis;trophoblastic tumor;adrenocortical cancer;coronary artery disease;Wiedemann-Beckwith syndrome;bladder cancer;melanoma;myeloproliferative polycythaemia vera;hepatocelluar cancer;meningioma;breast adenocarcinoma;neuroblastoma;embryonal cancer;osteosarcoma;esophageal cancer;kidney cancer;malignant digestive cancer;chronic myeloid leukemia;mullerian aplasia;malignant hematopoiesis;gastric cardia adenocarcinoma;cervical cancer;gallbladder cancer;pheochromocytoma;germ cell tumor;colorectal cancer;hydatidiform mole;Pancreatic ductal adenocarcinoma;pre-eclampsia;atherosclerosis;esophageal squamous cell cancer;calcific aortic valve disease;gastric cancer;osteoarthritis;choriocarcinoma;chronic myeloproliferative disorders;neural tube defects;skin cancer;ulcerative colitis;type 2 diabetes;thyroid cancer;pneumoconiosis;infertility;liver cancer;heart failure;medulloblastoma;laryngeal squamous cell cancer;Silver-Russell syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;growth restriction;Prader-Willi syndrome;diabetic cardiomyopathy;obesity;lung cancer;Parkinson's disease;renal cell cancer;Wilms' tumor | |
HSALNT0288932 | HSALNG0097105 | DLEU1 | BCM, BCMS1,DLB1,LEU1,LEU2,LINC00021,NCRNA00021,XTP6 | transcriptional regulation;ceRNA | pathogenic process | lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;hematopoietic and solid tumors;chronic lymphocytic leukemia;inherited bone marrow failure disorder;lymphoma;breast cancer;head and neck squamous cell cancer | |
HSALNT0289493 | HSALNG0141604 | DBH-AS1 | NCRNA00118,BPR | NA | pathogenic process | hepatocellular cancer | |
HSALNT0088415 | HSALNG0042101 | PART1 | DKFZP586D0823,NCRNA00206 | NA | pathogenic process | prostate cancer;glioblastoma | |
HSALNT0289463 | HSALNG0082197 | IGF2-AS | IGF2A,PEG8,IGF2-AS1 | transcriptional regulation | pathogenic process | liver cancer;type 1 diabetes;prostate cancer;Wilms' tumor;hepatocelluar cancer | |
HSALNT0269786 | HSALNG0131285 | GNAS-AS1 | GNASA, GNAS-A,SANG,NESP-A, NESPA, GNAS1A, NCRNA00075 | transcriptional regulation | pathogenic process | non-small cell lung cancer;pseudohypoparathyroidism type Ib | |
HSALNT0289252 | HSALNG0051709 | SNHG5 | C6orf160,MGC16362,bA33E24.2,U50HG,NCRNA00044,LINC00044 | NA | pathogenic process | gastric cancer;lymphoma;melanoma | |
HSALNT0023827 | HSALNG0011462 | DISC2 | DISC1-AS1,DISC1O, NCRNA00015 | transcriptional regulation | pathogenic process | bipolar disorder;affective disorder;major depressive affective disorder;schizophrenia;autism spectrum disorder;depression | |
HSALNT0203415 | HSALNG0097806 | ATXN8OS | SCA8,KLHL1A,NCRNA00003 | transcriptional regulation | pathogenic process | spinocerebellar ataxia;spinocerebellar ataxia | |
HSALNT0290312 | HSALNG0142427 | TRAF3IP2-AS1 | C6UA, C6orf3,NCRNA00248,TRAF3IP2-AS2 | transcriptional regulation | pathogenic process | schizophrenia;cocaine abuse | |
HSALNT0289008 | HSALNG0054049 | HYMAI | NCRNA00020 | NA | pathogenic process | transient neonatal diabetes | |
HSALNT0288968 | HSALNG0071146 | FAM201A | C9orf122 | NA | pathogenic process | leukemia | |
HSALNT0288969 | HSALNG0093910 | FAM222A-AS1 | NA | NA | pathogenic process | NA | |
HSALNT0289484 | HSALNG0138575 | FAM226A | CXorf50,NCRNA00246,NCRNA00246A,LINC00246A,MGC34827 | NA | pathogenic process | NA | |
HSALNT0289497 | HSALNG0141608 | FAM215A | C17orf88,APR-2,LINC00530 | NA | pathogenic process | ovarian cancer;leukemia | |
HSALNT0289230 | HSALNG0025991 | RBM5-AS1 | LUST | transcriptional regulation | pathogenic process | tumor | |
HSALNT0002923 | HSALNG0001554 | LINC00339 | NCRNA00339,HSPC157 | NA | pathogenic process;developmental process | Pancreatic ductal adenocarcinoma | |
HSALNT0144027 | HSALNG0068615 | ASAP1-IT1 | ASAP1-IT,ASAP1IT,ASAP1IT1,DDEF1IT1,HSPC054,NCRNA00050 | NA | pathogenic process | ovarian cancer | |
HSALNT0289212 | HSALNG0021208 | PCGEM1 | NCRNA00071,LINC00071,PCAT9 | transcriptional regulation;ceRNA | pathogenic process | osteoarthritis;prostate cancer;glioma | |
HSALNT0289016 | HSALNG0082243 | KCNQ1DN | BWRT,HSA404617 | NA | pathogenic process | aging;Wilms' tumor | |
HSALNT0288933 | HSALNG0097101 | DLEU2 | DLB2,BCMSUN,RFP2O,LEU2,TRIM13O, NCRNA00022,LINC00022,MIR15AHG | transcriptional regulation | pathogenic process | lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;chronic lymphocytic leukemia;non-small cell lung cancer | |
HSALNT0217624 | HSALNG0104558 | PWAR4 | PAR4,PAR-4 | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome | |
HSALNT0289165 | HSALNG0103778 | MEG8 | SNHG23,SNHG24,NCRNA00024,Irm,Rian,Bsr,LINC00024,AL132709.8,lnc-MGC | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome;temple syndrome | |
HSALNT0289482 | HSALNG0133856 | CECR7 | SAHL1 | NA | pathogenic process | hepatocellular cancer;cat eye syndrome | |
HSALNT0074223 | HSALNG0035451 | PCAT4 | GDEP,PCAN1,PCA4 | NA | pathogenic process | prostate cancer | |
HSALNT0061175 | HSALNG0029318 | PISRT1 | NCRNA00195 | transcriptional regulation | developmental process;pathogenic process | blepharophimosis syndrome | |
HSALNT0190912 | HSALNG0092137 | IFNG-AS1 | Tmevpg1,LincR-Ifng-3'A, NEST | transcriptional regulation | pathogenic process | Hashimoto's thyroiditis;primary immune thrombocytopenia;multiple sclerosis;Sjögren syndrome | |
HSALNT0038178 | HSALNG0018067 | FAM138B | F379 | NA | NA | NA | |
HSALNT0145703 | HSALNG0069515 | FAM138C | F379 | NA | NA | NA | |
HSALNT0288963 | HSALNG0000006 | FAM138A | F379 | NA | NA | NA | |
HSALNT0183947 | HSALNG0088434 | FAM138D | F379 | NA | NA | NA | |
HSALNT0226092 | HSALNG0108677 | FAM138E | F379 | NA | NA | NA | |
HSALNT0253925 | HSALNG0122829 | FAM138F | F379 | NA | NA | NA | |
HSALNT0289326 | HSALNG0141632 | LINC00312 | LOH3CR2A,NCRNA00312,NAG7,NAG-7,ERR10,ERR-10,LMCD1DN | transcriptional regulation | pathogenic process | nasopharyngeal cancer;bladder cancer;non-small cell lung cancer | |
HSALNT0288886 | HSALNG0054798 | AIRN | AIR,NCRNA00088,IGF2RA, IGF2R-AS1 | transcriptional regulation | pathogenic process | NA | |
HSALNT0254857 | HSALNG0123415 | MIR7-3HG | C19orf30,NCRNA00306,LINC00306,PGSF1,PGSF1a,PGSF1b,Huh7,uc002mbe.2 | NA | pathogenic process | liver cancer;hepatocelluar cancer | |
HSALNT0185751 | HSALNG0089375 | LOH12CR2 | LOH2CR12 | NA | pathogenic process | pre-B acute lymphoblastic leukaemia | |
HSALNT0289479 | HSALNG0133055 | DSCR8 | C21orf65,MTAG2,CT25.1a,CT25.1b,MMA-1a,MMA-1b | NA | pathogenic process | Down syndrome;melanoma | |
HSALNT0289030 | HSALNG0133422 | LINC00313 | C21orf84,NCRNA00313, | NA | pathogenic process | lung cancer | |
HSALNT0289029 | HSALNG0132830 | LINC00310 | C21orf82,NCRNA00310 | NA | pathogenic process | NA | |
HSALNT0272435 | HSALNG0132500 | LINC00161 | C21orf100,NCRNA00161 | ceRNA | pathogenic process | osteosarcoma | |
HSALNT0289184 | HSALNG0132027 | MIR99AHG | C21orf35,FLJ38295,C21orf34,LINC00478,MONC | NA | pathogenic process | myeloid leukemia | |
HSALNT0289005 | HSALNG0056865 | HOXA11-AS | HOXA11A,HOXA11-AS1,HOXA11, HOXA-AS5,NCRNA00076 | ceRNA | pathogenic process | uterine cervix cancer;ovarian cancer;glioma;cervical cancer;gastric cancer | |
HSALNT0193654 | HSALNG0093342 | RMST | NCRM, NCRNA00054,LINC00054 | transcriptional regulation | developmental process;pathogenic process | breast cancer;rhabdomyosarcoma | |
HSALNT0290079 | HSALNG0142194 | ncR-PAR | NCRUPAR,ENSG00000225407 | transcriptional regulation | developmental process;pathogenic process | gastric cancer;colorectal cancer | |
HSALNT0289167 | HSALNG0061370 | MESTIT1 | MEST-AS1,MEST-IT,MEST-IT1,NCRNA00040,PEG1-AS | NA | pathogenic process | Silver-Russell syndrome | |
HSALNT0273791 | HSALNG0133168 | DSCAM-AS1 | M41 | NA | pathogenic process | adolescent idiopathic scoliosis;breast cancer | |
HSALNT0289391 | HSALNG0104546 | PWARSN | PAR-SN,PARSN | NA | pathogenic process | NA | |
HSALNT0127791 | HSALNG0060774 | ST7-AS1 | ST7OT1,ST7AS1 | NA | pathogenic process | glioma;autism | |
HSALNT0206298 | HSALNG0099122 | DAOA-AS1 | DAOAA, DAOA-A,G30 | NA | pathogenic process | panic disorder;schizophrenia;bipolar disorder | |
HSALNT0167060 | HSALNG0080104 | OLMALINC | C10orf75,NCRNA00263,LINC00263,bA34D15.5,FLJ12974,HI-LNC80 | NA | pathogenic process | type 2 diabetes | |
HSALNT0026878 | HSALNG0012802 | LINC00299 | C2orf46,NCRNA00299,FLJ45673 | NA | pathogenic process;developmental process | intellectual and developmental disability;neurodevelopmental disabilities | |
HSALNT0289081 | HSALNG0039816 | LINC01020 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0101186 | HSALNG0048016 | LINC00518 | C6orf218,MGC40222 | NA | pathogenic process | NA | |
HSALNT0083960 | HSALNG0039909 | LINC01018 | SRHC | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289361 | HSALNG0031463 | LPP-AS2 | MYCLo-5,MYCLo-6 | NA | NA | NA | |
HSALNT0143233 | HSALNG0068292 | LINC00964 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289364 | HSALNG0094063 | MAPKAPK5-AS1 | C12orf47,FLJ39616 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289053 | HSALNG0027872 | LINC00635 | NA | NA | pathogenic process | lung cancer | |
HSALNT0289327 | HSALNG0141633 | LINC00636 | NA | NA | pathogenic process | breast cancer | |
HSALNT0262657 | HSALNG0127758 | ZNF582-AS1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289020 | HSALNG0000022 | LINC00115 | NCRNA00115,FLJ22639 | ceRNA | pathogenic process | lung adenocarcinoma | |
HSALNT0289254 | HSALNG0075291 | SNHG7 | MGC16037,NCRNA00061 | NA | pathogenic process | lung cancer | |
HSALNT0289162 | HSALNG0020412 | MAP3K20-AS1 | MLK7-AS1 | NA | pathogenic process | gastric cancer | |
HSALNT0145357 | HSALNG0069280 | RHPN1-AS1 | C8orf51,MGC3113 | NA | NA | NA | |
HSALNT0289343 | HSALNG0138602 | XIST | DXS399E,NCRNA00001,DXS1089,swd66,LINC00001 | transcriptional regulation;ceRNA | pathogenic process | non-small cell lung cancer;B-cell acute lymphoblastic leukemia;bladder cancer;testicular germ cell tumor;colorectal cancer;cancer;ovarian cancer;female cancers;renal collecting duct cancer;membranous nephropathy;Trisomy 21;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;Klinefelter's syndrome;glioblastoma;breast cancer;cystic fibrosis | |
HSALNT0289389 | HSALNG0128330 | PRNT | M8 | NA | pathogenic process | NA | |
HSALNT0288942 | HSALNG0080912 | EMX2OS | NCRNA00045,EMX2-AS1 | transcriptional regulation | pathogenic process | NA | |
HSALNT0200443 | HSALNG0096546 | LINC00598 | TTL | NA | pathogenic process | NA | |
HSALNT0289517 | HSALNG0141628 | TTTY17A | NCRNA00140 | NA | NA | NA | |
HSALNT0027901 | HSALNG0013206 | MYCNOS | NCYM,N-CYM,MYCN-AS1 | transcriptional regulation | pathogenic process | neuroblastoma | |
HSALNT0047175 | HSALNG0022192 | DIRC3 | FLJ14199 | NA | pathogenic process | familial renal cell cancer;breast cancer | |
HSALNT0289363 | HSALNG0084905 | MALAT1 | PRO1073,MALAT-1,NCRNA00047,HCN,NEAT2,LINC00047,mascRNA | splicing regulation;;translational control;transcriptional regulation;protein localization;ceRNA | pathogenic process | prostate cancer;glioma;cancer;breast cancer;ovarian cancer;amyotrophic lateral sclerosis;proliferative vitreoretinopathy;glioblastoma;endometrial stromal sarcoma;oral squamous cell cancer;acute myocardial infarction;hemangioma;pancreatic cancer;endometrioid endometrial cancer;melanoma;tongue squamous cell cancer;HIV;hepatocelluar cancer;bladder cancer;neuroblastoma;lung cancer;nasopharyngeal cancer;osteosarcoma;esophageal cancer;kidney cancer;hepatic steatosis;urothelial cancer;diabetes;triple-negative breast cancer;liver fibrosis;cervical cancer;uterus cancer;gallbladder cancer;decreased myogenesis;esophageal squamous cell cancer;fibrosarcoma;colorectal cancer;Pancreatic ductal adenocarcinoma;pre-eclampsia;retinal neurodegeneration;small cell lung cancer;multiple myeloma;gastric cancer;lung adenocarcinoma;uveal melanoma;epithelial ovarian cancer;TDP-43-associated pathological states;thyroid cancer;congenital microtia;liver cancer;renal clear cell cancer;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;non-small cell lung cancer;pulmonary arterial hypertension;diabetic cardiomyopathy;vulvar squamous cell cancer;hyperglycaemia;papillary thyroid cancer;Parkinson's disease;renal cell cancer;lung cancer brain metastasis | |
HSALNT0289744 | HSALNG0141859 | DLG2-AS1 | DLG2A, DLG2-A,PSZA11q14,SZ-1 | NA | pathogenic process | schizophrenia;myotonic dystrophy type 1;heart failure | |
HSALNT0289164 | HSALNG0103778 | MEG3 | FP504,GTL2,LINC00023,NCRNA00023,PRO0518,PRO2160,onco-lncRNA-83,prebp1 | translational control;transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;phaeochromocytoma;prostate cancer;testicular germ cell tumor;glioma;cancer;osteosarcoma;non-functioning pituitary adenoma;heroin abuse;stroke;non-small cell lung cancer;thrombocytopenic purpura;acute myeloid leukemia;pancreatic cancer;bladder cancer;tongue squamous cell cancer;hepatocelluar cancer;meningioma;drug abuse;liver fibrosis;pancreatic neuroendocrine tumor;esophageal squamous cell cancer;myelodysplastic syndrome;retinoblastoma;chronic myeloid leukemia;type 1 diabetes;breast cancer;cervical cancer;kidney cancer;gallbladder cancer;cholestatic liver injury;colorectal cancer;neuroblastoma;multiple myeloma;gastric cancer;osteoarthritis;lung adenocarcinoma;endometrial cancer;Huntington disease;diabetes;type 2 diabetes;lung cancer;epithelial ovarian cancer;primary myelofibrosis;metabolic syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;vulvar squamous cell cancer;papillary thyroid cancer;renal cell cancer;Wilms' tumor | |
HSALNT0290298 | HSALNG0142413 | TERC | DKCA1,PFBMFT2,SCARNA19,TR,TRC3,hTR | NA | pathogenic process | prostate cancer;dyskeratosis congenita;lung squamous cell cancer | |
HSALNT0288907 | HSALNG0080948 | CASC2 | NA | ceRNA | pathogenic process | colorectal cancer;gastric cancer;endometrial cancer;lung cancer;renal cell cancer;glioma | |
HSALNT0205332 | HSALNG0098601 | MIR17HG | C13orf25,MIRHG1,FLJ14178,MIRH1,MIHG1,NCRNA00048,miR-17-92,LINC00048 | NA | pathogenic process | diffuse large B-cell lymphoma;syndromic developmental defect;cancer | |
HSALNT0288716 | HSALNG0141456 | TTTY6 | TTY6,TTTY6A,LINC00127 | NA | NA | NA | |
HSALNT0288731 | HSALNG0141468 | TTTY4 | TTY4,TTTY4A,LINC00123 | NA | NA | NA | |
HSALNT0288815 | HSALNG0141548 | TTTY3 | TTY3,TTTY3A,LINC00121 | NA | NA | NA | |
HSALNT0288703 | HSALNG0141450 | TTTY5 | TTY5,LINC00126 | NA | NA | NA | |
HSALNT0289255 | HSALNG0036656 | SNHG8 | NCRNA00060,LINC00060 | NA | pathogenic process | gastric cancer;malignant pleural mesothelioma | |
HSALNT0289486 | HSALNG0141597 | BCYRN1 | BC200,BC200a,NCRNA00004,LINC00004 | splicing regulation;translational control | pathogenic process | aging;lung cancer;glioma;ovarian cancer;esophageal squamous cell cancer;non-small cell lung cancer;esophageal cancer;Alzheimer's disease;tongue cancer;parotid cancer;breast cancer;cervical cancer | |
HSALNT0144426 | HSALNG0068805 | ZFAT-AS1 | ZFATAS,ZFAT-AS,SAS-ZFAT,NCRNA00070 | NA | pathogenic process | autoimmune disease | |
HSALNT0289285 | HSALNG0077083 | ZEB1-AS1 | NA | NA | pathogenic process | esophageal squamous cell cancer;autoimmune thyroid disease;hepatocelluar cancer | |
HSALNT0289185 | HSALNG0135987 | MIRLET7BHG | linc-Ppara | NA | developmental process | NA | |
HSALNT0289374 | HSALNG0116616 | NBR2 | NCRNA00192 | transcriptional regulation | pathogenic process | gastric cancer;breast cancer;cancer | |
HSALNT0289417 | HSALNG0134930 | TUG1 | FLJ20618,NCRNA00080,LINC00080 | transcriptional regulation;ceRNA | pathogenic process | osteosarcoma;prostate cancer;glioma;ovarian cancer;glioblastoma;non-small cell lung cancer;B-cell neoplasms;chronic kidney disease;melanoma;bladder cancer;urothelial cancer of the bladder;esophageal squamous cell cancer;multiple sclerosis;breast cancer;hepatoblastoma;colorectal cancer;multiple myeloma;gastric cancer;Huntington disease;hepatocellular cancer;oesophageal squamous cell cancer;renal cell cancer | |
HSALNT0288973 | HSALNG0079552 | FAS-AS1 | FASA, FAS-A,SAF | transcriptional regulation | pathogenic process | ataxia telangiectasia | |
HSALNT0288996 | HSALNG0068110 | HAS2-AS1 | HAS2A, HAS2-A,HASNT,NCRNA00077 | transcriptional regulation | NA | NA | |
HSALNT0289390 | HSALNG0049245 | PSORS1C3 | NCRNA00196 | NA | pathogenic process | rheumatoid arthritis;psoriasis | |
HSALNT0289868 | HSALNG0141983 | HLA-AS1 | NA | NA | pathogenic process | psoriasis;liver injury;multiple sclerosis;AIDS | |
HSALNT0290154 | HSALNG0142269 | PRINS | NCRNA00074 | transcriptional regulation | pathogenic process | psoriasis;prostate cancer | |
HSALNT0262809 | HSALNG0127790 | PEG3-AS1 | PEG3AS,PEG3-AS,APEG3,NCRNA00155 | NA | NA | NA | |
HSALNT0289533 | HSALNG0141648 | 7SL | 7S RNA,SRP RNA,4.5S SRP RNA,4.5S RNA,RN7SL1 RNA,ENSG00000258486,lnc-LRR1-1:1 | protein localization | pathogenic process | AIDS;Leishmaniasis;dermatomyositis;polymyositis | |
HSALNT0290081 | HSALNG0142196 | NDM29 | 29A,lnc-C11orf16-1:1 | NA | pathogenic process | neuroblastoma | |
HSALNT0289382 | HSALNG0074439 | NRON | NCRNA00194 | NA | pathogenic process | AIDS;Down syndrome;HIV | |
HSALNT0289253 | HSALNG0065926 | SNHG6 | U87HG,HBII-276HG,NCRNA00058 | translational control;ceRNA | pathogenic process | hepatocellular cancer;hereditary haemorrhagic telangiectasia | |
HSALNT0289653 | HSALNG0141768 | Beta-globin transcript | AY195961.1,NONHSAT017674,AY034469.1,NONHSAT017675,AY034470.1,NONHSAT017676 | NA | NA | NA | |
HSALNT0290398 | HSALNG0142513 | Zfhx2as | Zfh-5AS,ENSG00000157306,ENST00000554403.1 | NA | NA | NA | |
HSALNT0011306 | HSALNG0005433 | MIR137HG | NA | NA | pathogenic process | schizophrenia;lung cancer;malignant lymphoma | |
HSALNT0289449 | HSALNG0056858 | HOXA-AS3 | HOXA6as | NA | pathogenic process | glioma | |
HSALNT0289451 | HSALNG0068551 | CCDC26 | MGC27434,RAM | transcriptional regulation | pathogenic process | hematological malignancies;glioma;acute myeloid leukemia;leukemia;pancreatic cancer;breast cancer | |
HSALNT0289893 | HSALNG0142008 | LINC00271 | C6orf217,NCRNA00271 | NA | pathogenic process | type 2 diabetes;schizophrenia | |
HSALNT0288892 | HSALNG0109621 | BCAR4 | NA | transcriptional regulation | pathogenic process | osteosarcoma;breast cancer;colorectal cancer | |
HSALNT0289890 | HSALNG0142005 | LINC00032 | C9orf14,NCRNA00032 | NA | pathogenic process | narcolepsy;melanoma | |
HSALNT0274572 | HSALNG0133591 | PICSAR | C21orf113,LINC00162,NCRNA00162,NLC1-C,NLC1C,PRED74 | transcriptional regulation | pathogenic process | testicular embryonal cancer;narcolepsy;cutaneous squamous cell cancer | |
HSALNT0256354 | HSALNG0124398 | UCA1 | CUDR,LINC00178,NCRNA00178,UCAT1,onco-lncRNA-36 | transcriptional regulation;ceRNA | developmental process;pathogenic process | oral squamous cell cancer;osteosarcoma;prostate cancer;ovarian cancer;non-small cell lung cancer;acute myocardial infarction;pancreaticobiliary maljunction;pancreatic cancer;melanoma;tongue squamous cell cancer;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;esophageal squamous cell cancer;esophageal cancer;liver cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;urinary bladder;gastric cancer;endometrial cancer;breast cancer;hepatocellular cancer;squamous cell cancer;lung cancer;renal cell cancer | |
HSALNT0003871 | HSALNG0002066 | SNHG3 | NCRNA00014,RNU17C,RNU17D,U17HG,U17HG-A,U17HG-AB | NA | pathogenic process | ovarian cancer;hepatocellular cancer;colorectal cancer;Alzheimer's disease | |
HSALNT0289475 | HSALNG0131591 | HAR1A | HAR1F,NCRNA00064,LINC00064 | transcriptional regulation | pathogenic process | Huntington disease;Alzheimer's disease | |
HSALNT0288995 | HSALNG0131589 | HAR1B | HAR1R,NCRNA00065,LINC00065 | transcriptional regulation | pathogenic process | Huntington disease;hereditary haemorrhagic telangiectasia;Alzheimer's disease | |
HSALNT0288958 | HSALNG0044150 | EPB41L4A-AS1 | C5orf26,NCRNA00219,TIGA1 | NA | pathogenic process | lung cancer;cancer | |
HSALNT0289170 | HSALNG0134655 | MIAT | C22orf35,FLJ25967,Rncr2,gomafu,NCRNA00066,LINC00066,lncRNA-MIAT | splicing regulation;ceRNA | pathogenic process | prostate cancer;chronic lymphocytic leukemia;cancer;drug abuse;diabetes-induced microvascular dysfunction;schizophrenia;acute myocardial infarction;dilated cardiomyopathy;lung adenocarcinoma;diabetic retinopathy;myocardial infarction;Alzheimer's disease | |
HSALNT0289007 | HSALNG0047947 | HULC | NCRNA00078,LINC00078,HCCAT1 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer;glioma;hepatocelluar cancer;osteosarcoma;atherosclerosis;gastric cancer;hepatocellular cancer;esophageal cancer;liver cirrhosis;diffuse large B-cell lymphoma;pancreatic cancer;papillary thyroid cancer;liver cancer;cervical cancer;colorectal cancer | |
HSALNT0288940 | HSALNG0023880 | EGOT | EGO,NCRNA00190 | NA | pathogenic process;developmental process | prostate cancer;breast cancer | |
HSALNT0289387 | HSALNG0001461 | PINK1-AS | PINK1-AS1,FLJ00387,PINK1A, naPINK1 | transcriptional regulation | pathogenic process | glucose metabolism disorder;Parkinson's disease;diabetes | |
HSALNT0289225 | HSALNG0068477 | PVT1 | NCRNA00079,LINC00079,onco-lncRNA-100,MIR1204HG,PVT | transcriptional regulation;translational control | pathogenic process | murine plasmacytomas;prostate cancer;cancer;ovarian cancer;renal cancer;B-cell lymphoma;non-small cell lung cancer;pancreatic cancer;Hodgkin's lymphoma;asthma;hepatocelluar cancer;bladder cancer;plasmacytoma;cleft lip;acute promyelocytic leukemia;diabetic nephropathy;esophageal cancer;kidney cancer;type 1 diabetes;breast cancer;cervical cancer;diabetic kidney disease;hematological malignancies;colorectal cancer;neuroblastoma;cardiac hypertrophy;multiple myeloma;gastric cancer;lymphoma;type 2 diabetes;thyroid cancer;pleural mesothelioma;lung squamous cell cancer;Burkitt lymphoma;hepatocellular cancer;renal cell cancer | |
HSALNT0289189 | HSALNG0073233 | NAMA | NA | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0246525 | HSALNG0119442 | NARF-AS1 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0147433 | HSALNG0070397 | CDKN2B-AS1 | CDKN2BA,ANRIL,RP11-145E5.4,NCRNA00089,p15A, CDKN2B-A, PCAT12 | siRNA;transcriptional regulation;ceRNA | pathogenic process | glaucoma;prostate cancer;glioma;cancer;osteosarcoma;neurofibromatosis;ischemic heart failure;stroke;non-small cell lung cancer;hypertension;intracranial aneurysm;aortic aneurysm;periodontitis;acute lymphoblastic leukemia;Alzheimer's disease;coronary artery disease;melanoma;bladder cancer;abdominal aortic aneurysm;ovarian cancer;esophageal cancer;basal cell cancer;breast cancer;cervical cancer;coronary heart disease;gallbladder cancer;acute myocardial infarction;colorectal cancer;neuroblastoma;peripheral artery disease;esophageal squamous cell cancer;atherosclerosis;leukemia;hereditary cutaneous malignant melanoma;gastric cancer;cardiovascular disease;coronary disease;frailty;diabetes;type 2 diabetes;thyroid cancer;primary open-angle glaucoma;ischemic stroke;plexiform neurofibroma;laryngeal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;myocardial infarction;lung cancer;endometriosis;primary myelofibrosis | |
HSALNT0050854 | HSALNG0024099 | GHRLOS | NCRNA00068,GHRL-AS1 | transcriptional regulation | NA | NA | |
HSALNT0288959 | HSALNG0026279 | ESRG | HESRG | NA | pathogenic process | embryonal cancer | |
HSALNT0287173 | HSALNG0140560 | FMR1-AS1 | FMR1A, FMR1-A,ASFMR1,FMR4 | transcriptional regulation | pathogenic process | fragile X syndrome;neurological disorder | |
HSALNT0289499 | HSALNG0141610 | HCG4 | HCGIV-10,HCGIV.9 | NA | pathogenic process | NA | |
HSALNT0288994 | HSALNG0038609 | HAND2-AS1 | DEIN,NBLA00301,FLJ11539 | NA | pathogenic process | neuroblastoma | |
HSALNT0289286 | HSALNG0019362 | ZEB2-AS1 | ZEB2A, ZEB2-A,ZEB2NAT | splicing regulation | pathogenic process | bladder cancer;hepatocellular cancer | |
HSALNT0017702 | HSALNG0008545 | GAS5 | SNHG2,NCRNA00030 | transcriptional regulation;ceRNA | pathogenic process | varicose great saphenous veins;prostate cancer;glioma;cancer;ovarian cancer;non-small cell lung cancer;hypertension;pancreatic cancer;B-cell neoplasms;melanoma;head and neck cancer;hepatocelluar cancer;bladder cancer;autoimmune disease;liver fibrosis;kidney cancer;breast cancer;cervical cancer;colorectal cancer;multiple myeloma;gastric cancer;osteoarthritis;endometrial cancer;lymphoma;type 2 diabetes;pleural mesothelioma;hepatocellular cancer;lung adenocarcinoma;lung cancer;renal cell cancer | |
HSALNT0288891 | HSALNG0087449 | BACE1-AS | BACE1A,FJ573250,NCRNA00177,BACE1-AS1 | translational control;transcriptional regulation | pathogenic process | ovarian cancer;colorectal cancer;Alzheimer's disease | |
HSALNT0289414 | HSALNG0133533 | TRPM2-AS | TRPM2-AS1 | NA | pathogenic process | melanoma;prostate cancer | |
HSALNT0288935 | HSALNG0008462 | DNM3OS | DNM3-AS1,MIR199A2HG | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0288930 | HSALNG0133982 | DGCR5 | NCRNA00037,LINC00037 | transcriptional regulation | pathogenic process | Huntington disease;DiGeorge syndrome;velocardiofacial syndrome;clear cell renal cell cancer | |
HSALNT0288893 | HSALNG0083307 | BDNF-AS | BDNFO,BT2A,BT2B,BT2C,BT2D,NCRNA00049,BDNF-AS1,BDNFAS | siRNA;transcriptional regulation | developmental process;pathogenic process | Huntington disease;schizophrenia;psychiatric disease;obesity | |
HSALNT0120317 | HSALNG0056850 | HOTAIRM1 | HOXA-AS1,NCRNA00179,HOXA1-AS1 | transcriptional regulation | pathogenic process;developmental process | colorectal cancer;Pancreatic ductal adenocarcinoma;promyelocytic leukemia;acute myeloid leukemia;infiltrating ductal cancers ;acute promyelocytic leukemia;leukemia;glioma | |
HSALNT0290158 | HSALNG0142273 | PTCSC1 | PTCSC,AK023948,NCRNA00197 | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0289004 | HSALNG0091318 | HOTAIR | HOXC-AS4,HOXC11-AS1,NCRNA00072 | siRNA;transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;prostate cancer;glioma;cancer;breast cancer;osteosarcoma;renal cancer;glioblastoma;non-small cell lung cancer;sarcoma;pancreatic cancer;large B-Cell lymphoma;bladder transitional cell cancer;B-cell neoplasms;melanoma;asthenozoospermia;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;aortic valve calcification;infiltrating ductal cancers ;ovarian cancer;diffuse large B-cell lymphoma;gastrointestinal stromal tumor;atypical teratoid rhabdoid tumor;urothelial cancer;triple-negative breast cancer;gastric cardia adenocarcinoma;cervical cancer;temporomandibular joint osteoarthritis;gallbladder cancer;esophageal squamous cell cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;rheumatoid arthritis;gastric cancer ;pre-eclampsia;acute leukemia;small cell lung cancer;multiple myeloma;gastric cancer;osteoarthritis;LPS-induced sepsis;endometrial cancer;head and neck squamous cell cancer;gastric adenocarcinoma;lung cancer;liver cancer;ischemic stroke;ischemic heart failure;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;papillary thyroid cancer;Parkinson's disease;renal cell cancer;gastrointestinal cancer | |
HSALNT0289192 | HSALNG0084892 | NEAT1 | NCRNA00084,TncRNA,MENepsilon/beta,LINC00084,VINC | transcriptional regulation;ceRNA | pathogenic process | oral squamous cell cancer;glioma;ovarian cancer;amyotrophic lateral sclerosis;paraspeckle disintegration;nasopharyngeal cancer;AIDS;frontotemporal lobar degeneration;prostate cancer;systemic lupus erythematosus;renal syndrome;TDP-43-associated pathological states;HIV;Huntington disease;chronic lymphocytic leukemia;acute promyelocytic leukemia;esophageal squamous cell cancer;multiple sclerosis;breast cancer;intrauterine growth restriction;colorectal cancer;leukemia;gastric cancer;malignant pleural mesothelioma;endometrial cancer;gastric adenocarcinoma;papillary thyroid cancer;infertility;bladder cancer;hepatocellular cancer;non-small cell lung cancer;obesity;lung cancer;Parkinson's disease;laryngeal squamous cell cancer | |
HSALNT0095094 | HSALNG0045213 | SNHG4 | U19H,NCRNA00059 | NA | pathogenic process | myelodysplastic syndrome | |
HSALNT0245443 | HSALNG0118855 | SNHG16 | ncRAN,Nbla12061,Nbla10727 | NA | pathogenic process | bladder cancer;bladder cancer;colorectal cancer;neuroblastoma | |
HSALNT0288897 | HSALNG0023698 | BOK-AS1 | BOKA,NCRNA00151,NAToB | NA | pathogenic process | esophageal squamous cell cancer;testicular cancer;cancer | |
HSALNT0289532 | HSALNG0141647 | 7SK | 7-3 RNA,K-RNA,7SK-RNA,7SK snRNA,RN7SK,ENSG00000202198,NONHSAT113149 | transcriptional regulation | developmental process;pathogenic process | cancer;cardiac hypertrophy;gastric cancer;AIDS;multiple sclerosis;colorectal adenocarcinoma | |
HSALNT0289182 | HSALNG0017872 | MIR4435-2HG | MIR4435-1HG,LINC00978,AGD2,AK001796,lncRNA-AWPPH,MORRBID | NA | pathogenic process | lung cancer | |
HSALNT0289200 | HSALNG0016500 | PARTICL | PARTICLE | transcriptional regulation | pathogenic process | low-dose irradiation | |
HSALNT0289172 | HSALNG0069266 | MINCR | LINC01604,TCONS_00015189 | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;Burkitt lymphoma | |
HSALNT0001792 | HSALNG0000905 | NPPA-AS1 | NPPAA, NPPA-AS | splicing regulation | pathogenic process | cardiovascular disease | |
HSALNT0290230 | HSALNG0142345 | RRP1B | NA | transcriptional regulation | pathogenic process | spinocerebellar ataxia;laryngeal squamous cell cancer;cancer | |
HSALNT0289467 | HSALNG0093062 | CLLU1 | NA | NA | NA | NA | |
HSALNT0289173 | HSALNG0087764 | MIR100HG | AGD1,lncRNA-N2,linc-NeD125 | NA | developmental process;pathogenic process | myeloid leukemia;myopia;cervical cancer;neuroblastoma | |
HSALNT0059175 | HSALNG0028235 | TUSC7 | LINC00902,LSAMP-AS1,LSAMP-AS3,LSAMPAS3,NCRNA00295 | transcriptional regulation;ceRNA | pathogenic process | glioma;Pancreatic ductal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;ischemic heart failure;gastric cancer;hepatocellular cancer;non-small cell lung cancer;acute myeloid leukemia;colorectal cancer | |
HSALNT0289647 | HSALNG0141762 | BC040587 | NA | NA | pathogenic process | osteosarcoma;breast cancer | |
HSALNT0059186 | HSALNG0028242 | LINC00901 | LSAMP-AS4,TCONS_00005428,BC040587 | NA | pathogenic process | osteosarcoma;gastric cancer;breast cancer | |
HSALNT0233366 | HSALNG0112604 | HCCAT5 | HTA,FJ222407 | NA | pathogenic process | hepatocellular cancer | |
HSALNT0290040 | HSALNG0142155 | LSINCT5 | NA | NA | pathogenic process | chronic heart failure;colorectal cancer;ovarian cancer;gastric cancer;lung cancer;breast cancer | |
HSALNT0179611 | HSALNG0086377 | DISC1FP1 | Boymaw | transcriptional regulation | pathogenic process | schizophrenia | |
HSALNT0217643 | HSALNG0104567 | SNHG14 | 115HG,IC-SNURF-SNRPN,LNCAT,NCRNA00214,U-UBE3A-AT, UBE3A-A, UBE3A-AS1,UBE3AATS | ceRNA | pathogenic process | Angelman syndrome;cerebral infarction;Prader-Willi syndrome | |
HSALNT0289273 | HSALNG0000343 | TP73-AS1 | KIAA0495,PDAM | NA | pathogenic process | esophageal squamous cell cancer;oligodendroglial tumors;non-small cell lung cancer;glioblastoma;multiple myeloma | |
HSALNT0290311 | HSALNG0142426 | TP53COR1 | Trp53cor1 | transcriptional regulation | pathogenic process | prostate cancer;colorectal cancer;hepatocelluar cancer;atherosclerosis;Burkitt lymphoma;chronic lymphocytic leukemia;B cell lymphoma;lung cancer;cervical cancer | |
HSALNT0289221 | HSALNG0068414 | PRNCR1 | CARLo-3,PCAT8 | transcriptional regulation | pathogenic process | gastric cancer;prostate cancer;glioma;colorectal cancer | |
HSALNT0020131 | HSALNG0009743 | PCAT6 | KDM5B-AS1,ncRNA-a2,PCAN-R1,KDM5BAS1,onco-lncRNA-96 | transcriptional regulation | pathogenic process | prostate cancer;triple-negative breast cancer;lung cancer | |
HSALNT0289277 | HSALNG0130723 | TRERNA1 | LINC00651,ncRNA-a7,treRNA | transcriptional regulation | NA | NA | |
HSALNT0014972 | HSALNG0007045 | FALEC | LINC00568,ncRNA-a1,FAL1 | transcriptional regulation | pathogenic process | ovarian cancer;thyroid cancer | |
HSALNT0290008 | HSALNG0142123 | LOC100887755 | Noncoding RNA activating7: ncRNA-a7,ENST00000431460.1,ENSG00000231265,TRERNA1 | transcriptional regulation | pathogenic process | hepatocellular cancer | |
HSALNT0290248 | HSALNG0142363 | snaR | EU035784.1,lnc-BSPH1-1:1 | transcriptional regulation | NA | NA | |
HSALNT0289342 | HSALNG0138609 | JPX | NCRNA00183,ENOX,LINC00183,DCBALD06 | transcriptional regulation | pathogenic process | hepatocellular cancer | |
HSALNT0289231 | HSALNG0001716 | RCAN3AS | TCONS_00001428 | NA | NA | NA | |
HSALNT0289280 | HSALNG0069631 | VLDLR-AS1 | lincRNA-VLDLR | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0288982 | HSALNG0138614 | FTX | NCRNA00182,MIR374AHG,LINC00182,FLJ33139 | transcriptional regulation | pathogenic process | hepatocellular cancer;breast cancer;colorectal cancer;hepatocelluar cancer | |
HSALNT0091079 | HSALNG0043383 | MEF2C-AS1 | NA | NA | pathogenic process | gastric cancer;Prader-Willi syndrome and Angelman syndrome | |
HSALNT0189341 | HSALNG0091277 | PCBP2-OT1 | TUC338 | NA | pathogenic process | hepatocellular cancer;tongue squamous cell cancer | |
HSALNT0290373 | HSALNG0142488 | WRAP53 | NA | NA | pathogenic process | hepatocellular cancer;cancer;dyskeratosis congenita | |
HSALNT0289265 | HSALNG0049949 | TDRG1 | LINC00532,lincRNA-NRNA024015 | NA | pathogenic process | esophageal squamous cell cancer;gastric cancer;testicular cancer;aplastic anemia | |
HSALNT0289175 | HSALNG0132382 | MIR155HG | MIRHG2,BIC,NCRNA00172 | NA | pathogenic process | B-cell chronic lymphocytic leukemia;chronic lymphocytic leukemia;breast cancer;glioma | |
HSALNT0289051 | HSALNG0024293 | LINC00620 | NA | NA | pathogenic process | cervical cancer | |
HSALNT0120390 | HSALNG0056871 | HOTTIP | NCRNA00213,HOXA-AS6,RP1-170O19.3,HOXA13-AS1 | transcriptional regulation | pathogenic process | hirschsprung disease;colorectal cancer;prostate cancer;tongue squamous cell cancer;Pancreatic ductal adenocarcinoma;osteosarcoma;hepatocelluar cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;pancreatic cancer;lung cancer;glioma | |
HSALNT0289287 | HSALNG0130661 | ZFAS1 | C20orf199,NCRNA00275,ZNFX1-AS1,HSUP1,HSUP2 | transcriptional regulation;ceRNA | pathogenic process | gastric cancer;hepatocellular cancer;ductal cancer;colorectal cancer;breast cancer | |
HSALNT0289259 | HSALNG0045502 | SPRY4-IT1 | SPRIGHTLY | transcriptional regulation | pathogenic process | prostate cancer;melanoma;glioma;esophageal squamous cell cancer;pre-eclampsia;bladder cancer;renal clear cell cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung cancer;breast cancer;cervical cancer;colorectal cancer | |
HSALNT0105595 | HSALNG0049759 | PANDAR | PANDA | transcriptional regulation | pathogenic process | colorectal cancer;cancer;bladder cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;p53-associated pathological states;breast cancer;renal cell cancer | |
HSALNT0068185 | HSALNG0032415 | HTT-AS | HTT-AS1,HTTAS | NA | pathogenic process | Huntington disease | |
HSALNT0099036 | HSALNG0047200 | HEIH | LINC-HEIH,lncRNA-HEIH,LINC00848,HCCAT2 | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0222533 | HSALNG0107117 | NPTN-IT1 | lncRNA-LET | NA | pathogenic process | gallbladder cancer;colorectal cancer;hepatocelluar cancer;esophageal squamous cell cancer;lung squamous cell cancer;nasopharyngeal cancer;gastric cancer;hypoxia;squamous cell lung cancer;cervical cancer | |
HSALNT0289747 | HSALNG0141862 | DQ786243 | NA | transcriptional regulation | pathogenic process | crohn's disease;colorectal cancer;hepatocelluar cancer | |
HSALNT0289204 | HSALNG0068414 | PCAT1 | PCAT-1,PCA1 | transcriptional regulation;ceRNA | pathogenic process | prostate cancer;colorectal cancer;esophageal squamous cell cancer;bladder cancer;hepatocellular cancer;lung cancer | |
HSALNT0275894 | HSALNG0134403 | PCAT14 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0211999 | HSALNG0101780 | HIF1A-AS2 | 3'aHIF-1A,aHIF | translational control | pathogenic process | bladder cancer;osteosarcoma;renal cancer;glioblastoma;gastric cancer;acute myocardial infarction;kidney cancer;breast cancer | |
HSALNT0288999 | HSALNG0101776 | HIF1A-AS1 | 5'aHIF-1A,5'aHIF1alpha | NA | pathogenic process | acute myocardial infarction;non-small cell lung cancer;cardiovascular disease;aortic aneurysm;thoracoabdominal aorta aneurysm;kidney cancer | |
HSALNT0289258 | HSALNG0031034 | SOX2-OT | SOX2OT,DKFZp761J1324,NCRNA00043 | transcriptional regulation | pathogenic process | colorectal cancer;esophageal squamous cell cancer;lung squamous cell cancer;retinal neurodegeneration;neurodevelopmental syndromes associated with the SOX2 locus;hepatocellular cancer;lung cancer;breast cancer;Alzheimer's disease | |
HSALNT0289700 | HSALNG0141815 | CDR1-AS | CDR1NAT,ciRS-7,CDR1as | ceRNA | NA | NA | |
HSALNT0289149 | HSALNG0050599 | LINCMD1 | MIR133BHG,LINC-MD1 | ceRNA | developmental process;pathogenic process | Duchenne muscular dystrophy | |
HSALNT0288894 | HSALNG0082362 | BGLT3 | LINC01083,BGL3,lncRNA-BGL3 | ceRNA | pathogenic process | chronic myeloid leukemia | |
HSALNT0289042 | HSALNG0055058 | LINC00473 | C6orf176,bA142J11.1 | transcriptional regulation | pathogenic process | non-small cell lung cancer;renal cell cancer | |
HSALNT0101681 | HSALNG0048223 | LINC01108 | LncRNA-ES1 | NA | developmental process | NA | |
HSALNT0289418 | HSALNG0103465 | TUNAR | LINC00617,TUNA,HI-LNC78 | transcriptional regulation | developmental process;pathogenic process | breast cancer | |
HSALNT0289197 | HSALNG0105343 | OIP5-AS1 | cyrano,linc-OIP5 | NA | developmental process | NA | |
HSALNT0289046 | HSALNG0048515 | LINC00581 | NA | NA | pathogenic process | West Syndrome;West syndrome | |
HSALNT0289656 | HSALNG0141771 | BX118339 | NA | NA | pathogenic process | West syndrome | |
HSALNT0021726 | HSALNG0010465 | LINC00538 | Yiya,PROX1UT | NA | pathogenic process | colorectal cancer;cancer | |
HSALNT0273249 | HSALNG0132926 | CBR3-AS1 | PlncRNA-1,PlncRNA1 | ceRNA | pathogenic process | esophageal squamous cell cancer;hepatocellular cancer;prostate cancer | |
HSALNT0289179 | HSALNG0070363 | MIR31HG | LOC554202,hsa-lnc-31,LncHIFCAR | ceRNA | pathogenic process | bladder cancer;gastric cancer;breast cancer;colorectal cancer;Pancreatic ductal adenocarcinoma | |
HSALNT0288925 | HSALNG0034419 | DANCR | KIAA0114,SNHG13,ANCR,AGU2,lncRNA-ANCR | transcriptional regulation | developmental process;pathogenic process | prostate cancer;colorectal cancer;osteosarcoma;bone diseases;postmenopausal osteoporosis;hepatocellular cancer;breast cancer | |
HSALNT0290329 | HSALNG0142444 | uc.388 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289842 | HSALNG0141957 | FR0348383 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0289279 | HSALNG0141211 | TTTY15 | DKFZP434I143,NCRNA00138 | NA | pathogenic process | NA | |
HSALNT0289718 | HSALNG0141833 | CRNDE | LOC643911,LINC00180,CRNDEP | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;colorectal cancer;ovarian cancer;medulloblastoma;chronic lymphocytic leukemia;renal cell cancer;glioma | |
HSALNT0289685 | HSALNG0141800 | CCND1 | NA | NA | pathogenic process | tumor;cervical cancer | |
HSALNT0289935 | HSALNG0142050 | lincRNA-p21 | NA | transcriptional regulation | pathogenic process | lung cancer;cancer | |
HSALNT0290134 | HSALNG0142249 | PCNCR1 | NA | NA | pathogenic process | prostate cancer | |
HSALNT0289492 | HSALNG0141603 | DBET | DBE-T,DUX4L30 | transcriptional regulation | developmental process;pathogenic process | facioscapulohumeral muscular dystrophy | |
HSALNT0289455 | HSALNG0071734 | BANCR | LINC00586 | transcriptional regulation | pathogenic process | osteosarcoma ;lung cancer;melanoma;colorectal cancer;osteosarcoma;esophageal squamous cell cancer;bladder cancer;eosinophilic esophagitis;gastric cancer;hepatocellular cancer;non-small cell lung cancer;retinoblastoma;papillary thyroid cancer | |
HSALNT0209589 | HSALNG0100636 | PTCSC3 | NA | ceRNA | pathogenic process | papillary thyroid cancer;thyroid cancer | |
HSALNT0290063 | HSALNG0142178 | MVIH | NA | ceRNA | pathogenic process | hepatocellular cancer;non-small cell lung cancer;breast cancer;microvascular invasion in hepatocellular cancer;hepatocelluar cancer | |
HSALNT0289103 | HSALNG0052921 | LINC01268 | LOC285758 | NA | pathogenic process | NA | |
HSALNT0289070 | HSALNG0031716 | LINC00887 | linc-ATP13A4-8,HEIRCC | transcriptional regulation | pathogenic process | hypoxic and inflammatory renal epithelial injury;renal clear cell cancer | |
HSALNT0288931 | HSALNG0100075 | DHRS4-AS1 | C14orf167,PRO1488,AS1DHRS4 | transcriptional regulation | NA | NA | |
HSALNT0288974 | HSALNG0113304 | FENDRR | FOXF1-AS1,TCONS_00024240,lincFOXF1,onco-lncRNA-21 | transcriptional regulation | developmental process;pathogenic process | osteosarcoma;gastric cancer;non-small cell lung cancer;lung cancer | |
HSALNT0106473 | HSALNG0050235 | LINC01512 | LOC100132354,TCONS_00011120,HI-LNC77 | NA | pathogenic process | lung adenocarcinoma;type 2 diabetes | |
HSALNT0289059 | HSALNG0118547 | LINC00673 | HI-LNC75,HILNC75,LUCAIR1,SLNCR,SLNCR1 | transcriptional regulation | pathogenic process | pancreatic cancer;type 2 diabetes;non-small cell lung cancer;melanoma;Pancreatic ductal adenocarcinoma | |
HSALNT0289107 | HSALNG0128306 | LINC01433 | LOC728228 | NA | pathogenic process | lung cancer | |
HSALNT0143571 | HSALNG0068424 | CCAT1 | CARLo-5,onco-lncRNA-40 | ceRNA | pathogenic process | gallbladder cancer;glioma;hepatocelluar cancer;ovarian cancer;acute myeloid leukemia;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung adenocarcinoma;endometrial cancer;lung cancer;breast cancer;colorectal cancer | |
HSALNT0289408 | HSALNG0123467 | TINCR | ENST00000448587.1,FLJ90734,NCRNA00036,LINC00036,onco-lncRNA-16 | translational control | pathogenic process;developmental process | bladder cancer;colorectal cancer;esophageal squamous cell cancer;gastric cancer;skin desease;squamous cell cancer | |
HSALNT0289152 | HSALNG0060113 | LNCPRESS1 | lncPRESS1 | translational control | NA | NA | |
HSALNT0289145 | HSALNG0075843 | LINC02561 | RP11-445P17.8 | NA | pathogenic process | cystic fibrosis | |
HSALNT0289065 | HSALNG0140616 | LINC00850 | KUCG1 | NA | pathogenic process | Duchenne muscular dystrophy | |
HSALNT0289431 | HSALNG0032699 | AFAP1-AS1 | AFAP1A, AFAP1-A,MGC10981 | NA | pathogenic process | non-small cell lung cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;esophageal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;pancreatic cancer;Barrett's Esophagus;lung cancer | |
HSALNT0289519 | HSALNG0141630 | XACT | NA | NA | NA | NA | |
HSALNT0248684 | HSALNG0120344 | GATA6-AS1 | locus5689,BM742401 | NA | pathogenic process | gastric cancer;chronic lymphocytic leukemia | |
HSALNT0289222 | HSALNG0073144 | PTCSC2 | NA | transcriptional regulation | pathogenic process | papillary thyroid cancer | |
HSALNT0289655 | HSALNG0141770 | BTG3-AS1 | ASBEL | translational control | pathogenic process | ovarian cancer;colorectal cancer | |
HSALNT0289224 | HSALNG0070801 | PTENP1 | NONHSAT130775,PTENpg1,PTEN2,ENSG00000237984 | transcriptional regulation;ceRNA | pathogenic process | gastric cancer;prostate cancer;renal cell cancer;cancer;hepatocelluar cancer | |
HSALNT0290129 | HSALNG0142244 | PAN | NA | transcriptional regulation | pathogenic process | Kaposi's sarcoma | |
HSALNT0289939 | HSALNG0142054 | LINC-ROR | lincRNA-RoR,lincRNA-ST8SIA3,ROR | transcriptional regulation;ceRNA | pathogenic process | gallbladder cancer;liver cancer;glioma;malignant melanoma;unveal melanoma;breast cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;pancreatic cancer;endometrial cancer;triple-negative breast cancer;colorectal cancer | |
HSALNT0290322 | HSALNG0142437 | UBE3A-ATS | NA | NA | pathogenic process | Angelman syndrome | |
HSALNT0091004 | HSALNG0043367 | LINC00461 | EyeLinc1,Visc-1a,Visc-1b,Visc-2,LOC645323 | NA | pathogenic process;developmental process | retinal and visual function | |
HSALNT0289491 | HSALNG0141602 | CTBP1-AS | PCAT10 | transcriptional regulation | pathogenic process | chronic hepatitis C;prostate cancer;polycystic ovary syndrome | |
HSALNT0037401 | HSALNG0017694 | GACAT1 | LINC00876,AC096655.1-002 | NA | pathogenic process | gastric cancer | |
HSALNT0120344 | HSALNG0056854 | HOXA-AS2 | HOXA3as | transcriptional regulation | pathogenic process | promyelocytic leukemia;gastric cancer | |
HSALNT0091313 | HSALNG0043441 | LUCAT1 | SCAL1 | transcriptional regulation | pathogenic process | non-small cell lung cancer;lung cancer | |
HSALNT0289425 | HSALNG0009941 | BLACAT1 | linc-UBC1,LINC00912,onco-lncRNA-30 | transcriptional regulation | pathogenic process | bladder cancer;gastric cancer | |
HSALNT0149012 | HSALNG0071221 | GLIDR | LINC01172,MGC21881,TCONS_00015562 | NA | pathogenic process | glioblastoma | |
HSALNT0217561 | HSALNG0104548 | PWAR5 | PAR5,PAR-5 | NA | pathogenic process | glioblastoma;Prader-Willi syndrome and Angelman syndrome;Prader-Willi syndrome | |
HSALNT0289272 | HSALNG0059377 | TP53TG1 | TP53AP1,H_RG012D21.9,LINC00096 | NA | pathogenic process | non-small cell lung cancer;ataxia telangiectasia | |
HSALNT0289598 | HSALNG0141713 | AK126698 | NA | NA | pathogenic process | non-small cell lung cancer | |
HSALNT0217598 | HSALNG0104558 | IPW | NCRNA00002 | transcriptional regulation | pathogenic process | Prader-Willi syndrome | |
HSALNT0143633 | HSALNG0068443 | CCAT2 | NCCP1,LINC00873 | transcriptional regulation | pathogenic process | non-small cell lung cancer;oral squamous cell cancer;colorectal cancer;ovarian cancer;esophageal squamous cell cancer;bladder cancer;small cell lung cancer;gastric cancer;hepatocellular cancer;prostate cancer;cervical squamous cell cancer;lung cancer;breast cancer;cervical cancer | |
HSALNT0289026 | HSALNG0129180 | LINC00261 | C20orf56,NCRNA00261,bA216C10.1,HCCDR1,TCONS_00027846,ALIEN,DEANR1,onco-lncRNA-17 | NA | pathogenic process | pancreatic cancer;non-small cell lung cancer;gastric cancer | |
HSALNT0289078 | HSALNG0000303 | LINC00982 | FLJ42875 | NA | pathogenic process | gastric cancer | |
HSALNT0290082 | HSALNG0142197 | NEAT1_2 | NEAT1_2 | protein localization | pathogenic process | amyotrophic lateral sclerosis | |
HSALNT0288989 | HSALNG0076040 | GATA3-AS1 | NA | transcriptional regulation | pathogenic process | renal cell cancer | |
HSALNT0289427 | HSALNG0004297 | GNG12-AS1 | NA | transcriptional regulation | NA | NA | |
HSALNT0290395 | HSALNG0142510 | YAM1 | Yam-1 | transcriptional regulation | pathogenic process;developmental process | skeletal myogenesis | |
HSALNT0289202 | HSALNG0018036 | PAX8-AS1 | NA | NA | pathogenic process | malignant pleural mesothelioma;cervical cancer | |
HSALNT0054469 | HSALNG0026023 | RASSF1-AS1 | ANRASSF1 | transcriptional regulation | pathogenic process | breast cancer | |
HSALNT0290261 | HSALNG0142376 | SUMO1P3 | SUMO1P3 | NA | pathogenic process | bladder cancer;gastric cancer | |
HSALNT0289002 | HSALNG0094549 | HNF1A-AS1 | C12orf27,NCRNA00262,FLJ38690,HAS1 | ceRNA | pathogenic process | esophageal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;adenocarcinoma;lung adenocarcinoma;pancreatic cancer | |
HSALNT0289377 | HSALNG0041218 | NIPBL-AS1 | NIPBL-DT,NIPBL-AS | NA | pathogenic process | autism spectrum disorder | |
HSALNT0289249 | HSALNG0057702 | SNHG15 | C7orf40,FLJ38860,MYO1GUT,Linc-Myo1g | NA | pathogenic process | gastric cancer;hepatocellular cancer;hereditary haemorrhagic telangiectasia | |
HSALNT0235898 | HSALNG0113835 | MIR22HG | C17orf91,MGC14376,DKFZp686O06159 | NA | pathogenic process | ovarian cancer | |
HSALNT0235898 | HSALNG0113835 | MIR22HG | C17orf91,MGC14376,DKFZp686O06159 | NA | NA | NA | |
HSALNT0288984 | HSALNG0119881 | GACAT2 | MTCL1-AS1,HMlincRNA717 | NA | pathogenic process | pancreatic cancer;non-small cell lung cancer;gastric cancer | |
HSALNT0289369 | HSALNG0134448 | MIF-AS1 | LOC284889,MIF-AS | transcriptional regulation | pathogenic process | malaria;nephrolithiasis | |
HSALNT0129086 | HSALNG0061385 | LINC-PINT | MKLN1-AS1,FLJ43663,PINT,LincRNA-Pint | transcriptional regulation | pathogenic process | colorectal cancer;heart failure | |
HSALNT0289240 | HSALNG0020769 | SCHLAP1 | LINC00913,SChLAP1,PCAT11 | transcriptional regulation | pathogenic process | bladder cancer;prostate cancer | |
HSALNT0193241 | HSALNG0093119 | SOCS2-AS1 | NA | transcriptional regulation | pathogenic process | prostate cancer | |
HSALNT0138824 | HSALNG0066261 | CASC9 | ESCCAL-1,ESSCAL1,LINC00981 | NA | pathogenic process | esophageal squamous cell cancer;esophageal cancer | |
HSALNT0267627 | HSALNG0130306 | HNF4A-AS1 | uc002xlx | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289194 | HSALNG0131196 | NKILA | NA | NA | pathogenic process | nasopharyngeal cancer;breast cancer;tongue squamous cell cancer | |
HSALNT0289304 | HSALNG0088539 | LINC00942 | NA | NA | pathogenic process | ovarian cancer;autism spectrum disorder | |
HSALNT0289187 | HSALNG0062700 | MNX1-AS1 | CCAT5,LOC645249 | NA | pathogenic process | ovarian cancer;colorectal cancer | |
HSALNT0289518 | HSALNG0141629 | VPS9D1-AS1 | MYU | NA | pathogenic process | ovarian cancer;colorectal cancer | |
HSALNT0290266 | HSALNG0142381 | TC0101441 | NA | NA | pathogenic process | epithelial ovarian cancer | |
HSALNT0289426 | HSALNG0009856 | ERLNC1 | TC0101441,ElncRNA1 | NA | pathogenic process | ovarian cancer | |
HSALNT0290050 | HSALNG0142165 | Mdgt | NA | NA | NA | NA | |
HSALNT0043560 | HSALNG0020594 | HAGLR | HOXD-AS1,Mdgt | NA | pathogenic process | bladder cancer;neuroblastoma | |
HSALNT0289092 | HSALNG0017541 | LINC01158 | PANTR1,linc-Brn1a,linc-POU3F3 | transcriptional regulation | pathogenic process;developmental process | esophageal squamous cell cancer;gastric cancer;glioma | |
HSALNT0289448 | HSALNG0062110 | GHET1 | lncRNA-GHET1 | NA | pathogenic process | bladder cancer;gastric cancer;colorectal cancer | |
HSALNT0289514 | HSALNG0141625 | PEG13 | NA | transcriptional regulation | pathogenic process | intellectual disabilities | |
HSALNT0289183 | HSALNG0140233 | MIR503HG | MGC16121,H19X | NA | pathogenic process | choriocarcinoma | |
HSALNT0289201 | HSALNG0083445 | PAUPAR | NA | transcriptional regulation | pathogenic process;developmental process | uveal melanoma | |
HSALNT0288956 | HSALNG0094171 | LINC01234 | LCAL84,onco-lncRNA-32 | ceRNA | pathogenic process | oesophageal squamous cell cancer;breast cancer | |
HSALNT0289021 | HSALNG0016642 | CYTOR | C2orf59,NCRNA00152,MGC4677 | transcriptional regulation;ceRNA | pathogenic process | colorectal cancer;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;renal cell cancer | |
HSALNT0289706 | HSALNG0141821 | CHRF | NA | ceRNA | pathogenic process | cardiac hypertrophy;silicosis | |
HSALNT0143635 | HSALNG0068436 | CASC8 | LINC00860,CARLo-1 | NA | pathogenic process | lung cancer | |
HSALNT0143672 | HSALNG0068465 | CASC11 | TCONS_00014535,LINC00990,CARLo-7,ENST00000518376 | transcriptional regulation | pathogenic process | hepatocellular cancer;colorectal cancer | |
HSALNT0289032 | HSALNG0133191 | LINC00323 | PRED42,FLJ37173 | NA | pathogenic process | breast cancer;hereditary haemorrhagic telangiectasia | |
HSALNT0024655 | HSALNG0011845 | LINC01139 | LINK-A,TCONS_00000027 | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0289018 | HSALNG0036270 | LEF1-AS1 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia;colorectal cancer | |
HSALNT0247326 | HSALNG0119753 | LINC00667 | NA | NA | pathogenic process | hereditary haemorrhagic telangiectasia | |
HSALNT0290145 | HSALNG0142260 | POU3F3 | NA | transcriptional regulation | pathogenic process | esophageal squamous cell cancer;glioma | |
HSALNT0199349 | HSALNG0096112 | LINC00426 | NA | NA | pathogenic process | primary Sjögren's syndrome | |
HSALNT0155974 | HSALNG0074744 | LINC00963 | MetaLnc9 | NA | pathogenic process | prostate cancer;renal cell cancer | |
HSALNT0289211 | HSALNG0086124 | PCF11-AS1 | NA | NA | pathogenic process | hepatocellular cancer;adolescent idiopathic scoliosis | |
HSALNT0289534 | HSALNG0141649 | 91H | NA | transcriptional regulation | pathogenic process | osteosarcoma;esophageal squamous cell cancer;breast cancer;colorectal cancer | |
HSALNT0289446 | HSALNG0055679 | ELFN1-AS1 | MYCLo-2 | transcriptional regulation | pathogenic process | colorectal cancer | |
HSALNT0288883 | HSALNG0079547 | ACTA2-AS1 | uc001kfo.1,ZXF1 | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289443 | HSALNG0059132 | APTR | RSBN1L-AS1 | transcriptional regulation | pathogenic process | liver fibrosis;glioblastoma | |
HSALNT0289986 | HSALNG0142101 | lncRNA-MVIH | NA | NA | pathogenic process | hepatocellular cancer;non-small cell lung cancer | |
HSALNT0289977 | HSALNG0142092 | lncRNA-ATB | NA | ceRNA | pathogenic process | colorectal cancer;hepatocelluar cancer;gastric cancer;pancreatic cancer;renal cell cancer;pneumoconiosis | |
HSALNT0289622 | HSALNG0141737 | ATB | NA | ceRNA | pathogenic process | prostate cancer;glioma;keloid;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;colorectal cancer | |
HSALNT0289586 | HSALNG0141701 | AK057054 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0278370 | HSALNG0135702 | LINC01315 | lnc-C22orf32-1,C22orf32-1 | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0055601 | HSALNG0026583 | ADAMTS9-AS2 | NA | NA | pathogenic process | non-small cell lung cancer;glioma | |
HSALNT0289383 | HSALNG0009103 | PACERR | PACER,PTGS2-AS1 | transcriptional regulation | pathogenic process | osteosarcoma;osteoarthritis;inflammation and cancer | |
HSALNT0289268 | HSALNG0010604 | TGFB2-OT1 | FLJ11812 | ceRNA | NA | NA | |
HSALNT0288938 | HSALNG0027860 | DUBR | LINC00883 | ceRNA | pathogenic process | asthma and chronic obstructive pulmonary disease | |
HSALNT0290147 | HSALNG0142262 | POXCUT | TCONS_00011636 | NA | NA | NA | |
HSALNT0289440 | HSALNG0047407 | FOXCUT | LINC01379,TCONS_00011636 | transcriptional regulation | pathogenic process | esophageal squamous cell cancer;basal-like breast cancer;oral squamous cell cancer | |
HSALNT0288924 | HSALNG0059521 | CYP51A1-AS1 | ENST00000453068,LRRD1-AS1 | NA | pathogenic process | renal cell cancer | |
HSALNT0289395 | HSALNG0036288 | RPL34-AS1 | FLJ37673,RP11-462C24.1 | NA | pathogenic process | gastric cancer;colorectal cancer | |
HSALNT0289435 | HSALNG0045015 | C5orf66-AS1 | CTC-276P9.1,Epist | NA | pathogenic process | esophageal squamous cell cancer;bladder cancer | |
HSALNT0289052 | HSALNG0006924 | LINC00623 | NA | NA | pathogenic process | nasopharyngeal cancer | |
HSALNT0289831 | HSALNG0141946 | FER1L4 | FER1L4 | ceRNA | pathogenic process | gastric cancer;endometrial cancer;colorectal cancer | |
HSALNT0288985 | HSALNG0013215 | GACAT3 | LINC01458,lncRNA-AC130710 | NA | pathogenic process | ovarian cancer;gastric cancer | |
HSALNT0288881 | HSALNG0058863 | ABHD11-AS1 | WBSCR26,LINC00035,NCRNA00035 | NA | pathogenic process | gastric cancer;mutant huntingtin | |
HSALNT0282263 | HSALNG0137651 | ZNF674-AS1 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289207 | HSALNG0106864 | PCAT29 | NA | NA | pathogenic process | prostate cancer;glioma;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma | |
HSALNT0289672 | HSALNG0141787 | CADM1 | NA | NA | NA | NA | |
HSALNT0289297 | HSALNG0007253 | LINC01527 | lnc-SPRR2D-1,RP1-13P20.6 | NA | pathogenic process | squamous cell cancer | |
HSALNT0289158 | HSALNG0108520 | LUNAR1 | NA | transcriptional regulation | pathogenic process | diffuse large B-cell lymphoma;T cell acute lymphoblastic leukemia | |
HSALNT0289830 | HSALNG0141945 | FAR2P1 | NA | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | |
HSALNT0289263 | HSALNG0053580 | TARID | EYA4-AS1 | transcriptional regulation | pathogenic process | kidney clear cell sarcoma | |
HSALNT0145373 | HSALNG0069286 | MAFA-AS1 | RP11-909N17.3,TCONS_00014882 | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | |
HSALNT0290229 | HSALNG0142344 | RPLP0P2 | RPLP0P2 | NA | pathogenic process | lung adenocarcinoma | |
HSALNT0289291 | HSALNG0133273 | ZNF295-AS1 | C21orf121,NCRNA00318,PRED87 | NA | pathogenic process | lung adenocarcinoma;epithelial ovarian cancer | |
HSALNT0084473 | HSALNG0040150 | LINC01513 | RP11-1C1.7,TCONS_00009352 | NA | pathogenic process | NA | |
HSALNT0289471 | HSALNG0108507 | IRAIN | IGF1R-AS | transcriptional regulation | pathogenic process | pancreatic cancer;acute myeloid leukemia;non-small cell lung cancer;breast cancer | |
HSALNT0290402 | HSALNG0142517 | ZNRD1-AS1 | NA | NA | pathogenic process | hepatocellular cancer;lung cancer;cervical cancer | |
HSALNT0289504 | HSALNG0141615 | LCAL1 | onco-lncRNA-27 | NA | pathogenic process | lung cancer | |
HSALNT0289169 | HSALNG0100038 | MHRT | Myheart | transcriptional regulation | pathogenic process | heart hypertrophy;acute myocardial infarction | |
HSALNT0289859 | HSALNG0141974 | HA117 | NA | NA | pathogenic process | hirschsprung disease | |
HSALNT0026673 | HSALNG0012722 | NRIR | lncRNA-CMPK2 | transcriptional regulation | pathogenic process | chronic hepatitis C;HCV | |
HSALNT0289887 | HSALNG0142002 | LET | NA | NA | pathogenic process | gallbladder cancer;esophageal squamous cell cancer;gastric cancer;nasopharyngeal cancer;renal cell cancer;cervical cancer | |
HSALNT0007921 | HSALNG0004023 | NFIA-AS1 | RP5-833A20.1 | transcriptional regulation | pathogenic process | atherosclerosis;glioma | |
HSALNT0247156 | HSALNG0119710 | GAPLINC | LINC01540,TCONS_00026238,lncRNA-uc002kmd.1 | siRNA | pathogenic process | gastric cancer;colorectal cancer | |
HSALNT0288917 | HSALNG0079313 | CERNA2 | HOST2,lncRNA-HOST2 | ceRNA | pathogenic process | hepatocellular cancer;epithelial ovarian cancer | |
HSALNT0289113 | HSALNG0050689 | LINC01564 | TCONS_00011314 | NA | pathogenic process | prostate cancer | |
HSALNT0289088 | HSALNG0012685 | LINC01105 | FLJ30594,LOC150622 | NA | pathogenic process | gastric cancer;leukemia and neuroblastoma | |
HSALNT0289464 | HSALNG0091650 | AGAP2-AS1 | LOC100130776,PUNISHER | transcriptional regulation | pathogenic process | non-small cell lung cancer;glioma;leukemia and neuroblastoma | |
HSALNT0288960 | HSALNG0106834 | EWSAT1 | TMEM84,NCRNA00277,LINC00277,FLJ33768 | transcriptional regulation | pathogenic process | Ewing sarcoma | |
HSALNT0289242 | HSALNG0074573 | SLC25A25-AS1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0289317 | HSALNG0130331 | KCNK15-AS1 | RP11-445H22.4 | NA | pathogenic process | osteoarthritis;breast cancer | |
HSALNT0289864 | HSALNG0141979 | HIF2PUT | NA | NA | pathogenic process | osteosarcoma;colorectal cancer | |
HSALNT0289267 | HSALNG0019370 | TEX41 | DKFZp686O1327,LINC00953 | transcriptional regulation | NA | NA | |
HSALNT0290361 | HSALNG0142476 | UFC1 | NA | transcriptional regulation;ceRNA | pathogenic process | osteoarthritis;hepatocellular cancer | |
HSALNT0289886 | HSALNG0142001 | LEIGC | NA | NA | pathogenic process | gastric cancer | |
HSALNT0289367 | HSALNG0049188 | MDC1-AS1 | MDC1-AS | NA | pathogenic process | bladder cancer;glioma | |
HSALNT0289190 | HSALNG0048542 | NBAT1 | CASC14,NBAT-1 | transcriptional regulation | pathogenic process | breast cancer;renal clear cell cancer;neuroblastoma | |
HSALNT0234826 | HSALNG0113287 | LINC00917 | NA | NA | pathogenic process | intervertebral disc degeneration;breast cancer | |
HSALNT0289419 | HSALNG0094327 | LINC00173 | NCRNA00173,FLJ42957 | NA | pathogenic process | HIV-1-infected;hepatocelluar cancer | |
HSALNT0290138 | HSALNG0142253 | PEG10 | NA | NA | pathogenic process | diffuse large B-cell lymphoma;esophageal cancer | |
HSALNT0289136 | HSALNG0041549 | LINC02224 | BRCAT107,ENST00000505706 | NA | pathogenic process | active tuberculosis | |
HSALNT0289866 | HSALNG0141981 | HIT | NA | transcriptional regulation | pathogenic process | non-small cell lung cancer;breast cancer | |
HSALNT0003927 | HSALNG0002075 | SNHG12 | ASLNC04080,C1orf79,LINC00100,NCRNA00100,PNAS-123 | NA | pathogenic process | osteosarcoma;endometrial cancer | |
HSALNT0289099 | HSALNG0002236 | LINC01225 | NA | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0290047 | HSALNG0142162 | MALAT2 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0176345 | HSALNG0084672 | SNHG1 | LINC00057,NCRNA00057,U22HG,UHG,lncRNA16 | NA | pathogenic process | astrocytoma;hepatocellular cancer;non-small cell lung cancer;Parkinson's disease;neuroblastoma | |
HSALNT0094592 | HSALNG0044933 | WSPAR | TCONS_00009511-XLOC_004555,lncTCF7 | transcriptional regulation | pathogenic process | hepatocellular cancer;liver cancer | |
HSALNT0289308 | HSALNG0118552 | LINC00511 | onco-lncRNA-12 | NA | pathogenic process | lung adenocarcinoma;breast cancer | |
HSALNT0289452 | HSALNG0069321 | FAM83H-AS1 | onco-lncRNA-3 | NA | pathogenic process | NA | |
HSALNT0289041 | HSALNG0051162 | LINC00472 | C6orf155,dJ288M22.3,FLJ13189 | NA | pathogenic process | ovarian cancer;breast cancer | |
HSALNT0289925 | HSALNG0142040 | linc-ITGB1 | NA | NA | pathogenic process | gallbladder cancer;breast cancer | |
HSALNT0016239 | HSALNG0007801 | LINC01133 | lncRNA-PAGBC | transcriptional regulation | pathogenic process | non-small cell lung cancer;colorectal cancer;lung squamous cell cancer | |
HSALNT0289489 | HSALNG0141600 | CCEPR | CCHE1,lncRNA-CCHE1 | transcriptional regulation | pathogenic process | hepatocellular cancer;cervical cancer | |
HSALNT0289402 | HSALNG0098682 | SOX21-AS1 | NA | NA | pathogenic process | lung adenocarcinoma;oral squamous cell cancer | |
HSALNT0288905 | HSALNG0048533 | CASC15 | LINC00340,lnc-SOX4-1 | NA | pathogenic process | basal cell cancer;melanoma;neuroblastoma | |
HSALNT0289555 | HSALNG0141670 | AC104699.1 | NA | NA | pathogenic process | gastric cancer | |
HSALNT0096322 | HSALNG0045923 | CLMAT3 | SPARC-AS1 | NA | pathogenic process | colorectal cancer | |
HSALNT0289233 | HSALNG0043698 | RGMB-AS1 | NA | NA | pathogenic process | lung adenocarcinoma;non-small cell lung cancer | |
HSALNT0289908 | HSALNG0142023 | LINC01419 | LVCAT7,TCONS_00014497 | NA | pathogenic process | hepatocelluar cancer | |
HSALNT0289541 | HSALNG0141656 | AB209630 | NA | NA | pathogenic process | hypopharyngeal squamous cell cancer | |
HSALNT0289608 | HSALNG0141723 | AOC4P | AOC4P | NA | pathogenic process | colorectal cancer;hepatocelluar cancer | |
HSALNT0289082 | HSALNG0040781 | PURPL | LINC01021,LOC643401,RP11-46C20.1 | NA | pathogenic process | NA | |
HSALNT0196121 | HSALNG0094605 | LINC01089 | LIMT | NA | pathogenic process | breast cancer;astrocytoma | |
HSALNT0123080 | HSALNG0058166 | EGFR-AS1 | NA | NA | pathogenic process | hepatocellular cancer | |
HSALNT0289539 | HSALNG0141654 | AB073614 | NA | NA | pathogenic process | ovarian cancer;glioma | |
HSALNT0242418 | HSALNG0117322 | CACNA1G-AS1 | NA | NA | pathogenic process | keloid | |
HSALNT0170814 | HSALNG0081992 | MIR210HG | NA | transcriptional regulation | pathogenic process | hypoxic and inflammatory stress | |
HSALNT0288979 | HSALNG0113319 | FOXC2-AS1 | ODRUL | NA | pathogenic process | osteosarcoma | |
HSALNT0289022 | HSALNG0132865 | LINC00160 | C21orf52,NCRNA00160 | NA | pathogenic process | breast cancer | |
HSALNT0105274 | HSALNG0049582 | LINC01016 | NA | NA | pathogenic process | breast cancer | |
HSALNT0288904 | HSALNG0045753 | CARMN | MIR143HG,CARMEN | transcriptional regulation | pathogenic process | cardiac differentiation | |
HSALNT0289123 | HSALNG0121579 | LINC01630 | LOC100287225 | NA | pathogenic process | colorectal cancer | |
HSALNT0288971 | HSALNG0104253 | FAM30A | C14orf110,KIAA0125,HSPC053 | NA | pathogenic process | gallbladder cancer | |
HSALNT0289506 | HSALNG0141617 | LINC00346 | C13orf29,NCRNA00346 | NA | pathogenic process | hepatocellular cancer;breast cancer | |
HSALNT0289643 | HSALNG0141758 | BC032469 | NA | ceRNA | pathogenic process | esophageal squamous cell cancer;gastric cancer | |
HSALNT0289580 | HSALNG0141695 | AK024171 | NA | NA | pathogenic process | intervertebral disc degeneration;gastric cancer | |
HSALNT0290187 | HSALNG0142302 | RP11-284N8.3.1 | NA | NA | pathogenic process | ovarian cancer | |
HSALNT0289839 | HSALNG0141954 | FMR6 | NA | NA | pathogenic process | fragile X syndrome;fragile X-associated premature ovarian insufficiency | |
HSALNT0290152 | HSALNG0142267 | PRAL | lncRNA-PRAL | NA | pathogenic process | hepatocellular cancer;lung cancer | |
HSALNT0289380 | HSALNG0129818 | NORAD | LINC00657 | transcriptional regulation;translational control | pathogenic process | breast cancer | |
HSALNT0086803 | HSALNG0041283 | LIFR-AS1 | NA | NA | pathogenic process | preterm | |
HSALNT0076183 | HSALNG0036373 | PANCR | NA | NA | pathogenic process | atrial fibrillation | |
HSALNT0288975 | HSALNG0060982 | FEZF1-AS1 | NA | transcriptional regulation | pathogenic process | gastric cancer;colorectal cancer | |
HSALNT0238475 | HSALNG0115230 | CCDC144NL-AS1 | NA | ceRNA | pathogenic process | ovarian cancer;cardiac hypertrophy | |
HSALNT0290102 | HSALNG0142217 | NR_026689 | NA | NA | pathogenic process | ovarian cancer;lung cancer | |
HSALNT0289522 | HSALNG0075559 | ADARB2-AS1 | C10orf109,NCRNA00168,bA466B20.1 | NA | pathogenic process | breast cancer;pancreatic ductal adenocarcinoma | |
HSALNT0288936 | HSALNG0018139 | DPP10-AS1 | BC032913 | NA | pathogenic process | breast cancer;colorectal cancer | |
HSALNT0289474 | HSALNG0113682 | GAS8-AS1 | C16orf3 | NA | pathogenic process | papillary thyroid cancer;breast cancer | |
HSALNT0289063 | HSALNG0075802 | MANCR | LINC00704 | NA | pathogenic process | NA | |
HSALNT0289238 | HSALNG0026715 | SAMMSON | LINC01212 | NA | pathogenic process | melanoma | |
HSALNT0289027 | HSALNG0007238 | LINC00302 | C1orf46,NCRNA00302,XP33 | NA | developmental process | NA | |
HSALNT0245543 | HSALNG0118895 | SNHG20 | C17orf86,NCRNA00338,LINC00338,PRO0872,FLJ25582,DKFZp686L05235,SCARNA16HG | transcriptional regulation | pathogenic process | hepatocellular cancer;colorectal cancer | |
HSALNT0015631 | HSALNG0007463 | DCST1-AS1 | RP11-307C12.11 | NA | pathogenic process | ovarian cancer | |
HSALNT0149810 | HSALNG0071682 | PGM5-AS1 | FAM233A,LOC572558 | NA | pathogenic process | bladder cancer | |
HSALNT0290236 | HSALNG0142351 | SBF2-AS1 | NA | transcriptional regulation | pathogenic process | non-small cell lung cancer | |
HSALNT0290325 | HSALNG0142440 | uc.338 | NA | transcriptional regulation | pathogenic process | hepatocellular cancer;lung cancer | |
HSALNT0289973 | HSALNG0142088 | LNCRI | lnc-RI | ceRNA | NA | NA | |
HSALNT0290002 | HSALNG0142117 | LOC100130476 | NA | NA | pathogenic process | esophageal squamous cell cancer;gastric cardia adenocarcinoma | |
HSALNT0289049 | HSALNG0063356 | LINC00599 | Rncr3 | NA | pathogenic process | diabetes | |
HSALNT0020406 | HSALNG0009871 | LINC00628 | NA | transcriptional regulation | pathogenic process | gastric cancer | |
HSALNT0289478 | HSALNG0133031 | DSCR4 | DCRB | NA | pathogenic process | Down syndrome | |
HSALNT0017675 | HSALNG0008546 | GAS5-AS1 | NA | NA | pathogenic process | oral submucous fibrosis;non-small cell lung cancer | |
HSALNT0289523 | HSALNG0048782 | HCG11 | bK14H9.3,FLJ14049,FLJ30357 | NA | pathogenic process | prostate cancer | |
HSALNT0134828 | HSALNG0064314 | LINC02099 | AC145110.1 | NA | pathogenic process | rheumatoid arthritis;breast cancer | |
HSALNT0209098 | HSALNG0100348 | G2E3-AS1 | CAT1647 | NA | pathogenic process | bladder cancer | |
HSALNT0289139 | HSALNG0015506 | LINC02245 | lnc-SERTAD2-3,AC007386.2 | NA | pathogenic process | ovarian cancer | |
HSALNT0008167 | HSALNG0004109 | FOXD3-AS1 | pasFOXD3 | transcriptional regulation | pathogenic process | glioma | |
HSALNT0289335 | HSALNG0060638 | LINC00998 | NA | NA | pathogenic process | major depression disorder | |
HSALNT0289379 | HSALNG0041522 | NNT-AS1 | NA | NA | pathogenic process | colorectal cancer | |
HSALNT0055497 | HSALNG0026555 | PSMD6-AS1 | ENST00000462717,lnc00462717 | NA | pathogenic process | papillary thyroid cancer;glioma | |
HSALNT0289130 | HSALNG0119047 | LINC02081 | CTD-2357A8.3,XLOC_012582 | NA | pathogenic process | esophageal cancer | |
HSALNT0289306 | HSALNG0107939 | LINC00052 | TMEM83,NCRNA00052,FLJ31461 | ceRNA | pathogenic process | hepatocellular cancer;breast cancer | |
HSALNT0199070 | HSALNG0095970 | PLUT | PDX1-AS1,PLUTO,HI-LNC71 | transcriptional regulation | pathogenic process | type 2 diabetes | |
HSALNT0289341 | HSALNG0073476 | LINC01505 | RP11-308N19.1 | NA | pathogenic process | NA | |
HSALNT0289315 | HSALNG0020625 | LINC01116 | TALNEC2 | transcriptional regulation | pathogenic process | prostate cancer;glioblastoma | |
HSALNT0006439 | HSALNG0003395 | FOXD2-AS1 | MGC12982 | NA | pathogenic process | lung cancer | |
HSALNT0252387 | HSALNG0122085 | LINC00305 | C18orf20,NCRNA00305,MGC39571,HsT1235 | NA | NA | NA | |
HSALNT0289473 | HSALNG0110794 | FBXL19-AS1 | NCRNA00095,MGC125469,MGC125470,MGC125472 | NA | pathogenic process | colorectal cancer | |
HSALNT0187807 | HSALNG0090479 | LINC02555 | AC079630.2 | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0251493 | HSALNG0121679 | LINC01929 | CTD-2171N6.1 | NA | pathogenic process | papillary thyroid cancer | |
HSALNT0244776 | HSALNG0118529 | LINC01152 | TCONS_00025128,CMPD | NA | pathogenic process | NA | |
HSALNT0284591 | HSALNG0139113 | DIAPH2-AS1 | NA | NA | pathogenic process | Hodgkin's disease | |
HSALNT0289226 | HSALNG0104558 | PWAR1 | PAR1,PAR-1 | NA | pathogenic process | Prader-Willi syndrome and Angelman syndrome | |
HSALNT0289339 | HSALNG0070961 | LINC00950 | FP588 | NA | NA | NA | |
HSALNT0289740 | HSALNG0141855 | DGCR12 | DGS-E | NA | pathogenic process;developmental process | DiGeorge syndrome | |
HSALNT0275220 | HSALNG0133987 | DGCR9 | DGS-A,POM121L5P | NA | pathogenic process | DiGeorge syndrome | |
HSALNT0288929 | HSALNG0133982 | DGCR10 | DGS-B | NA | pathogenic process | NA | |
HSALNT0289494 | HSALNG0141605 | DGCR11 | DGS-D | NA | pathogenic process | NA |